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ii. Abstract  
Background Patellofemoral pain (PFP) is a common complaint characterised by diffuse 
retropatellar or peripatellar pain during activities such as running, stair descent or 
squatting. We aimed to determine the influence of lower limb biomechanics on the 
development, persistence and management of PFP in recreational runners.  
Methods Two systematic reviews with meta-analysis explored risk factors for, and the 
associations between, PFP and lower limb biomechanics respectively. A case-control 
study investigated lower limb kinematics during treadmill running and a feasibility 
study explored recruitment, retention and delivery of a step rate intervention in 
mixed-sex runners. Finally, a validity study investigated the potential for two-
dimensional (2D) video to predict three-dimensional (3D) running kinematics. 
Results Understanding of which variables contribute to PFP development is 
inadequate, requiring further exploration. Multiple retrospective associations between 
and potential treatment mechanisms for lower limb biomechanics and PFP were 
identified, but prospective data is lacking. A mixed-sex cohort of runners 
demonstrated higher peak hip adduction compared to controls. Higher peak hip 
adduction was also observed when comparing females with PFP to controls, but data 
for males were non-significant. Recruitment and retention of a mixed-sex cohort of 
runners with PFP to a step rate intervention was feasible. Clinically relevant changes in 
pain and potential kinematic treatment mechanisms were identified post-retraining, 
though these mechanisms were not detectable with 2D video.    
Conclusion Potential influences of lower limb biomechanics once a recreational runner 
has PFP are well established. Further work is required to determine what 
biomechanical variables may contribute to PFP development, with novel approaches 
required. Sex influences lower limb kinematics and as such, males and females may 
have different symptom drivers requiring individual treatment strategies. Step rate 
retraining demonstrated potential efficacy and treatment mechanisms that warrant 
further appraisal in an adequately powered randomised controlled trial to long-term 
follow up.   
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1. Introduction  
Patellofemoral pain (PFP) is a common musculoskeletal complaint, affecting 22.7% of 
the United Kingdom (UK) general population (1). Long-term treatment outcomes are 
suboptimal, with more than one in two patients reporting an unfavourable outcome 
more than five years after diagnosis (2). PFP is thought to be the start of a continuum 
which may culminate in Patellofemoral Osteoarthritis (3). This means improving 
management in young adults may have positive implications for both individuals and 
the health care system in both the short and long term. Aggravating factors associated 
with PFP include squatting, stair ascent/descent, running or hopping/jumping (4). 
There is no singular diagnostic test for PFP (5), with a clinical diagnosis instead reached 
in the presence of pain located at, around or behind the patella (4) after the exclusion 
of alternative or concomitant pathologies such as patella tendinopathy, iliotibial band 
syndrome or tibiofemoral pathology as the primary symptom driver. Imaging is not 
recommended as part of the primary diagnostic process owing to the questionable 
relevance of articular structure changes, which are prevalent in symptomatic and 
asymptomatic individuals (6).  
1.1. Running participation and health benefits  
Participation in recreational running has nearly doubled in the past 6 years. 
Specifically, the number of people running once per week in the UK throughout 2016 
approached 30,000 people, compared to just 15,000 in 2010 (7). The popularity of 
running is likely due to the ease of accessibility and relative low cost associated with 
recreational running participation (8). Running is also associated with multiple positive 
health benefits. A recent systematic review and meta-analysis reports moderate 
evidence that running improves cardiovascular function and aerobic fitness, and 
reduces adiposity (9). There is further level one evidence that regular running reduces 
body fat percentage, blood triglycerides and resting heart rate in inactive individuals 
(10). Finally, regular running has been reported to reduce all-cause mortality by 30-
45% after adjustment for age and sex (11). 
1.2. Running injury prevalence  
Despite multiple health benefits, recreational running also increases risk of 
musculoskeletal injury (12). Dependent on the chosen source and injury definition (8, 
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13), 18-79% of recreational runners are reported to sustain a musculoskeletal injury in 
a calendar year. PFP is reported as the most prevalent injury, accounting for 17% of all 
running-related injuries presenting to Sports Medicine facilities (14), twice as common 
as the next most prevalent injury (iliotibial band syndrome, 8%). Additionally, a recent 
injury surveillance study completed in the UK reported that 49.8% of recreational 
runners described themselves as having a musculoskeletal injury related to running, 
with injury to the knee region the most prevalent (15).  
1.3. PFP incidence  
New incident cases of PFP appear to vary dependent on the population studied. A 
recent meta-analysis from Smith et al (16) reported that the incidence of PFP within 
military recruits ranges from 9.7 to 574.1 cases per 1,000 person-years and from 5.1-
14.9% amongst adolescent athletes. Among recreational runners, new incident cases 
of PFP have been reported to range from 17% to 26% during a ten-week ‘start to run 
programme’ (17, 18) and from 3% to 4% over a one to two year period (19, 20). 
1.4. Influence of sex on PFP incidence 
Amongst military recruits, females have been reported to be twice as likely to develop 
PFP compared to males (21). Both high (43%) (22) and low (3%) (23) incidence rates 
have been reported amongst military recruits, with the higher figure coming from an 
all female cohort. Amongst adolescent athletes, there is further support for the notion 
of a female sex bias in PFP, with studies by Foss et al (24) and Herbst et al (25) 
reporting the highest incidence of 15% from all female cohorts, compared to the lower 
incidence of 5% reported by Finnoff et al (26), who investigated a mixed-sex cohort. 
However, it should be stressed that higher incidence rates have been reported by 
studies involving mixed-sex or male dominant cohorts in the military (27) and low rates 
of PFP incidence reported by studies involving adolescent females (28, 29).   
Amongst recreational runners there is further confliction regarding the role of sex and 
PFP development, with Noehren et al (20) and Ramskov et al (19) having reported 
identical incidence figures of 4% despite a clear sex discrepancy in populations studied. 
Overall, the role of sex as a confounding factor in PFP development is conflicting and 
requires further exploration.  
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1.5. Factors associated with PFP development and persistence   
Two recent systematic reviews have synthesised research evaluating factors associated 
with PFP (30, 31). A prospective review, summarising work to November 2010, 
highlighted a dearth of evidence, with just seven studies eligible for inclusion at the 
time of searching (30). Multiple risk factors were investigated in single studies, which 
require further exploration in future studies to allow for data pooling. A review of 
cross-sectional literature highlighted a greater breadth of evidence, with 47 eligible 
studies and data pooling possible for eight factors (31). Additionally, a number of other 
systematic reviews evaluating the cross-sectional relationship of various factors with 
PFP have been published (32-37). 
1.5.1. Quadriceps function 
The strongest risk factor for future PFP development reported by Lankhorst et al (30) 
was reduced knee extension strength, with standardised mean differences (SMD) 
ranging from small (0.11) to moderate (0.84). These pooled data included only two 
studies investigating military recruits (22, 38). Therefore, it is unknown if knee 
extension weakness is a risk factor for PFP development in other cohorts such as 
recreational runners.  
Two cross-sectional studies have reported an association between lower peak knee 
extensor torque and PFP in recreational runners, compared to asymptomatic runners 
(31, 39, 40). Global atrophy of the quadriceps (41) and delayed vastus medialis obliqus 
(VMO) onset during functional tasks (42) has also been reported in people with PFP. 
Not all cohorts with PFP have demonstrated such muscle weakness, with Selfe et al 
(43) reporting a cross-sectional subgroup with significantly greater isokinetic 
quadriceps strength. This subgroup were predominantly male and demonstrated 
higher levels of both function and quality of life, suggesting that muscle deficits in 
those with PFP may be subgroup specific.       
1.5.2. Hip muscle function 
The association between hip muscle strength and PFP is conflicting. A recent 
systematic review by Rathleff et al (44) reported moderate evidence of no association 
between isometric hip strength and future PFP development. There is moderate 
evidence of an association between reduced isometric hip abduction and extension 
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strength and persistent PFP in both sexes (31, 32), but also evidence of a subgroup 
that demonstrate significantly greater isokinetic hip abductor strength (43). Delayed 
gluteus medius (GMED) onset and reduced activation duration, measured with surface 
electromyography (sEMG), have also been reported during both stair negotiation and 
running (34).  
Since the review of Rathleff et al (32), studies have emerged reporting that increased 
isometric hip abduction strength is predictive of future PFP development in 
adolescents (25, 26). However, Ramskov et al (19) reported that higher eccentric hip 
abduction strength was associated with a lower risk of future PFP development in an 
adult novice running cohort. These conflicting data suggest that the relationship 
between hip strength and PFP may be individual within specific homogenous 
populations, and that variable methods of testing (e.g. hand held versus isokinetic 
dynamometers) may result in differing outcomes.  
1.5.3. Lower limb biomechanics 
There is an extensive body of literature investigating lower limb biomechanics in 
individuals with PFP, owing to the theory that PFP is intrinsically related to abnormal 
tracking of the patella relative to the underlying trochlear groove (45). This prevalent 
theory is summarised by the recently published pathoanatomical model of PFP (see 
figure 1) (46). Theoretically, altered patella tracking is thought to result in increased 
patellofemoral joint stress, by reducing patellofemoral contact area over which 
subsequent patellofemoral joint reaction force is applied (47). This is suggested to 
contribute to articular cartilage pathology and result in increased nociceptive output 
from the highly innervated subchondral bone (48). However, to date there is a lack of 
confirmatory evidence that increased patellofemoral joint stress, reported in some 
cohorts during some tasks, relates strongly to pain. Nonetheless, a large body of 
research has explored biomechanics related to this theoretical paradigm. 
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1. The pathoanatomical model of PFP reproduced from Powers et al (46) 
1.5.4. Hip kinematics 
As the quadriceps tendon anchors the patella to the femur during closed chain tasks, 
recent literature has focused on the influence of frontal and transverse plane hip 
kinematics underneath this stable extensor mechanism (45). Both increased hip 
adduction (HADD) and internal rotation (HIR) have been reported to increase lateral 
patella displacement during weight bearing in observational studies (49, 50), which will 
theoretically increase patellofemoral joint stress. Prospectively, Noehren et al (20) 
reported that increased peak HADD during running is a risk factor for future PFP 
development in female runners. In addition, Boling et al (23) reported that an increase 
in peak HIR during a jump-landing task is a risk factor for future PFP development in in 
a mixed-sex military cohort.  
Multiple studies report significant cross-sectional associations between altered hip 
kinematics and PFP during running (39, 51-54), with data predominantly coming from 
mixed sex cohorts. Only Willy et al (51) has presented data for both sexes separately, 
reporting significantly greater HADD in females with PFP compared to males with PFP. 
Overall, the influence of sex on lower limb biomechanics in relation to PFP 
development and persistence is under-evaluated and warrants further investigation 
(55), since this may lead to differences in treatment targets. Currently, a number of 
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proximally targeted interventions have been explored for both female and mixed sex 
cohorts in the literature (56).  
1.5.5. Foot biomechanics 
Despite the historic suggestion that foot kinematics, specifically increased rearfoot 
eversion, are associated with patellofemoral loading (57), evidence for this relationship 
is conflicting (55). Individuals with PFP have been reported to have a more pronated 
foot posture than controls (31), which has also been observed prospectively in a 
military cohort using navicular drop (36). However, these static tests are not strongly 
related to dynamic foot function (58-60), and no dynamic differences in foot function 
are reported to exist in those with PFP compared to controls during running (52). 
Furthermore, variation in foot kinematics during gait in asymptomatic individuals is 
reported to be both varied and normal (61). Consistent evidence suggests that 
individuals with PFP exert higher forces through specific regions of the foot (lateral 
forefoot and medial metatarsal heads) during running (18), although ability to measure 
these forces in clinical practice is limited.  
1.5.6. Non-mechanical contributors to PFP 
There is growing evidence to support the role of non-physical factors in persistent 
musculoskeletal pain (35). Consistent with this suggestion, local and widespread 
hyperalgesia have been reported in both adolescents (62) and adults (63) with PFP, 
thought to reflect peripheral and central sensitization. Higher levels of depression, 
anxiety and catastrophising behavior have also been reported in individuals with PFP 
(35), alongside a lower quality of life (33), all of which are reported to alter an 
individual’s pain processing (55). The suggestion of a singular nociceptive tissue source 
in PFP is also questioned by the work of Boudreau et al (64), who report considerably 
heterogeneous visual pain maps amongst a cohort of adolescents and young adults 
with PFP (see figure 2).  
 31 
 
2. Heterogeneous visual pain maps in PFP from Boudreau et al (64) 
1.6. Passive PFP interventions  
Some treatment adjuncts are advocated in the management of pain that is severe or 
irritable as part of a combined treatment battery (65). A recent systematic review 
reports statistically, but not clinically significant reductions in pain after local manual 
therapy in participants with PFP (66), though the methodology of this review has 
recently been challenged (67). Patellar mobilisation, except in the presence of 
objective patellar hypomobility (65), therapeutic ultrasound (68) and stretching (69) 
are not supported by the current patellofemoral consensus statement (65). 
Furthermore, dry needling has been reported to add no additional benefit to 
multimodal Physiotherapy consisting of manual therapy and strengthening exercise 
(70).  
1.6.1. Taping  
Patellar taping was developed to target theoretical abnormal patella tracking (45, 71, 
72). A Cochrane review including only data from randomized controlled trials (RCT) to 
2011 reports insufficient evidence to support the effectiveness of patellar taping (71). 
However, a more recent systematic review including data from multiple study designs 
to 2013 supports the use of tailored patellar taping to immediately reduce pain during 
stair ambulation and squatting (73). The mechanisms of effect for patellar taping are 
poorly understood, with Ho et al (74) reporting no significant alterations in patellar 
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arthrokinematics during a step down task after the application of either McConnell or 
Kinesio taping designed to improve frontal plane alignment. Pelletier et al (75) report 
significant favourable alterations in both hip and knee flexion angles at initial contact 
during treadmill running in individuals with PFP, but no inference on symptoms was 
made by this observational study. Effects of patellar taping are therefore yet to be 
evaluated in a recreational running cohort.  
1.6.2. Foot orthoses 
Whilst the evidence surrounding both static and dynamic foot function and PFP 
development and persistence is conflicting, there is supporting evidence for the use of 
prefabricated foot orthoses to effectively reduce pain at six week follow up compared 
to both sham devices and a ‘wait and see’ approach (76, 77). In a recreational running 
cohort, orthoses intervention is reported to reduce both peak rearfoot eversion and 
eversion velocity (78), but again no inference on symptoms was made by this 
observational study. Positive effects of foot orthoses were recently reported in a 
recreational running cohort by Bonacci et al (79), but were inferior to step rate 
retraining and minimalist shoe use in this pilot randomised controlled trial (RCT).  
1.7. Active PFP interventions  
1.7.1. Exercise therapy 
Exercise therapy is the gold standard conservative intervention for PFP (65, 69, 80), 
with level one evidence to support the use of both hip (proximal) and knee (local) 
exercise (56, 81). This aligns well with the proximal and local muscle weaknesses 
reported in those with PFP in comparison to asymptomatic controls (31, 32). In a 
running specific population, exercise therapy is reported to result in significant 
improvements in both pain and function (82-84) at short-term follow up. However, 
only one of these case series identified a potential mechanism of effect, being a 
reduced knee abduction moment during the stance phase of running (84), with no 
significant running kinematic changes reported. Moreover, the recent three-arm RCT 
of Esculier et al (85) reported that exercise therapy was no more effective than load 
management education, or load management education combined with step rate 
retraining. Thus, the mechanism(s) for improved outcomes following exercise therapy 
in runners with PFP remains unclear. This lack of clarity limits the ability of clinicians 
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and researchers to act on the suggestion that interventions should be tailored to 
specific individual deficits (43), and questions the role for exercise therapy as an 
intervention for runners with PFP that may primarily be associated with altered lower 
limb kinematics.  
1.7.2. Running retraining in PFP: emerging effects and mechanisms   
Multiple observational studies involving asymptomatic participants report no 
significant differences to either hip or knee kinematics during running after hip 
strengthening programmes, irrespective of significant increases in hip abductor or 
external rotator strength (86-88). A novel finding reported by Willy et al (88) was a 
significant reduction in both HADD and HIR during a single leg squat task post-exercise 
therapy. The authors hypothesised that these changes may reflect the acquisition of a 
new movement skill as opposed to being the result of increased isometric strength 
(88). In keeping with this suggestion, an intervention termed ‘running retraining’ has 
an emerging evidence base and is best described as ‘the implementation of any cue or 
strategy designed to alter an individual’s running biomechanics, or technique’ (89).  
A large number of observational studies indicate running cues can alter an individual’s 
running biomechanics (90). Multiple studies report that increasing running step rate 
(the number of steps a runner takes in a given period of time) by 5-10% results in 
reduced peak HADD (91-93). Studies also report that increasing running step rate 
results in reduced patellofemoral joint stress (94, 95) and increased gluteal muscle 
activation duration (96). However, as all of these studies have been observational, 
mostly in asymptomatic runners, inferences in relation to runners with PFP should be 
made with caution.  
Barefoot running as a potential tool to facilitate changes to running technique has 
been reported to reduce patellofemoral joint stress (97), although not greater than the 
aforementioned work on step rate increase (94, 95). A trial investigating the effects or 
mechanisms of barefoot running in a PFP population is yet to be completed. Cueing 
transition from a rearfoot to a forefoot strike pattern has also been reported to reduce 
patellofemoral joint stress (98, 99), although again not greater than step rate cues 
(99).  
 34 
Two initial case series in female runners with PFP (100, 101) have reported significant 
improvements in both pain (measured with a visual analogue scale {VAS}) and function 
(measured with the lower extremity functional scale {LEFS}). Despite employing 
differing forms of feedback, a live display of real-time HADD during stance and mirror 
feedback respectively, both reported similar reductions in peak HADD (5˚) that may 
provide a potential kinematic mechanism for pain reduction. Both authors suggest that 
this reduction in peak HADD was likely to alter nociceptive output from the 
subchondral bone by way of reducing patellofemoral joint stress. In addition, a smaller 
case study (n=2) by Willy et al (102) reported similar kinematic outcomes but also 
earlier GMED onset relative to foot contact and a longer GMED activation duration 
post-mirror gait retraining, measured with sEMG.  
The primary limitation of these case series was the investigation of an all female 
cohort, making these data inapplicable to male runners with PFP. Further limitations 
include the absence of a control group and the lack of clinical applicability of the 
feedback provided. Specifically, Noehren et al (100) delivered live visual feedback via 
laboratory-based technology (three dimensional {3D} motion analysis), which is not 
commercially available. The work of Willy et al (101, 102) is more clinically applicable, 
involving mirror feedback, but involved eight intervention sessions in a two-week 
period, which is likely to be an unrealistic expectation of the average clinical facility.  
More recently, two small RCT’s have been published in the literature. The first was 
conducted by Roper et al (103), who reported a significant reduction in pain when 
transitioning a PFP cohort to a forefoot strike pattern over and above a control group 
consisting of a graduated increase in running. However, the potential negative of 
transitioning to a forefoot strike pattern is the load that may be shifted 
consequentially to the ankle joint (104), reflected by a 25% rate of secondary ankle 
pain in the treatment group at one month follow up. A second pilot RCT conducted by 
Bonacci et al (79), reported a significant reduction in pain in a cohort of runners with 
PFP after a combined step rate and minimalist shoe intervention, compared to 
prescription of prefabricated foot orthoses. Whilst positive effects were observed in 
this pilot RCT, the combined approach of increasing step rate and graduated use of a 
minimalist shoe make it impossible to determine what aspect of the retraining 
protocol resulted in the positive outcome.   
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3. Summary of run retraining interventions and outcomes in PFP 
Key: RCT; randomised controlled trial; VAS=visual analogue scale; KOOS; knee osteoarthritis outcome 
score; AVLR; average vertical loading rate; HADD=hip adduction; LEFS=lower extremity functional scale; 
NNT=number needed to treat.   
One proposed explanation for the positive clinical benefits from running retraining 
interventions, is that they are derived as a result of load management (105). The 
monitoring and subsequent manipulation of workload has been reported to be an 
effective method of reducing injury risk in elite sport (106). As running retraining 
protocols contain a progressive increase in running duration (100, 101), it is certainly 
plausible that a load management mechanism is at least partially involved in the 
positive effects derived.  
This hypothesis is supported by the recent high quality RCT conducted by Esculier et al 
(85), who reported that increasing step rate and/or transitioning to a forefoot strike 
pattern was no more effective than load management education alone, or load 
management education combined with exercise therapy. All groups within this RCT 
improved significantly for the outcomes of usual, worst and running-related pain, as 
well as improvements in the activities of daily living subscale of the Knee Osteoarthritis 
Outcome Score (KOOS). The running retraining group was reported to have a 
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significant reduction in average vertical loading rate (AVLR) compared to both 
education and exercise, but this identified mechanism did not affect the primary 
outcome.  
Whilst this RCT identifies the novel benefit of an education intervention in runners 
with PFP, there are some limitations to the design of their step rate retraining 
intervention. Step rate retraining was completed without adhering to a faded feedback 
protocol, used successfully by previous studies and reported to be necessary to 
facilitate skill acquisition (107). This is supported by the recent RCT of Roper at al 
(103), which reported significant improvements in both pain and function in runners 
with PFP compared to a load management control. Whilst both groups in this trial 
completed a graduated return to running, only the intervention group was given a cue 
designed to induce a forefoot strike pattern. There was also no monitoring of 
adherence in the field, with adherence closely controlled in previous studies.  
1.8. Literature gaps of relevance to this thesis  
1.8.1. PFP epidemiology  
When last reviewed, the dearth of prospective literature limited ability to define causal 
relationships between given variables and the risk of future PFP, particularly in 
recreational runners. An updated systematic review of the prospective literature was 
hypothesised to result in a greater understanding of causal relationships for PFP. There 
are reported associations between several kinematic variables and PFP, with the most 
consistent evidence indicating the presence of greater peak HADD. However, the 
majority of data is presented pooled for both sexes. There is currently minimal 
evidence comparing males and females with PFP, with a significant increase in peak 
HADD reported in female runners (46) when data are presented for individual sexes. 
This requires further exploration as if consistent, will indicate that males and females 
with PFP may present with potentially differing kinematic treatment targets.  
1.8.2. Running retraining  
Short-term effects of running retraining and associated biomechanical mechanisms 
indicate further research is warranted in relation to this treatment approach for 
recreational runners. Feedback approaches previously explored in PFP cohorts have 
inherent limitations. The work of Noehren et al (100) and Willy et al (101) lack clinical 
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applicability due to the technology involved and the frequency of sessions delivered. 
Transitioning from a rearfoot to a forefoot strike which was investigated by Roper et al 
(103) may result in the adverse outcome of secondary ankle pain. Increasing step rate 
has only been explored in combination with a minimalist shoe (79), or without the use 
a faded feedback protocol (85). Additionally, all previous running retraining studies 
have a significant female sex bias in sampling. Given the plausibility of increasing step 
rate reported in observational cohort studies (91, 94), an investigation into increasing 
step rate in a mixed-sex PFP cohort with increased clinical applicability is warranted. 
Additional exploration of both kinematic and muscle function post-intervention is also 
justified, to aid in understanding the mechanisms of any observed positive effects.      
1.8.3. Clinical applicability of biomechanics  
A further limitation to current running retraining research is the divide between 
research and clinical practice, with respect to the measurement of human 
biomechanics. This fault lies not with our understanding of how biomechanics can 
contribute to PFP, but with the paucity of validated tools suitable for use in a clinical 
setting that can measure the relevant variables described in the literature. A pragmatic 
and clinically applicable solution to this problem is the use of two-dimensional (2D) 
video. Maykut et al (108) reported a moderate correlation with 3D peak HADD during 
over ground running (r=0.62). Furthermore, Dingenen et al (109) recently reported a 
significant, positive correlation between 3D and 2D measurement for femoral 
adduction (FADD), contralateral pelvic drop (CLPD) and HADD during running stance 
phase in asymptomatic runners.  
A limitation of all work completed to date is the normative cohorts chosen for 
validation, as one cannot presume that participants with pain will move in the same 
way as those who are asymptomatic. Furthermore, all previous studies have used 
Dartfish software, which is not fully clinically applicable due to prohibitive costs. 
Analysis of software that is free at the point of access may reduce barriers between 
laboratory biomechanical analysis and clinical practice. In addition, the correlation 
between 3D biomechanics and 2D video for the knee in the sagittal plane is yet to be 
explored. Whilst knee position in the sagittal plane has been reported to be unaffected 
by patellofemoral taping or bracing during step descent (110), it has been reported to 
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correlate positively with patellofemoral joint stress during running (94) and can be 
successfully manipulated using step rate retraining.  
This opening thesis chapter has broadly explored the literature surrounding the 
development, persistence and management of PFP, with a specific focus on PFP in the 
recreational runner.    
This remainder of this thesis will: 
1. Further explore the magnitude of the patellofemoral problem by exploring the 
epidemiology and incidence of PFP.  
2. Synthesise the literature relating to biomechanical factors of interest for PFP 
development, persistence and treatment in a running specific cohort.  
3. Explore the reliability of kinematic marker placement, before determining the 
kinematic differences between males and females during treadmill running.   
4. Present data on the feasibility, effects, biomechanical mechanisms and clinical 
applicability of a step rate intervention in a mixed sex recreational running 
population with PFP. 
5. Investigate the validity of high frame rate 2D video in relation to 3D kinematic 
motion capture.    
The subsequent aims and objectives of this PhD thesis in chapter two arise from the 
research space described within this introduction. 
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2. Aims, objectives, impact and hypotheses    
The overarching aim of this thesis was to synthesise and extend the existing knowledge 
base, in order for clinicians to have the information and procedures required to 
understand lower limb biomechanics in relation to PFP in recreational runners. More 
specifically, I aimed to better understand and generate answers to unaddressed 
questions in the literature relating to the influence(s) of running biomechanics on the 
development, persistence and management of PFP.  
The impact should be improved clinical outcomes and better engagement with running 
as an exercise for health initiative in a large group of people with recurrent problems. 
More specifically, this information should allow clinicians to better implement 
biomechanical strategies for managing PFP in the recreational runner, resulting in 
longer-term treatment effects and potentially the development of preventative 
strategies.  
2.1. Specific aims and objectives 
The aims of the introduction were to provide a broad overview of the existing 
literature, to identify the resultant research space, to consider strengths and 
weaknesses of potential methodologies and to orientate the reader to the subsequent 
experimental chapters.  
The studies completed as part of this thesis had the following aims, objectives and 
alternate hypotheses:  
1. Quantify the etiology of PFP in multiple cohorts and determine the strength of 
identified evidence. The objectives for this aim were: 
a. Review and critically appraise the current prospective literature for risk 
factors for future PFP development (performing meta-analyses for 
variables where homogeneity allows), to determine factors of highest 
relevance (chapter three).  
b. Calculate the specific incidence of PFP from studies included within this 
systematic review (chapter three). 
H1 – that there would be an extended range, and increased strength of 
evidence, for potentially modifiable risk factors for PFP development, 
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both associative and causative, since the previous review. In addition, 
these risk factors would be of relevance to clinicians treating people 
with PFP.  
The impact of successfully achieving aim one should be to inform clinicians about the 
current evidence base relating to PFP incidence and risk factors for development, and 
the extent to which they can apply this knowledge to specific patient groups.  
2. Determine the role of lower limb biomechanics on the development, 
persistence and management running-related PFP, determining the strength of 
identified evidence. The objectives for this aim were: 
a. Review and critically appraise the current literature for risk factors, 
associated factors and treatment effects/mechanisms specific to lower 
limb biomechanics in running specific PFP cohorts (performing meta-
analyses for variables where homogeneity allows) and determine the 
factors of greatest relevance (chapter four). 
H1 – that a coherent narrative would emerge of modifiable 
biomechanical factors specific to a running population, that are also 
amenable to treatment. Further, that there would be multiple 
treatments of proven efficacy, but that the populations to which this 
was of proven relevance would be limited. 
b. Perform preliminary reliability testing on marker placement for 
kinematic motion analysis (chapter five). 
c. Conduct a case-control study to further determine the kinematic 
differences between runners with and without PFP during a treadmill 
run, to understand how prolonged running might influence mechanics 
and intervention design and simultaneously investigate the difference 
between the sexes (chapter five).    
H1 – that kinematic data collected during a prolonged run would identify 
significant differences when comparing PFP runners to matched 
controls, but also when comparing males and females. 
The impact of successfully achieving aim two should be to inform clinicians about the 
current evidence base relating to lower limb biomechanics and their contribution to 
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PFP development and persistence, and how these factors can extend to treatment 
mechanisms in recreational runners.  
3. To guide clinicians with respect to whether running retraining, formed of a 
7.5% step rate increase, in a mixed sex PFP cohort, has similar efficacy and 
biomechanical mechanisms to those established in previous studies. The 
objectives for this aim were:  
a. Obtain feasibility study funding (chapter six). 
b. Conduct a feasibility study to determine if a running retraining 
intervention (increasing step rate by 7.5% cued with an audio 
metronome) is feasible in a mixed-sex, UK cohort, at short-term (six 
week) follow up (chapter six). 
c. Collect symptom, function and mechanisms data throughout the course 
of a feasibility study to begin to inform upon biomechanical 
mechanisms, comparing to current existing literature (chapter six).   
H1 - that recruitment of a mixed sex cohort of runners with PFP would 
be successful and that a six-week step rate intervention would achieve 
significant changes in both pain and function. Furthermore, the likely 
kinematic mechanism through which these positive effects are derived 
would be predominantly hip driven.   
The impact of successfully achieving aim three should be to affirm the potential for 
running retraining (delivered using step rate feedback) in a mixed-sex UK cohort, giving 
clinicians a tailored treatment to apply where indicated.  
4. Increase the subsequent clinical applicability of biomechanical interventions to 
maximise impact and ensure that the procedures can be readily applied in 
usual clinical practice. The objectives for this aim were: 
a. Determine the validity and intra-rater reliability of high frame rate 2D 
video with respect to 3D kinematic motion capture (chapter seven).   
H1 - that high frame rate 2D video would give useful data that has 
acceptable accuracy with respect to 3D kinematic analyses.   
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The impact of successfully achieving aim four should be to inform clinicians whether 
they can use a pragmatic, clinically applicable tool to measure relevant running 
biomechanics in patients with PFP, particularly pre/post intervention.   
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3. Risk factors for patellofemoral pain: a systematic review & 
meta-analysis  
In the introduction chapter, only a limited number of risk factors associated with the 
development of PFP were identified based on pooled data from previous meta-analysis. 
Additionally, the most recent systematic review synthesising research related to risk 
factors completed their search in 2010, eight years ago. Consequently, a review of the 
epidemiology of PFP (risk factors and incidence) are presented in this chapter.  
Preliminary results of this review were presented at the 2017 International 
Patellofemoral Pain Research Retreat in Australia and the 2018 Danish Sports Medicine 
Congress in Copenhagen. This review was accepted for publication in the British 
Journal of Sports Medicine (Impact Factor 6.557) after two comprehensive rounds of 
peer review (appendix A), with proofs yet to be provided.    
The results presented within this chapter informed the subsequent systematic review 
investigating the association between lower limb biomechanics and recreational 
runners with PFP (chapter four), given the absence of data pertaining to risk factors for 
PFP development in this patient group group.  
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3.1. Introduction 
PFP is characterised by diffuse retropatellar or peripatellar symptoms throughout 
activities that load the knee during flexion, such as running, stair descent or squatting 
(4). It is described as a common pathology in both adolescents (111) and adults (21), 
with prevalence in the general population reported as 22.7% (16). However, the 
factors associated with PFP development and the incidence of the condition across a 
variety of populations remains under-evaluated due to limited prospective data and 
the homogeneity of studied populations (16, 112). As PFP is reported to be common 
across the lifespan and may be the precursor to patellofemoral osteoarthritis (3, 113), 
an improved understanding of the factors associated with the development of PFP and 
its incidence in differing populations is essential to prevent symptom development.  
With the incidence of PFP reported to be high (16) and symptoms persisting despite 
evidence based interventions (2), further investigation is warranted to understand 
variables that are associated with PFP development and subsequently deliver evidence 
based preventative strategies. In 1992, Van Mechelen et al. presented a theoretical 
model described as the ‘sequence of prevention’ for sports injury (see figure 4) to 
guide injury prevention development (114). With the incidence of PFP defined across 
populations (16) (stage one), an understanding of the aetiology (stage two) is required 
to identify the variables associated with the pathology development. A variable that 
has been found to be associated with future pathology development should be 
manipulated as a preventative strategy within a randomised controlled trial (RCT) 
(stage 3). The effectiveness of the implemented strategy should then be appraised by 
re-examining the incidence within a specific population (stage 4).  
 
 45 
 
4. The Van Mechelen model of injury prediction 
In 2012, Lankhorst et al. completed a systematic review of risk factors for PFP 
development (30), which identified a clear association between low knee extension 
strength and subsequent risk of PFP irrespective of measurement method, but no 
associations with other investigated variables. This is likely due to the low number of 
included studies (n=7), high data heterogeneity and data pooling being possible for just 
13 out of 137 identified variables, but was unexpected given the known crossectional 
association between PFP and multiple pathomechanical variables such as muscle 
function and lower limb biomechanics (46). 
Additional risk factors for future PFP development have been identified within other 
systematic reviews using data from single studies. Increased navicular drop in military 
recruits (36), greater peak hip adduction during running (82) and increased forces at 
foot level during both walking and running (37) have all been shown to increase the 
risk of future PFP development. Whilst these findings are statistically significant, the 
absence of data pooling and the small to moderate effect sizes limit the impact and 
clinical applicability. Given the number of subsequently published prospective studies, 
an updated systematic review on this topic is now appropriate. 
The aim of this systematic review was to provide researchers and clinicians with 
evidence synthesis concerning predictive variables for PFP to aid the development of 
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preventative interventions. The review was designed to synthesise the available 
evidence at stage two (aetiology) of the Van Mechelen model (see figure 1), and 
enable addressing stage three (preventative strategies). A secondary aim was to 
determine the incidence of PFP within the included studies, both as a heterogeneous 
condition and within specific homogenous cohorts. Specific objectives were to (i) 
establish prospective links between all investigated variables and future PFP 
development (ii) identify risk factors and PFP incidence specific to individual 
homogenous cohorts and (iii) inform future studies on PFP prevention.   
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3.2. Methods 
This systematic review was completed in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (115) and was 
registered with PROSPERO prior to completion of the initial search (registration 
number: CRD42016049327). 
3.2.1. Search strategy 
The search terms used by Lankhorst et al (30) were duplicated for the purpose of this 
review. The following terms were used for PFP: arthralgia AND knee joint OR anterior 
knee pain OR (patell* OR femoropatell* OR femoro-patell* OR retropatell*) AND (pain 
OR syndrome OR dysfunction). Key words used for risk factors were: risk factor OR as-
sociation OR relative risk OR odds ratio. We searched MEDLINE, Web of Science and 
SCOPUS from inception until February 2017, limited to papers published in the English 
language involving human subjects.  
MEDLINE was searched as it is listed as an essential database by the Cochrane group, 
with approximately 50% of RCTs indexed for MEDLINE (116). Web of Science was 
searched as it is reported as a minimum requirement of a systematic search by a 
recent exploratory study (117). SCOPUS was searched as an additional third database 
given its wide, interdisciplinary coverage and reported complimentary design to Web 
of Science (118) In order to be compliant with a PRISMA systematic search strategy, 
(116), an additional citing reference search was undertaken using Google Scholar up to 
March 2018, as well as hand searching of the reference lists of identified papers.  
3.2.2. Inclusion criteria 
A single investigator (AR) exported all studies identified by the search strategy to 
Endnote X7 (Thomson Reuters, Philadelphia). Eligibility criteria were adapted from the 
original review of Lankhorst et al (30), described as follows: (i) studies involving male 
or female subjects who developed subsequent PFP (synonyms including retropatella 
pain, chondromalacia or anterior knee pain); (ii) at least one variable investigated as a 
risk factor for PFP; and (iii) prospective study designs. Studies with less than 20 PFP 
subjects were excluded by the review of Lankhorst et al (30), but were included in this 
review. Two independent authors (BN and NL) reviewed all abstracts to determine 
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eligibility. Full texts were screened where eligibility could not be determined by the 
abstract alone and any discrepancies were resolved at a consensus meeting.  
3.2.3. Quality assessment  
Methodological quality and risk of bias of included studies was determined by 
combining the Newcastle-Ottawa scale (119) (NOS) and appraising the number of 
events per variable described by Peduzzi et al (120). The NOS is advocated by the 
Cochrane group for determining epidemiological cohort study quality (121) and was 
used successfully by the previous review of Lankhorst et al (30). The number of events 
per variable described by Peduzzi et al (120) was employed so that studies previously 
excluded by Lankhorst et al (30) could be included, but the eventual level of evidence 
appropriately adjusted should studies be found to have a high risk of bias. 
Eligible studies were independently rated by two authors blind to study authors and 
institutions (SL and NL), with discrepancies resolved at a consensus meeting. The NOS 
contains 8 categories relating to methodological quality and each study was given an 
eventual score out of a maximum of 8 points. A score of 0-3 points equated to a low 
quality (LQ) study, a score of 4-6 points equated to a moderate quality (MQ) study, 
with a score of 7-8 points required for a study to be given a score of high quality (HQ). 
In addition, HQ or MQ studies were reduced to either MQ or LQ respectively if they 
were determined to have a high risk of bias as a result of having less than 10 PFP 
participants for each investigated variable within their total sample (120). Inter-rater 
reliability of the NOS was calculated using the percentage agreement method.  
3.2.4. Data extraction 
Data related to study characteristics were initially extracted from all included studies 
by one author (AR) and subsequently reviewed by a second author (BN). This included 
participant numbers (separating those who developed PFP and those who did not), 
characteristics of these groups (such as population), study duration and publication 
details (author and year). A second author (BN) extracted all data pertaining to 
potential risk variables to be included in the meta-analysis. Means and standard 
deviations (SD) were extracted for variables of interest, which included (but were not 
limited to: anthropometrics and demographics (such as sex, body mass index (BMI)), 
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biomechanical variables (such as kinematics and kinetics) and muscle function (such as 
strength or onset timing).  
3.2.5. Statistical methods  
Statistical analyses were undertaken using Review Manager 5.0 (The Cochrane 
Collaboration, Copenhagen, Denmark). Analyses were completed initially by one 
author (BN) and subsequently reviewed by a second author (SL). Means and SD’s were 
extracted for continuous scaled variables and used to calculate a standardised mean 
difference (SMD) with 95% confidence intervals (CI’s). Calculated individual or pooled 
SMDs were categorised as small (0.59), medium (0.60–1.19) or large (1.20) as 
described by Hume et al (122). For nominal scaled variables, raw counts of injured and 
uninjured participants (e.g. PFP incidence in males and females) were extracted and 
used to calculate risk ratios (RR) with 95% CI’s, with a small effect indicated by a RR ≥ 
2.0 and a large effect by a RR ≥ 4.0 (122).  
Data were pooled and has been presented as both a heterogeneous PFP cohort and 
further pooled by specific homogeneous subgroup where possible. Where 
methodological approaches between studies were deemed to be adequately 
comparable a meta-analysis was performed and the level of statistical heterogeneity 
for pooled data were determined using I2 statistics (heterogeneity defined as I2 > 50%, 
p < 0.05). A random effects model (rather than a fixed effects model) was used due to 
the variation in study methods and populations, and the typically low number of 
studies, therefore reducing the possibility of a type 1 error (123). This decision was 
made apriori, as the Cochrane group state that the choice between a fixed-effects and 
random-effects meta-analysis should never be made on the basis of a statistical test 
for heterogeneity.     
Only outcomes incorporating data from a minimum of two studies are presented in the 
main body of the review, due to the risk of reporting inappropriate levels of evidence 
where data pooling were not possible.  
3.2.6. Evidence based recommendations  
Levels of evidence were assigned to each calculated variable (pooled or otherwise) as 
described by Van Tulder et al (116), which incorporate both assigned methodological 
quality of included studies and statistical outcomes:  
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Strong evidence: Pooled results derived from three or more studies, including a 
minimum of two high quality studies that are statistically homogenous.  
Moderate evidence: Pooled results derived from multiple studies, including at least 
one high quality study, that are statistically heterogeneous; or from multiple moderate 
or low quality studies which are statistically homogenous.  
Limited evidence: Results from one high quality study or multiple moderate or low 
quality studies that are statistically heterogeneous.  
Very limited evidence: Results from one moderate or low quality study.  
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3.3. Results 
3.3.1. Search results 
The search resulted in 3044 titles and abstracts identified for screening.  Following the 
removal of duplicates and studies that did not meet the inclusion criteria of the 
review, 18 studies involving a total of 4818 participants were included (see figure 5) 
(17-20, 22, 23, 25-29, 38, 42, 124-128), 483 of whom went on to develop symptoms 
consistent with PFP. This is indicative of a heterogeneous PFP incidence of 10%. 
Extracted data relating to study characteristics are presented in table 1.
 
5. Search flow chart for risk factors systematic review & meta-analysis adhering to PRISMA guidelines 
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1. Study characteristics for risk factors systematic review & meta-analysis 
Study NOS 
Score 
Risk 
of 
Bias 
Cohort PFP Sample 
Size 
Incidence Study 
Duration 
(Months) 
Boling ‘09 (23) H L Military 
(USA) 
40 
(M=16, 
F=24) 
1319 3% 30 
Duvigneaud ‘08 
(22) 
H 
 
L Military 
(Belgium) 
26 (F=26) 62 42% 1.5 
Finnoff ‘11 (26) MD H Adolescents 
(USA) 
5 (M=2, 
F=3) 
98 5% 9 
Foss ‘12 
(124) 
H L Adolescents 
(USA) 
39 (F=39) 262 15% 24 
Herbst ‘15 (25) H L Adolescents 
(USA) 
38 (F=38) 255 15% 12 
Hetsroni ‘06 (126) H L Military 
(Israel) 
61 
(M/F=?) 
405 15% 4 
Holden ‘15 (29) MD H Adolescents 
(Ireland) 
8 (F=8) 76 11% 24 
Luedke ‘16 (127) MD H Recreational 
Runners 
(USA) 
3 (M=1, 
F=2) 
57 5% 12 
Milgrom ‘91 (125) MD L Military 
(Israel) 
60 
(M=60) 
390 15% 3.5 
Myer ‘10 (28) MD H Adolescents 
(USA) 
14 145 10% 9 
Noehren ‘13 (20) MD H Recreational 
Runners 
(USA) 
15 (F=15) 400 3% 24 
Ramskov ‘15 (19) H L Recreational 
Runners 
(Denmark) 
24 
(M=10, 
F=14) 
629 4% 12 
Thijs ‘07 (27) H L Military 
(Belgium) 
36 
(M=25, 
F=11) 
84 43% 1.5 
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Thijs ‘08 (18) MD H Recreational 
Runners 
(Belgium) 
17 (M=1, 
F=16) 
102 17% 2.5 
Thijs ‘11 (17) MD H Recreational 
Runners 
(Belgium) 
16 (F=16) 77 21% 2.5 
Van Tiggelen ‘04 
(38) 
H L Military 
(Belgium) 
31 
(M=31) 
96 32% 1.5 
Van Tiggelen ‘09 
(42) 
H L Military 
(Belgium) 
26 
(M=26) 
79 33% 1.5 
Witvrouw ‘00 
(128) 
MD H Adolescents 
(Belgium) 
24 
(M=11, 
F=13) 
282 9% 24 
Key: H=high; MD=moderate; L=low; M=male; F=female, USA=United States of America 
3.3.2. Subgroups and PFP incidence  
Three distinct subgroups were identified during the data extraction process. There 
were a total of seven studies involving military recruits (22, 23, 27, 38, 42, 125, 126), 
six studies involving adolescents (25, 26, 28, 29, 124, 128) and five studies involving 
recreational runners (17-20, 127). Studies involving military recruits involved a total of 
2435 participants, 280 of whom went on to develop PFP, reflective of an incidence of 
11% (range 3%-43%). Studies involving adolescents involved a total of 1118 
participants, 128 of whom went on to develop PFP, reflective of an incidence of 11% 
(range 5%-15%). Studies involving recreational runners involved a total of 1265 
participants, 75 of whom went on to develop PFP, reflective of an incidence of 6% 
(range 4%-21%). 
3.3.3. Quality assessment  
After evaluation of study quality and risk of bias (119, 120), a total of 9 HQ studies (19, 
22, 23, 25, 27, 38, 42, 124, 126) and a further 9 MQ studies were identified (17, 18, 20, 
26, 28, 29, 125, 127, 128). Mean percentage agreement for the NOS was 95% (range 
89%-100%), indicating high inter-rater reliability (see table 2). The questions with the 
lowest percentage agreement were question five (does the study control for any 
confounding variables) and question seven (was follow up time clearly defined).    
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2. Individual study NOS scores and percentage agreement for risk factor systematic review & meta-analysis 
Question The cohort was 
truly or somewhat 
representative of a 
typical PFP cohort 
Selection of the 
non-PFP cohort was 
from the same 
community as the 
PFP cohort 
Ascertainment of 
PFP was made via 
secure record OR 
structured 
interview 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Cohorts were 
comparable on the 
basis of the design 
OR confounders 
controlled for 
Assessment of 
outcome was 
independent 
OR linked to 
medical records 
Follow up time 
was clearly 
defined 
Follow up was 
adequate (all 
subjects 
accounted for or 
≤20% attrition) 
 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2 
Boling (‘09) (23) Y Y Y Y Y Y Y Y Y Y Y Y N N Y Y 
Duvigneaud (‘08) (22) Y Y Y Y Y Y Y Y Y ? Y Y Y N Y Y 
Finnoff (‘11) (26) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Foss (‘12) (124) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Herbst (‘15) (25) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Hetsroni (‘06) (126) Y Y Y Y Y Y N N N Y Y Y Y Y Y Y 
Holden (‘15) (29) Y Y Y Y Y Y Y Y N N Y Y Y Y Y Y 
Luedke (‘16) (127) Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y 
Milgrom (‘91) (125) N Y N Y Y Y Y Y N Y Y Y Y Y Y Y 
Myer (‘10) (28) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Noehren (‘13) (20) Y Y Y Y Y Y Y Y Y Y Y Y Y Y N ? 
Ramskov (‘15) (19) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
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Thijs (‘07) (27) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Thijs (‘08) (18) Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N 
Thijs (‘11) (17) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Van Tiggelen (‘04) (38) Y Y Y Y Y Y Y Y Y ? Y Y Y Y Y Y 
Van Tiggelen (‘09) (42) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Witvrouw (‘00) (128) Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N 
Percentage Agreement 94% 94% 100% 100% 89% 100% 89% 94% 
Key: R=rater; Y=yes; N=no; ?=unable to determine
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3.3.4. Anthropometrics and demographics 
Data pooling were possible for seven individual variables (sex, height, weight, BMI, 
body fat percentage, age and limb length).  
Sex 
There is moderate evidence from three HQ (19, 23, 27) and four MQ (18, 26, 127, 128) 
studies that sex is not a risk factor for future PFP development (I2=73%, RR 1.33, CI 
0.76,2.34) (see figure 6). This outcome does not change when pooling data only for 
military subjects (moderate evidence, I2=91%, RR 0.82, CI 0.25,2.74), adolescents 
(moderate evidence, I2=0%, RR 1.23, CI 0.38,2.07) or recreational runners (moderate 
evidence, I2=76%, RR 3.08, CI 0.59,15.99). Whilst subgroup data pooling were non-
significant, six of the seven included studies that reported data on sex had a greater 
proportion of females in their PFP cohort (19, 23, 26, 27, 127, 128), the highest of 
which was observed in the recreational runner subgroup.  
 
6. Forrest plot detailing risk ratios for sex when comparing participants who developed PFP with 
controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain 
Height 
There is strong evidence from five HQ (19, 22, 27, 38, 42) and seven MQ (17, 18, 26, 
28, 29, 125, 128) studies that height is not a risk factor for future PFP development 
(I2=0%, SMD -0.08, CI -0.21,0.05) (see figure 7). This outcome does not change when 
pooling data for only military recruits (strong evidence, I2=41%, SMD -0.15, CI -
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0.42,0.12), adolescents (moderate evidence, I2=0%, SMD 0.06, CI -0.23,0.35) or 
recreational runners (moderate evidence, I2=0%, SMD -0.15, CI -0.43,0.13).  
 
7. Forrest plot detailing standardised mean differences for height when comparing participants who 
developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain 
Weight 
There is strong evidence from five HQ (19, 22, 27, 38, 42) and seven MQ (17, 18, 26, 
28, 29, 125, 128) studies that weight is not a risk factor for future PFP development 
(I2=0%, SMD 0.02, CI -0.11,0.16) (see figure 8). This outcome does not change when 
pooling data for only military recruits (strong evidence, I2=0%, SMD 0.05, CI -0.12,0.23), 
adolescents (moderate evidence, I2=28%, SMD -0.10, CI -0.46,0.25) or recreational 
runners (moderate evidence, I2=0%, SMD 0.10, CI -0.18,0.37). 
 
8. Forrest plot detailing standardised mean differences for weight when comparing participants who 
developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain 
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BMI 
There is strong evidence from four HQ (19, 22, 38, 124) and three MQ (17, 18, 26) 
studies that BMI is not a risk factor for future PFP development (I2=33%, SMD 0.10, CI -
0.12,0.32) (see figure 9). This outcome does not change when pooling data for only 
military recruits (moderate evidence, I2=65%, SMD 0.09, CI -0.48,0.65), adolescents 
(moderate evidence, I2=75%, SMD 0.23, CI -0.72,1.18) or recreational runners 
(moderate evidence, I2=0%, SMD 0.15, CI -0.13,0.43).  
 
9. Forrest plot detailing standardised mean differences for BMI when comparing participants who 
developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain; BMI – body mass index  
Body fat percentage 
There is moderate evidence from one HQ study (124) and 1 MQ study (128) that body 
fat percentage is not a risk factor for future PFP development in adolescents (I2=0%, 
SMD -0.13, CI -0.40,0.13) (see figure 10). This variable was not investigated in either 
military recruits or recreational runners.  
 
10. Forrest plot detailing standardised mean differences for body fat percentage when comparing 
adolescents who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; A – adolescents; SD – standard 
deviation; IV – inverse variance; CI – confidence intervals PFP – patellofemoral pain; % - percentage  
  
58 
Age 
There is strong evidence from three HQ (19, 27, 42) and five MQ studies (17, 18, 20, 
28, 29) that age is not a risk factor for future PFP development (I2=13%, SMD 0.06, CI -
0.13,0.25) (see figure 11). This outcome does not change when pooling data for only 
military recruits (moderate evidence, I2=0%, SMD -0.05, CI -0.36,0.27), adolescents 
(limited evidence, I2=80%, SMD 0.04, CI -0.98,1.07) or recreational runners (moderate 
evidence, I2=0%, SMD 0.16, CI -0.09,0.40).  
 
11. Forrest plot detailing standardised mean differences for age when comparing participants who 
developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain;  
Limb length 
There is limited evidence from two MQ studies (26, 125) that limb length is not a risk 
factor for future PFP development (I2=0%, SMD -0.01, CI -0.28,0.25). This variable was 
not investigated in recreational runners and no data pooling were possible within any 
individual subgroups.  
3.3.5. Lower limb alignment  
Data pooling were only possible for static Q-angle. Limited evidence from one HQ (23) 
and one MQ study (17) indicates that Q-angle is not a risk factor for future PFP 
development (I2=0%, SMD 0.06, CI -0.22,0.33) (see figure 12). No data pooling were 
possible for any identified subgroup.  
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12. Forrest plot detailing standardised mean differences for Q-angle when comparing participants who 
developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; R – recreational 
runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – patellofemoral 
pain;  
3.3.6. Strength measures 
Quadriceps strength  
When pooling all available data for quadriceps strength, regardless of cohort or 
measurement method, there is strong evidence that low quadriceps strength is a risk 
factor for future PFP development (moderate evidence, I2=65%, small SMD -0.32, CI -
0.42, -0.22).  
Data pooling were only possible for the military subgroup for all quadriceps strength 
measures. There is moderate evidence from two HQ studies (22, 38) that lower 
quadriceps strength is a risk factor for future PFP development when measured with 
an isokinetic dynamometer concentrically at 60˚/second (I2=0%, moderate SMD -0.66, 
CI -0.99,-0.32) (see figure 13) or concentrically at 240˚/second (I2=17%, small SMD -
0.49, CI -0.85,-0.12) (see figure 14).  
 
13. Forrest plot detailing standardised mean differences for Quadriceps strength measured 
concentrically at 60˚/s when comparing military recruits who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; SD – standard 
deviation; IV – inverse variance; CI – confidence intervals PFP – patellofemoral pain;  
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14. Forrest plot detailing standardised mean differences for Quadriceps strength measured 
concentrically at 240˚/s when comparing military recruits who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; SD – standard 
deviation; IV – inverse variance; CI – confidence intervals PFP – patellofemoral pain;  
For normalised quadriceps strength measured with an isokinetic dynamometer, there 
is moderate evidence from two HQ studies (22, 38) that lower quadriceps strength is a 
risk factor for future PFP development when normalised by body mass  at 60˚/second 
(I2=0%, moderate SMD -0.61, CI -0.94,-0.28) (see figure 15) or at 240˚/second (I2=0%, 
small SMD -0.53, CI -0.87,-0.20) (see figure 16). When normalised by BMI, moderate 
evidence remains that lower quadriceps strength is a risk factor for future PFP 
development when measured at both 60˚/second (I2=0%, moderate SMD -0.69, CI -
1.02,-0.35) (See figure 17) and 240˚/second (I2=0%, small SMD -0.51, CI -0.84,-0.18) 
(see figure 18).  
 
15. Forrest plot detailing standardised mean differences for Quadriceps strength normalized by body 
mass and measured concentrically at 60˚/s when comparing military recruits who developed PFP 
with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; SD – standard 
deviation; IV – inverse variance; CI – confidence intervals PFP – patellofemoral pain;  
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16. Forrest plot detailing standardised mean differences for Quadriceps strength normalized by body 
mass and measured concentrically at 2400˚/s when comparing military recruits who developed PFP 
with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; SD – standard 
deviation; IV – inverse variance; CI – confidence intervals PFP – patellofemoral pain;  
 
17. Forrest plot detailing standardised mean differences for Quadriceps strength normalized by BMI and 
measured concentrically at 60˚/s when comparing military recruits who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; SD – standard 
deviation; IV – inverse variance; CI – confidence intervals PFP – patellofemoral pain;  
 
18. Forrest plot detailing standardised mean differences for Quadriceps strength normalized by BMI and 
measured concentrically at 240˚/s when comparing military recruits who developed PFP with 
controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; SD – standard 
deviation; IV – inverse variance; CI – confidence intervals PFP – patellofemoral pain;  
For quadriceps strength measured isometrically with a hand-held dynamometer (HHD), 
there is moderate evidence from one HQ (23) and one MQ study (125) that lower 
quadriceps strength is not a risk factor for future PFP development  (I2=82%, small 
SMD -0.25, CI -0.74,0.25).  
Hamstrings strength 
There is moderate evidence from two HQ studies (22, 38) that hamstring strength is 
not a risk factor for future PFP development in the military when measured with an 
isokinetic dynamometer concentrically at 60˚/second (I2=0%, SMD -0.09, CI -0.42,0.24) 
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or 240˚/second (I2=0%, SMD -0.10, CI -0.43,0.22). This variable was not investigated in 
either adolescents or recreational runners.  
Hip strength  
There is moderate evidence from one HQ (23) and two MQ studies (17, 26) that hip 
extension (I2=0%, SMD -0.18, CI -0.44,0.09) (see figure 19), hip internal rotation 
(I2=20%, SMD -0.09, CI -0.42,0.23) (see figure 20) and hip external rotation (I2=0%, 
SMD -0.17, CI -0.43,0.10) (see figure 21) strength, measured isometrically with a HHD, 
are not risk factors for future PFP development.  There is also limited evidence from 
two MQ studies (17, 26) that both hip adduction strength (I2=0%, SMD -0.20, CI -
0.67,0.28) (see figure 22) and hip flexion strength (I2=52%, SMD -0.08, CI -0.82,0.67) 
(see figure 23) are not risk factors for future PFP development when measured with a 
HHD. No data pooling were possible for any identified subgroup for these strength 
measures.  
 
19. Forrest plot detailing standardised mean differences for hip extension strength when comparing 
participants who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain;  
 
20. Forrest plot detailing standardised mean differences for hip internal rotation strength when 
comparing participants who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain;  
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21. Forrest plot detailing standardised mean differences for hip external rotation strength when 
comparing participants who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain;  
 
22. Forrest plot detailing standardised mean differences for hip adduction strength when comparing 
participants who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain;  
 
23. Forrest plot detailing standardised mean differences for hip flexion strength when comparing 
participants who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain;  
There is moderate evidence from two HQ (23, 25) and two MQ (17, 26) that hip 
abduction strength is not a risk factor for future PFP development  (I2=86%, SMD 0.25, 
CI -0.38,0.88) (see figure 24) when measured isometrically with a HHD. When data 
were pooled for the adolescent cohort, there is moderate evidence from one HQ (25) 
and one MQ study (26) that higher hip abduction strength is a risk factor for future PFP 
development (I2=0%, SMD 0.71, CI 0.39,1.04) (see figure 25) when measured with 
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isometrically a HHD. Data pooling were not possible for the military or recreational 
runner subgroups.  
 
24. Forrest plot detailing standardised mean differences for hip abduction strength when comparing 
participants who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain;  
 
25. Forrest plot detailing standardised mean differences for hip abduction strength when comparing 
adolescents who developed PFP with controls.  
Key: HQ – high quality; MQ – medium quality; LQ – low quality; M – military recruits; A – adolescents; R 
– recreational runners; SD – standard deviation; IV – inverse variance; CI – confidence intervals PFP – 
patellofemoral pain;  
3.3.7. Biomechanics 
Dynamic knee valgus angle  
Moderate evidence from one HQ study (23) and one MQ study (29) indicates that knee 
valgus angle during a jump land task is not a risk factor for future PFP development 
(I2=99%, SMD 4.17, CI -4.19,12.53). No data pooling were possible for any identified 
subgroup. 
Foot kinetics 
One HQ study (27) and one MQ study (18) investigated foot kinetics during walking 
and running respectively. When these data were pooled, moderate evidence indicates 
no significant associations between time to peak force at any investigated region of 
the foot, which included the hallux, the metatarsal heads and the medial/lateral heel.       
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3.4. Discussion  
This systematic review aimed to provide a synthesis of the evidence concerning 
predictive variables for PFP development. Despite the inclusion of 11 additional 
prospective studies and 55 additional variables when compared to the previous review 
of Lankhorst et al (30), high data heterogeneity and a limited ability to pool da/ta 
remained. Just two predictive variables, lower isokinetic quadriceps strength in the 
military and higher isometric hip abduction strength in adolescents, were identified. 
Heterogeneous incidence of PFP was found to be 10%, with incidence also identified 
within the specific homogenous cohorts of military recruits (11%), adolescents (11%) 
and recreational runners (6%).  
The finding that lower isokinetic quadriceps strength is predictive of future PFP 
development in a military cohort (22, 38) is in agreement with the previous review of 
Lankhorst et al (30). Unfortunately, the strength of this evidence has not changed, as 
no new prospective studies using an isokinetic dynamometer to measure quadriceps 
strength have been published since 2011. Data from two studies investigating 
isometric quadriceps strength in military cohorts (23, 125), not included by Lankhorst 
et al, have been included in this review and demonstrated no significant association 
with future PFP development. Whilst this could be interpreted as conflicting evidence, 
it could be that isometric muscle testing may not be sensitive enough to identify 
military recruits at risk of PFP. This limits the clinical applicability of these results, as 
isometric testing with a HHD is a more accessible tool for clinicians to use when 
measuring muscle strength.  
Data from a single study (25) reports that low baseline isokinetic quadriceps strength 
was not identified as a risk factor for future PFP development in an adolescent group. 
Whilst this further validates the importance of investigating risk factors within 
homogenous groups, it is also important to consider the implications of these findings 
in relation to risk modification interventions within differing populations.  A similar 
disparity between adult and adolescent populations has been observed 
crossectionally, with no differences in hip or knee strength having been reported when 
comparing adolescents with PFP to a group of asymptomatic controls matched for 
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both age and sex (129), but significant strength deficits identified in adults with PFP 
compared to control groups (31, 44). These findings offer indications as to why 
rehabilitation programmes have been shown to be of significant benefit in adults with 
PFP (130, 131), but are of only limited additional benefit to education alone in 
adolescents (132). 
In contrast to the quadriceps data, low baseline hip strength, regardless of test 
direction, was not found to be a risk factor for future PFP development in military 
recruits or recreational runners. However, pooled data from two studies (25, 26) 
indicate that higher baseline isometric hip abduction strength predicts future PFP 
development in adolescents. Herbst et al (25) make the suggestion that greater hip 
abduction strength could be the result of increased eccentric hip abductor demands 
due to increased peak hip adduction during dynamic tasks. When pooling data from 
both military and adolescent cohorts, dynamic knee valgus angle was also not found to 
be a risk factor for future PFP development. However, Holden et al (29) reported 
higher knee valgus displacement in adolescent females who develop PFP (mean 
difference 7.8˚). Despite these reported kinematic deficits, hip strength and altered 
kinematics during dynamic tasks are consistently negatively correlated (133), 
contradicting this hypothesis.  
A more plausible explanation for the association between higher isometric hip 
abduction strength and future PFP in young adolescents is a high level of physical 
activity, common within this age group (134). The mean age of the Herbst et al (25) 
cohort is 12.7 years and may therefore have higher lower limb muscle strength as a 
consequence of high physical activity levels. It may be that lower limb muscle strength 
correlates with duration of symptoms in adolescents, with strength deficits presenting 
later in life when symptoms persist and if activity levels subsequently reduce (129). As 
a result, it is sensible to question the role of increasing muscle strength in adolescent 
cohorts as a preventative measure. It is advised that future prospective studies both 
report and stratify for activity levels when investigating the association between 
strength variables and future PFP development.  
In 2011 Coppack et al (135) reported a significant reduction in PFP risk after 
completion of a quadriceps and gluteal strengthening programme when compared to a 
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non-specific control group. It is surprising that an exercise intervention designed to 
increase quadriceps strength has not been investigated further, given both level one 
(30) and two (135) evidence identifying quadriceps weakness as a preventative 
treatment target. Future studies aiming to reduce the incidence of PFP in the military 
should give priority to exercise protocols designed to increase quadriceps strength. 
Whilst higher baseline hip abduction strength was found to increase the risk for future 
PFP development in adolescents, this is potentially a surrogate indicator of activity 
level. Given the promise that education and load management interventions are 
demonstrating within this population (132), we suggest that these strategies are 
prioritised in future studies designed to reduce the incidence of PFP in adolescents.   
Multiple variables often described as risk factors for future PFP development, perhaps 
due to strong associations in cross-sectional studies, were not found to be so in this 
meta-analysis. Participant height, weight, BMI, body fat percentage, age and Q-angle 
were not to predict future PFP development in any cohort. The recent systematic 
review of Hart et al (136) reports a crosssectional association between high BMI and 
both PFP and patellofemoral osteoarthritis (PFOA) in adults, again perhaps due to a 
reduction in activity levels after symptom development (137). Higher BMI was not 
reported to be a risk factor for future PFP development in either adults or adolescents, 
nor was a high BMI linked to intervention outcomes in participants with PFP (136). 
Whilst these data question the biologically plausible suggestion that a high BMI 
contributes to PFP development, it remains plausible that high BMI may influence 
treatment outcomes and this suggestion requires further investigation (136).   
Using data from the work of Boling et al (23), the previous 2012 review of Lankhorst et 
al (30) reported that females are at a higher risk of developing PFP within the military 
(odds ratio: 2.23, 95% CI 1.16,4.10). Our results are in conflict with this, with pooled 
data from 7 studies (18, 19, 23, 26, 27, 127, 128) identifying no significant links 
between the female sex and future PFP development. Pooling data for the identified 
individual subgroups is also non-significant, but six of the seven studies including data 
on sex report a greater proportion of females developing subsequent PFP. The largest 
proportion of females occurs amongst the recreational runner subgroup and this is in 
fact statistically significant when a fixed-effects model is used for the meta-analysis, 
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meaning observed results are most likely a result of selection bias in source studies. 
However, given the low number of studies (n=3) and high heterogeneity, a fixed-
effects model is inappropriate and increases the chance of sustaining a type I error 
(123). Given the absence of a causal association between the female sex and future 
PFP development, the frequent bias towards the female sex in trial sampling and the 
need to control for sex as a confounder may not be necessary. 
Using data only from studies included in this review, heterogeneous incidence of PFP 
was found to be 10%, demonstrating that PFP affects up to one in ten persons across 
multiple populations. The recent systematic review of PFP incidence and prevalence by 
Smith et al (16) identified a wide range of PFP incidence amongst military recruits (9.7-
571.4 cases per 1000 person-years), which is similar to the incidence range identified 
by this review (3-43%). The variance is likely explained by the four studies (22, 38, 42, 
126) included in this review not included by Smith et al (16), and the three studies 
included by Smith et al (16) not eligible for inclusion within this review (135, 138, 139). 
The incidence range for PFP within adolescent cohorts are identical (5-15%), despite 
two studies from this review (29, 124) not being included by Smith et al (16).  
3.4.1. Limitations and future research directions 
This review is not without limitations, which must be considered when interpreting the 
results. There is currently no accepted method for determining study methodological 
quality or ascertaining risk of bias. Whilst the NOS is advocated by the Cochrane 
Group, it is possible that using a different quality appraisal tool may have yielded 
different levels of eventual evidence. It should also be considered that the NOS does 
not have a component pertaining to the reliability of exposure data collection, 
focussing more on the validity of outcome data. As per the PRISMA guidelines (115) 
three databases were searched, but is it also possible that increasing the number of 
databases searched may have yielded additional studies for inclusion. An attempt was 
made to mitigate this risk by completing a citing reference search in Google Scholar in 
addition to hand searching the reference lists of included studies. It must be stressed 
that incidence data has been calculated only from included studies, and the addition of 
other epidemiology studies that do not fit the inclusion criteria of this review would 
have affected the figures reported. It was also not possible to express incidence data 
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relative to a timeframe given the high heterogeneity observed between included 
studies.      
Some included studies provided data that were not suitable for inclusion in a meta-
analysis (i.e. no mean/SD or raw counts) and efforts to obtain raw data directly from 
study authors were unsuccessful. Despite the addition of 11 new studies, ability to 
pool data were limited, which is partly attributable to the 116 individual variables 
investigated across the 18 included studies that could not be pooled. A total of 8 
studies (17, 18, 20, 26, 28, 29, 127, 128) failed to adhere to the rule of 10 (120), that is 
ensuring a minimum of 10 PFP events for each variable of interest, resulting in a high 
risk of bias and reduced methodological quality. Future studies are encouraged to 
investigate an appropriate number of variables within an adequate sample, that have 
the potential for future pooling with existing data to affect the strength of level 1 
evidence, unless there is clear plausibility to investigate a novel variable.  
Given the lack of associations identified by this review (pooled data or otherwise), it is 
sensible to suggest that perhaps the current body of research is not placing 
appropriate focus on variables of interest. Altered hip and knee kinematics during 
running are known to have moderate to strong cross-sectional association with PFP 
(82), yet there remains just one prospective investigation of these variables in female 
runners only (20). There is also an emerging evidence base surrounding the association 
between psychological variables and PFP, with levels of anxiety, depression, 
catastrophising and fear of movement reported to be elevated in persons with PFP by 
a recent systematic review (35). Future studies should focus on attempting to establish 
an association between these variables and PFP development.  
The prospective studies included within this review have sought to detect an 
association between single variables and risk of PFP development. The inherent 
limitation of this approach is the inability to consider interactions between multiple 
variables. Consequently, research needs to move towards a complex systems approach 
to better understand injury aetiology (140). Rather than endeavouring to identify a 
singular causal factor, studies should be designed to investigate the interactions 
between a ‘web of determinants’ that are likely to be non-linear in nature (141). This 
approach has significant methodological challenges and requires the use of a statistical 
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learning approach such as a Bayesian network (142). Examples of variables that could 
fit into a web of determinants for PFP from the published literature include muscle 
strength (quadriceps and gluteal), hip/knee kinematics, activity levels/sporting 
workload and psychosocial measures (see figure 26).  
 
26. Potential causal inference diagram for PFP   
No variable included within this systematic review identified a link with future PFP 
development in recreational runners. High peak hip adduction is known to be 
associated with future PFP development in female runners (20), and future studies 
should further explore the causal associations between lower limb kinematics and PFP. 
Whist not presented in a fashion that allowed for data pooling, Ramskov et al (19) 
report that higher eccentric hip abduction strength reduces the risk of future PFP 
development in recreational runners, using a time to event analysis. The distinct 
limitation of this study design is that no guidance was given to the included runners 
regarding training frequency or intensity which is likely to be a significant confounder, 
as more aggressive run volume progressions have been shown to increase the risk of 
injury development (143). Future studies should focus on further exploring the causal 
associations between both muscle strength and activity level with respect to future 
PFP development in recreational runners.         
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3.5. Conclusion 
Low quadriceps strength, measured using an isokinetic dynamometer and whether or 
not normalised to either bodyweight or BMI, is a risk factor for future PFP 
development in military recruits and should be investigated as a preventative strategy 
in a future RCT. Whilst higher hip abduction strength is a risk factor for future PFP 
development in adolescents, this may simply be a composite of activity level. PFP is a 
common pathology in multiple populations, with incidence found to be 10%, with a 
higher incidence seen amongst military recruits and adolescents compared to 
recreational runners. Overall, our understanding of what contributes to the 
development of PFP is inadequate and requires further scientific exploration, though 
the relationship between given variables and PFP risk is likely to be both complex and 
individual. This work represents a strong case for future trials requiring stronger 
preliminary risk factor identification to improve outcomes.      
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4. Runners with patellofemoral pain have altered biomechanics 
which targeted interventions can modify: a systematic 
review and meta-analysis  
Limited risk factors for the development of future PFP were identified in the systematic 
review that forms chapter three. Furthermore, no risk factors associated with the 
development of running-related PFP from pooled data were identified. As a result, a 
systematic review of the specific biomechanical factors that are associated with the 
development, persistance and management of running-related PFP are presented in 
this chapter.  
Preliminary results of this review were presented at the 2015 Danish Sports Medicine 
Congress in Copenhagen and the 2015 International Patellofemoral Pain Research 
Retreat in Manchester. This review was accepted for publication in Gait & Posture 
(Impact Factor 2.347) after two rounds of comprehensive peer review (appendix B). A 
translational publication for the Physio First ‘In Touch’ journal was also produced as 
part of a special issue on PFP, based on data from this systematic review (appendix C).   
The results presented within this chapter informed the subsequent case-control study 
(chapter five), by identifying a dearth of literature investigating running kinematics 
when comparing between the sexes. Additionally, the results informed the subsequent 
step rate feasibility study (chapter six), by identiying potential efficacy and kinematic 
treatment targets following  running retraining interventions.  
  
  
73 
4.1. Introduction  
Participation in running has increased in recent years, as a result of the increased 
awareness of exercise for good health (8). Although running has been linked to 
improvements in cardiovascular disease (144), improved mental health (145) and a 
reduced risk of diabetes (146), it is also associated with a greater incidence of 
musculoskeletal injury (12). Dependent on the source (8, 13), the overall lower 
extremity injury incidence is suggested to range from 18% to 92%, with the most 
significant risk factor for injury being a previous running injury (12). The most common 
running overuse injury is patellofemoral pain (PFP), with an incidence of 3% to 15% in 
active populations stated amongst the literature (23, 112, 126).  
The source of symptoms in PFP remains highly debated (147). A well-established 
explanatory reason is increased patellofemoral joint stress. Elevated patellofemoral 
joint stress has been reported in individuals with PFP during fast walking (148) and 
squatting tasks (149) and is thought to result in afferent nociceptive drive from 
subchondral bone (48), although it must be stated that the most recent PFP consensus 
statement highlighted that the source of pain in PFP remains unclear (80). Small 
changes in patellofemoral joint kinematics, of the order of five degrees of femoral 
internal rotation, have been shown to increase osteochondral shear stress (50), and 
therefore increased patellofemoral lateral patella facet contact pressures. Increases in 
vertical loading rates (and subsequent patellofemoral reaction forces) have also been 
reported in runners with PFP (150). Therefore, a link between possible biomechanical 
mechanisms and pain development can be suggested, making such variables of great 
interest from a treatment mechanism perspective.   
The cause of altered kinematics and PFJ stress in PFP is considered multifactorial, with 
various intrinsic and extrinsic factors thought to contribute. Several kinematic factors, 
including excessive frontal/transverse plane motion of the lower limb (dynamic knee 
valgus), have been theorised to increase loading forces acting on the lateral facet of 
the patella (45). One previous systematic review summarising literature to 2008 (151) 
reported that rearfoot eversion, knee external rotation and hip adduction were 
increased in runners with PFP (151). However, findings related to hip internal rotation 
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and adduction were reported to be inconsistent, with a paucity of data preventing 
meta-analysis. Further, a dearth of prospective research at that time prevented 
conclusions about causal relationships between kinematics and PFP presentation and 
intervention outcomes (151). 
Alongside kinematics, muscle function of the quadriceps and gluteals is thought to play 
a role in both the development and management of PFP. Reduced knee extension 
strength has been identified as a risk factor (30). Additionally, weakness or delayed 
activation of vastus medialis obliquus (VMO) is also historically described as a risk 
factor and rehabilitation target for PFP, although recent research has questioned its 
importance (152). There is known to be an association between reduced gluteal 
strength and PFP (34), but the causative relationship of this factor has recently been 
questioned, highlighting a discrepancy between prospective and cross-sectional 
findings (17, 32, 34).  
PFP is often recalcitrant, with as many as 91% of suffers continuing to report 
symptoms beyond four years following diagnosis (153). This is particularly problematic 
given the recent suggestion that PFP may be an early stage of a continuum ultimately 
leading to patellofemoral joint osteoarthritis (3). Typical exercise interventions 
(encompassing both the hip and the knee) appear to have a positive effect on pain and 
function (56, 154, 155), but have been reported not to alter running kinematics such as 
knee valgus linked to PFP (88).  Given that a kinematic mechanism may be required to 
achieve a long-term resolution in PFP, research surrounding movement feedback 
interventions and running retraining are starting to be explored (156, 157). Foot 
orthoses are another intervention which aims to alter lower limb kinematics and have 
been shown to improve outcomes in PFP patients at six weeks follow up, but their 
long-tem outcomes and place within a multi-modal rehabilitation, particularly in a 
running population, remains unclear (69).  
The aim of this systematic review was to guide the treatment and prevention of PFP by 
synthesising prospective, observational and intervention studies that measure clinical 
and biomechanical outcomes in symptomatic running populations. Specific objectives 
included (i) to establish the biomechanical differences (including kinematics, kinetics 
and neuromuscular) between individuals with and without PFP in a running 
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population, identifying causal relationships where possible; and (ii) define the 
biomechanical outcomes of interventions used in the conservative management of 
PFP. It is anticipated that the impact of this review will be to improve upon the 
prevention and treatment outcomes of PFP during running by identifying when 
biomechanical variables should be targeted as part of a management plan, and by 
what mechanisms these variables may be best approached.  
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4.2. Methods 
The protocol for this systematic review was designed in accordance with the PRISMA 
statement (115).  
4.2.1. Search strategy 
MEDLINE, Web of Science and CINAHL were searched from inception until April 2015. 
MEDLINE and Web of Science were searched using the rationale described in chapter 
three. CINAHL was searched as an allied health professional specific database that 
offers an alternative source of primary studies, and has been reported to result in 
unique search results (158). The search strategy was limited to publications in the 
English language and those involving human subjects. In order to be compliant with a 
PRISMA systematic search strategy (116), additional hand searching of the reference 
lists of identified papers and discussions with field experts (e.g. physiotherapists and 
podiatrists) regarding relevant publications were conducted, alongside a citing 
reference search using Google Scholar.  
4.2.2. Eligibility criteria 
All studies identified by the search strategy were exported to Endnote version X7 
(Thomson Reuters, Philadelphia) by one investigator. Adapted from the original review 
of Barton et al (151), eligibility criteria applied to manuscript titles were: (i) studies 
involving male or female subjects with PFP (multiple terms including retropatellar pain, 
chondromalacia or anterior knee pain) ; (ii) a 3D kinematic, kinetic or EMG outcome 
measure captured during treadmill or over-ground running; and (iii) prospective, case-
control or intervention study design. Exclusion criteria included studies that used 2D 
methods of kinematic measurement (due to insufficient validity and reliability), studies 
where data was collected during a task other than running and studies using a case 
series methodology design.  Two authors (BN and PH) reviewed all abstracts to 
determine eligibility and full texts were screened to confirm eligibility where there was 
uncertainty from the abstract alone.  A third reviewer (CB) was available for any 
discrepancies but was not required.  
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4.2.3. Quality assessment  
The Downs and Black Quality Index (159) was used to determine quality for case-
control and prospective studies. Use of Downs and Black is advocated by the Cochrane 
Group (121) and is a validiated tool for both randomised and non-randomised control 
trials, with intra-class correlation coefficients (ICC) of 0.75 to 0.89 previously reported 
(159). A modified version for case-control studies (scored out of 16) as used by Barton 
et al (151), which has been reported to have good inter-rater reliability when grading 
similar studies, was applied. Studies with scores of eleven or greater were considered 
to be ‘high quality’ (HQ), studies with scores from six to ten were considered to be 
‘moderate quality (MQ) and studies with scores five or lower were considered to be 
‘low quality’ (LQ). 
The PEDro scale was used to determine the quality of the intervention studies, as it 
was specifically designed to evaluate the quality of physical therapy interventions 
(160).  The PEDro scale has previously been reported to be a valid and reliable tool, 
with ICC’s of 0.68 for consensus ratings (160). A score of 6-8 on the PEDro scale was 
considered to be HQ, scores of 4-5 were considered to be MQ and studies that scored 
below 4 were considered to be LQ, based on the work of Moseley (161).  
Two independent raters (BN and RG), blinded to author and publication details 
appraised each study, with any discrepancies resolved at a consensus meeting. Inter-
rater reliability was calculated using percentage agreement. 
4.2.4. Data management  
Data pertaining to study characteristics were extracted from all included studies by 
one author (162). This included participant numbers and characteristics of the PFP and 
control groups, publication details (author, year, and country), biomechanical variables 
analysed, examiner details, PFP outcome, duration of study and covariates 
investigated, for analysis of possible mechanisms (see tables 3 and 4). Corresponding 
authors were contacted where appropriate data was not included in the publication 
and recorded as ‘not reported’ (NR) if this was unsuccessful. Variables of interest in 
this review included (but were not limited to) peak hip adduction, internal rotation and 
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flexion, contralateral pelvic drop, rearfoot eversion, peak metatarsal force, 
patellofemoral joint stress and peak/average gluteal electromyography. 
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3. Summary of study characteristics for included prospective and case-control studies for biomechanics systematic review & meta-analysis 
 
Study Study Population Study Design Injury Outcome Injured Control Outcome 
Variables 
Total Age (Mean ±) Total Age (Mean ±) 
Rodrigues  
2013 (78) 
Heel Strike Runners Case-Control Anterior Knee Pain 17 29.8 ±7.0 19 34.0 ±10.0 Kinematics 
Rodrigues  
2013 (163) 
Heel Strike Runners Case-Control Anterior Knee Pain 17 29.8 ±7.0 19 34.0 ±10.0 Kinematics 
Souza  
2009 (39) 
Local Orthopaedic 
Clinics 
Case-Control Patellofemoral Pain 21 Not Reported 20 Not Reported  Kinematics, EMG 
Willson  
2011 (164) 
University Fitness 
Centre 
Case-Control Patellofemoral Pain 20 21.3 +2.6 20 21.6 ±4.5 Kinematics, EMG 
Besier  
2009 (165) 
Not Stated Case-Control Patellofemoral Pain 27 30.5 +4.5 (m) 
28.7 ±4.6 (f) 
16 27.2 +3.0 (m) 
28.8 ±4.7 (f) 
EMG 
Bazett-Jones  
2013 (166) 
University Community Case-Control Patellofemoral Pain 19 26.0 ±5.5 19 24.3 ±4.3 Kinematics 
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Cunningham  
2014 (167) 
Recreational Runners Case-Control Patellofemoral Pain 19 25.8 ±6.1 11 26.5 ±13.4 Kinematic 
Coupling 
Dierks  
2011 (168) 
Recreational Runners Case-Control Patellofemoral Pain 20 24.1 ±7.4 20 22.7 ±5.6 Kinematics 
Noehren  
2012 (52) 
Competitive Runners Case-Control Patellofemoral Pain 16 27.0 ±6.0 16 25.0 ±4.0 Kinematics 
Noehren  
2012 (53) 
Recreational Runners Case-Control Patellofemoral Pain 15 27.0 ±6.0 15 25.0 ±4.0 Kinematics 
Souza  
2009 (54) 
Local Physiotherapy 
Clinics 
Case-Control Patellofemoral Pain 19 27.0 ±6.0 19 26.0 ±4.0 Kinematics 
Stefanyshyn  
2006 (162) 
Sports Medicine Clinic Case-Control Patellofemoral Pain 20 34.6 ±9.8 20 34.3 ±10.3 Kinematics 
Willy  
2012 (51) 
University Running 
Club 
Case-Control Patellofemoral Pain 18 24.7 +4.9 (m) 
22.2 ±3.8 (f) 
18 23.4 ±3.6 Kinematics 
Willson  
2008 (169) 
 
Active Females Case-Control Patellofemoral Pain 20 23.3 ±3.1 20 23.7 ±3.6 Kinematics 
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Wirtz  
2012 (170) 
Recreational Runners Case-Control Patellofemoral Pain 20 21.3 ±2.6 20 21.6 ±4.4 Joint Stress 
Pal  
2011 (171) 
University Sports Clinic Case-Control Patellofemoral Pain 40 28.9 ±4.6 15 28.2 ±3.9 EMG 
Esculier  
2015 (172) 
Recreational Runners Case-Control Patellofemoral Pain 21 34.1 ±6.0 20 33.2 ±6.0 Kinematics, 
Kinetics, EMG 
Chen  
2014 (173) 
Orthopaedic Clinic Case-Control Patellofemoral Pain 20 27.9 ±6.7 20 26.1 ±7.2 Patellofemoral 
Reaction Force 
Thijs  
2008 (18) 
Novice Recreational 
Runners 
Prospective Patellofemoral Pain 17 39.4 ±10.3 85 37.6 ±9.4 Plantar 
Pressures 
Noehren  
2013 (20) 
Heel Strike Runners Prospective Patellofemoral Pain 15 27.0 ±10.0 15 27.0 ±10.0 Kinematics 
Macintyre  
1992 (174) 
Recreational Runners Case-Control Patellofemoral Pain 5 Not Reported  12 Not Reported EMG 
 
Key: ± = standard deviation; EMG = electromyography; m=male; f=female   
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4. Summary of study characteristics for included intervention studies for biomechanics systematic review & meta-analysis 
Study Study Population Intervention 
Period 
Injury Outcome Injured Control Outcome  
Variables 
Exercise Therapy    Total Age (Mean ±) Total Age (Mean ±)  
Earl   
2011 (84) 
Female College 
Students 
8 Weeks Patellofemoral 
Pain 
19 22.7 ±7.2 N/A N/A Kinematics, 
Kinetics 
Ferber  
2011 (83) 
Recreational 
Runners 
3 Weeks  Patellofemoral 
Pain 
15 35.2 ±12.2 10 29.9 ±8.3 Kinematics 
Orthoses         
Boldt  
2013 (175) 
Recreational 
Runners 
Immediate  Patellofemoral 
Pain 
20 21.3 ±2.6 20 21.6 ±4.5 Kinematics 
Rodrigues  
2014 (176) 
Heel Strike 
Runners 
Immediate  Patellofemoral 
Pain 
17 29.8 ±7.2 16 34.2 ±10.9 Kinematics 
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Running Retraining         
Noehren  
2012 (100) 
Recreational 
Runners 
2 Weeks  Patellofemoral 
Pain 
10 23.3 ±5.8 N/A N/A Kinematics, 
Kinetics 
Willy  
2012 (101) 
Recreational 
Runners 
2 Weeks  Patellofemoral 
Pain 
10 22.4 ±5.0 N/A N/A Kinematics 
Willson  
2014 (95) 
Heel Strike 
Runners 
Immediate Patellofemoral 
Pain 
10 20.8 ±3.7 10 21.0 ±2.3 Joint Stress 
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4.2.5. Statistical methods  
All statistical analyses were completed in Review Manager 5.0 (The Cochrane 
Collaboration, Copenhagen, Denmark) initially by one author (BN) and subsequently 
checked by a second author during a consensus meeting (CB).  Means and SD’s for 
continuous scaled variables were extracted and used to calculate standardised mean 
differences (SMD) with 95% confidence intervals (CI’s). No dichotomous data were 
identified in the results of any included study. Data for men and women were analysed 
independently and directly compared where this breakdown was published, also 
contributing to the pooled SMD produced where relevant. Meta-analysis was 
performed where homogeneity between studies was deemed to be adequate and the 
level of statistical heterogeneity for pooled data were established using I2 statistics 
(heterogeneity defined as I2 > 50%, p < 0.05) (177). Calculated individual or pooled 
SMDs were categorised as small (≤ 0.59), medium (0.60 to 1.19) or large (≥ 1.20) (122).  
4.2.6. Evidence based recommendations 
Based on the previous work of van Tulder et al (116), levels of evidence were assigned 
for each evaluated variable or intervention, incorporating statistical outcomes and the 
methodological quality of included studies.  
Strong evidence: pooled results derived from three or more studies, including a 
minimum of two high quality studies that are statistically homogenous; may be 
associated with a statistically significant or non-significant pooled result. 
Moderate evidence: statistically significant pooled results derived from multiple 
studies that are statistically heterogeneous, including at least one high quality study; 
or from multiple moderate quality or low quality studies which are statistically 
homogenous.  
Limited evidence: results from one high quality study or multiple moderate or low 
quality studies that are statistically heterogeneous.  
Very limited evidence: results from one moderate quality study or one low quality 
study. 
No evidence: pooled results insignificant and derived from multiple studies regardless 
of quality that are statistically heterogeneous.   
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4.3. Results 
4.3.1. Search results 
The electronic database search yielded 852 citations. After a sequential review of 
titles, abstracts and full texts, and removal of studies that were not completed using a 
running population or studies involving two dimensional kinematic analysis, 28 studies 
were included – three prospective studies (18, 20, 162) 18 case-control studies (39, 51-
54, 163-174, 176) and seven intervention studies (78, 83, 84, 95, 100, 101, 175) (Figure 
27).  
 
27. Search flow chart for biomechanics systematic review & meta-analysis adhering to PRISMA 
guidelines 
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4.3.2. Quality assessment of included studies 
Prospective/Case-Control studies 
Based on evaluation with the Down’s and Black, quality scores ranged from 6 to 14 
(out of a maximum score of 16). Of the 21 prospective and case-control studies 
included in this review, 13 studies were scored as HQ (18, 39, 51-54, 162, 165, 166, 
168, 170, 172, 173), 8 studies were scored as MQ (20, 163, 164, 167, 169, 171, 174, 
176) and no studies were scored a LQ. Inter-rater reliability was calculated using 
percentage agreement for all prospective and case-control studies and mean 
agreement was calculated to be 83%. For the 15 items included in the modified 
Down’s and Black evaluation, percentage agreement ranged from 35% to 100%, with a 
mean of 80%. Item 20, relating to the reliability and validity of the main outcome 
measures displayed the lowest percentage agreement, with perfect agreement 
identified for only 7 of the included studies.   
Intervention studies 
Based on evaluation with the PEDro scale, quality scores ranged from 3 to 6 (out of a 
maximum possible score of 10). Of the 7 intervention studies included in this review, 2 
studies were scored as HQ (95, 175), 4 studies were scored as MQ (78, 83, 100, 101) 
and 1 study was classified LQ (84). Inter-rater reliability was calculated using 
percentage agreement for all intervention studies and mean agreement was calculated 
to be 92%. For the 11 items included in the PEDro evaluation, percentage agreement 
ranged from 71% to 100%, with a mean of 94%. Item 3 concerning similarity at 
baseline regarding prognostic indicators displayed the lowest percentage agreement, 
with perfect agreement identified for only 5 included studies.   
4.3.3. Study characteristics 
Study characteristics are presented in tables 3 and 4, including recruitment population 
and participant characteristics to inform upon potential subgroups, observation 
periods and injury outcomes to inform upon potential recovery timeframes and 
biomechanical variable(s) to inform upon symptom development and intervention 
mechanisms. 
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Case-Control  
Unless a specific sex is mentioned, results described are in relation to a mixed sex 
cohort.  
4.3.4. Retrospective kinematics (peak) 
Proximal  
There is moderate evidence from 7 HQ studies (39, 51-53, 166, 172, 178) and one MQ 
study (169) of an association between PFP and increased peak hip adduction (I2 =84%, 
small significant SMD 0.37, 0.14 to 0.59) (see figure 28) and peak hip internal rotation 
(I2=83%, small significant SMD 0.35, 0.14 to 0.57) (see figure 29). Additionally, 
moderate evidence from 4 HQ studies (51, 52, 166, 172) indicates an association 
between PFP and increased peak contralateral pelvic drop (I2=63%, medium significant 
SMD 0.67, 0.37 to 0.97) (see figure 30). There is also limited evidence from one HQ 
study (166) of a significant association between PFP and reduced stance phase peak 
hip flexion (medium SMD -0.69, -1.32 to -0.06) (see figure 31).  
 
28. Forest plot detailing standardised mean difference for peak hip adduction when comparing runners 
with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
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29. Forest plot detailing standardised mean difference for peak hip internal rotation when comparing 
runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
30. Forest plot detailing standardised mean difference for peak contralateral pelvic drop when 
comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
31. Forest plot detailing standardised mean difference for peak hip flexion when comparing runners 
with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
Distal  
There is strong evidence from 2 HQ studies (52, 168) and 1 MQ (163) study of no 
association between PFP and increased peak rearfoot eversion (I2=28%, small non-
significant SMD -0.03, -0.41 to 0.35) (see figure 32). There is very limited evidence 
from one MQ study (176) of a significant reduction in ‘minimum time to contact the 
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ankle joint complex range of movement boundary’ (an expression of pronation 
velocity) in runners with PFP (medium SMD -0.74, -1.42 to -0.06) (see figure 33).  
 
32. Forest plots detailing standardised mean differences for peak rearfoot eversion when comparing 
runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
33. Forest plots detailing standardised mean differences for minimum time to contact ankle range of 
motion boundary when comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
4.3.5. Retrospective kinematics (peak): post-fatigue 
Three HQ studies (53, 166, 168) investigated the effect of fatigue on lower limb 
kinematics in runners with and without PFP. Limited evidence from one HQ study (166) 
indicates an association between increased peak hip flexion (medium SMD 0.76, 0.13 
to 1.40) and runners with PFP in a fatigued state (see figure 34).  
 
34. Forest plots detailing standardised mean differences for peak hip flexion when comparing runners 
with PFP to controls post-fatigue.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
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When analysing kinematic changes in runners with PFP as a result of fatigue, this same 
limited evidence of increased peak hip flexion remains (large SMD 1.42, 0.72 to 2.12) 
(see figure 35), as well as limited evidence of increased anterior pelvic tilt (medium 
SMD 1.00, 0.34 to 1.67), from the same HQ study (166) (see figure 36).  
 
35. Forest plots detailing standardised mean differences for peak hip flexion when comparing runners 
with PFP pre/post-fatigue.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
36. Forest plots detailing standardised mean differences for peak anterior pelvic tilt when comparing 
runners with PFP pre/post-fatigue.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
No significant differences were identified post-fatigue for any of the kinematic 
variables analysed by the above stated three HQ studies (53, 166, 168).  
4.3.6. Retrospective kinematics (peak): male compared to female  
Limited evidence from one HQ study (51) indicates that female runners with PFP have 
significantly increased peak hip adduction (large SMD -1.92, -2.73 to -1.12) in 
comparison to male runners with PFP (see figure 37).  
 
37. Forest plots detailing standardised mean differences for peak hip adduction when comparing male 
and female runners with PFP.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
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Limited evidence from the same HQ study also indicates that male runners with PFP 
have significantly increased peak knee adduction (medium SMD 1.17, 0.46 to 1.89) 
compared to female runners with PFP (see figure 38).  
 
38. Forest plots detailing standardised mean differences for peak knee abduction when comparing male 
and female runners with PFP.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
No significant differences were identified for any other kinematic variables 
investigated, including contralateral pelvic drop or hip internal rotation.  
4.3.7. Retrospective kinematics (coupling angle variability) 
Coupling angle variability is a measure used to describe the degree of variation of 
coordinated segments, with reduced variability thought to be associated with 
repetitive use injury development (167). However, very limited evidence from one MQ 
study (167) identified a significant association between greater kinematic coupling 
angle variability and runners with PFP in comparison to control, for the following 
variables: Knee Flexion/Extension and Ankle Dorsiflexion/Plantarflexion at heel strike 
(medium SMD 0.91, 0.12 to 1.69); Knee Internal/External Rotation and Ankle 
Dorsiflexion/Plantarflexion at mid-stance (medium SMD 0.81, 0.03 to 1.58); Knee 
Valgus and Ankle Dorsiflexion/Plantarflexion at swing acceleration (medium SMD 1.03, 
0.23 to 1.83); Knee Valgus and Ankle Inversion/Eversion at swing deceleration 
(medium SMD 1.05, 0.25 to 1.84); Knee Valgus and Ankle Dorsiflexion/Plantarflexion 
during the first 40% stance (medium SMD 1.10, 0.30 to 1.90) and Knee Valgus and 
Ankle Inversion/Eversion throughout the gait cycle (medium SMD 0.81, 0.04 to 1.59).  
4.3.8. Prospective kinematics (peak) 
Proximal  
Very limited evidence from one MQ study (20) indicates that increased peak hip 
adduction was predictive of PFP development in female runners, associated with a 
significant, medium SMD (0.90, 0.38 to 1.42) (see figure 39). No significant links were 
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identified for peak hip internal rotation (SMD 0.25, -0.27 to 0.76) or knee angular 
impulse (SMD 0.31, -0.52 to 1.15).  
 
39. Forest plots detailing standardised mean differences for prospective peak hip adduction when 
comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
Distal  
Very limited evidence from one MQ study (20) indicates that reduced peak rearfoot 
eversion is predictive of PFP development in female runners, associated with a small 
but significant SMD (-0.53, -1.05 to -0.01) (see figure 40).  
 
40. Forest plots detailing standardised mean differences for prospective rearfoot eversion when 
comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
4.3.9. Retrospective kinetics 
Two HQ studies (170, 173) investigated the correlation between joint stress or 
patellofemoral reaction forces and female runners with PFP. Limited evidence of no 
significant difference was identified for peak patellofemoral joint stress during running 
from one HQ study (170)  (SMD 0.46, -0.17 to 1.09).  Limited evidence of significantly 
lower patellofemoral reaction force during running in participants with PFP was also 
identified from one HQ study (173)  (large SMD -2.02, -2.79 to -1.24), but a significant 
increase in patellofemoral reaction force specific to the lateral facet of the patella was 
also identified in runners with PFP by the same HQ study (large SMD 3.16, 2.20 to 4.11) 
(see figure 41).  
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41. Forest plot detailing standardised mean differences for patellofemoral reaction force when 
comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
4.3.10. Prospective kinetics 
Limited evidence from one HQ study (18) indicates that runners who go on to develop 
PFP have a significantly higher peak vertical force under the second (medium SMD 
0.65, 0.12 to 1.17) (see figure 42) and third (medium SMD 0.60, 0.07 to 1.12) (see 
figure 43) metatarsals and a significantly lower time to peak force underneath the 
lateral heel (small SMD -0.56, -1.08 to -0.03) (see figure 44).   
 
42. Forest plots detailing standardised mean differences for peak vertical force under the 2nd metatarsal 
head when comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
43. Forest plots detailing standardised mean differences for peak vertical force under the 3rd metatarsal 
head when comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
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44. Forest plots detailing standardised mean differences for time to peak vertical force at the lateral 
heel when comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
4.3.11. Lower limb EMG 
One HQ study (172) and one MQ study (164) investigated the differences in gluteal 
muscle EMG in runners with PFP. Very limited evidence from one MQ study (164) was 
identified that female runners with PFP have significantly lower Gluteus Medius 
activation duration (medium SMD -0.85, -1.50 to -0.20) (see figure 45) and delayed 
onset prior to foot contact (medium SMD -0.74, -1.38 to -0.10) (see figure 46). No 
significant differences were identified for Gluteus Medius peak activation or average 
activation, or for any of the aforementioned variables for Gluteus Maxiumus from 
either study (164, 172).  
 
45. Forest plots detailing standardised mean differences for gluteus medius muscle activation duration 
when comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
46. Forest plots detailing standardised mean differences for gluteus medius muscle onset prior to foot 
contact when comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
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Additionally, very limited evidence of no significant differences in timing of VMO 
activation during running were identified by one MQ study (171), nor VMO peak 
activation from one HQ study (limited evidence) (172). Limited evidence from one HQ 
study (172) was identified that runners with PFP have a greater soleus activation 
duration (expressed as a percentage of the running cycle) compared to controls 
(medium SMD 0.68, 0.05 to 1.31) (see figure 47), but no significant differences were 
identified for any other muscle group investigated by this study, including the gluteals 
and quadriceps. 
 
47. Forest plots detailing standardised mean differences for soleus muscle activation duration when 
comparing runners with PFP to controls.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
4.3.12. Interventions and their effects  
Exercise  
Two studies investigated the effects of proximal (hip) strengthening exercise in the 
management of running-related PFP (83, 84), both of which provided data suitable for 
SMD calculation. There is limited pooled evidence that proximal strengthening exercise 
can reduce pain (large SMD 1.80, 1.21 to 2.38) (see figure 48) and very limited 
evidence that proximal strengthening exercise can improve function (medium SMD 
1.16, 0.47 to 1.86) (see figure 49) in runners with PFP. However, no significant 
differences were observed for any of the kinematic variables, including hip adduction 
and internal rotation, rearfoot eversion, knee abduction or genu valgum, with no data 
pooling being possible.  
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48. Forest plots detailing standardised mean differences for pain post-strengthening exercise in runners 
with PFP.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
49. Forest plots detailing standardised mean differences for function post-strengthening exercise in 
runners with PFP.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
Running retraining  
Three studies investigated the effects of running retraining in the management of 
females with running-related PFP (95, 100, 101). Limited evidence from two MQ 
studies (100, 101) indicates that running retraining using either visual display of real-
time hip adduction (100), or mirror feedback to reduce hip adduction (101) 
significantly reduces pain (large SMD 3.84, 2.70 to 4.98) (see figure 50) and improves 
function (large SMD 2.16, 1.29 to 3.03) (see figure 51) at short-term follow up. Limited 
evidence from the same MQ studies indicates that peak hip adduction during running 
is reduced post-intervention, associated with a large and significant pooled SMD 
(I2=0%, p=0.72, large SMD 2.10, 1.30 to 2.91) (see figure 52). No significant differences 
were identified for either hip internal rotation or contralateral pelvic drop at short-
term follow up. No significant differences in patellofemoral joint kinetics were 
identified from one HQ study using metronome cadence re-training (+/- 10% from 
baseline) (95), but a trend towards significance for vertical impact peak was identified 
from one MQ study using real-time visual feedback to reduce peak hip adduction (100) 
(medium SMD 0.91, -0.02 to 1.84).  
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50. Forest plots detailing standardised mean differences for pain post-running retraining in runners with 
PFP.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
51. Forest plots detailing standardised mean differences for function post-running retraining in runners 
with PFP.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
 
52. Forest plots detailing standardised mean differences for peak hip adduction post-running retraining 
in runners with PFP.  
Key: HQ – high quality; MQ – moderate quality; LQ – low quality; F – female; M – male; MS – mixed sex; 
G&P – Gait & Posture; CB – Clinical Biomechanics; SD – standard deviation; IV – inverse variance; CI – 
confidence interval; PFP – patellofemoral pain 
Orthoses  
Two studies (78, 175) investigated the kinematic effects of orthoses in runners with 
PFP, one of which (78) provided data suitable for SMD calculation. Neither study 
concurrently reported the effects of orthoses on either pain or function. Limited 
evidence from one MQ study (78) indicates that peak rearfoot eversion is reduced in 
runners with PFP following orthoses intervention, associated with a significant medium 
SMD (0.79, 0.29 to 1.29). There is also limited evidence from the same MQ study that 
orthoses intervention reduces peak ankle joint complex velocity (medium SMD -0.70, -
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1.20 to -0.20) and increases the ankle joint angle at foot strike (medium SMD 0.64, 
0.14 to 1.14), with both variables expressions of pronation velocity.  
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4.4. Discussion 
This systematic review identified very limited evidence that increased peak hip 
adduction is a risk factor for PFP development in female runners, which can be 
modified with symptomatic benefit using running retraining. Increased peak hip 
adduction in runners with PFP is further supported by moderate cross-sectional 
evidence. Additionally, significant associations of PFP with increased peak hip internal 
rotation and contralateral pelvic drop, and a reduction in peak hip flexion were 
identified in both female and mixed-sex PFP populations. An association was also 
identified between PFP and both delayed and shorter Gluteus Medius activation 
duration in female runners. There are, therefore, clear outcomes from this systematic 
review relevant to clinicians treating runners with PFP.   
Current findings related to the biomechanical effects of conservative interventions for 
management of runners with PFP indicate running retraining and proximal 
strengthening exercise both reduce pain. Running retraining was also found to reduce 
peak hip adduction; an established risk factor for PFP development (20), and this 
biomechanical change may provide a mechanistic explanation for running retraining 
effectiveness. Conversely, this review indicates that biomechanical mechanisms 
explaining the therapeutic effects of proximal strengthening exercise remain unclear. 
Foot orthoses were found to reduce peak rearfoot eversion, however without 
concurrent reporting of their effects on symptoms, it remains unclear if this kinematic 
mechanism can explain previously reported positive clinical outcomes (76, 77, 179). 
4.4.1. Biomechanics associated with PFP during running 
Very limited evidence that increased peak hip adduction was a risk factor for PFP 
development in female runners was identified (20), a finding supported by moderate 
cross-sectional evidence indicating greater hip adduction in individuals with existing 
PFP (39, 51-53, 166, 169, 172, 178). Additionally, meta-analysis revealed moderate 
evidence of greater peak hip internal rotation (39, 51-53, 166, 172, 178) and 
contralateral pelvic drop (51, 52, 166, 172) in individuals with PFP. Whilst hip 
adduction in both female and male symptomatic subjects was found to be greater than 
controls, limited evidence was identified that females with PFP may possess greater 
peak hip adduction in comparison to males with PFP, with males found to have 
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significantly greater knee adduction in one study (51). Considering that previous 
prospective research linking greater hip adduction to risk of PFP development was 
limited to a female population, future prospective research should include both sexes 
and sub-group them to establish if different biomechanical risk profiles exist in relation 
to the hip.  
Distally, very limited evidence was identified that reduced peak rearfoot eversion was 
a risk factor for PFP (20), which was inconsistent with strong evidence from pooled 
cross-sectional findings that identified no association between peak rearfoot eversion 
and PFP during running (52, 163, 168). It should be highlighted that two studies (40, 
180) which were excluded for 2D methods of quantifying rearfoot eversion do suggest 
that increased rearfoot eversion is associated with PFP. However, quantification of 2D 
rearfoot motion is known to have a measurement error up to four degrees (181), while 
the between group differences from these studies were below this figure (0.5 degrees 
(40) and 3.1 degrees (180)). Inclusion of these studies could have biased the findings of 
this review towards a false positive for this variable, hence their exclusion.  
Limited evidence of both greater peak force under the 2nd and 3rd metatarsals, as well 
as a shorter time to peak force under the lateral heel were identified as risk factors for 
PFP in runners (18). Thijs et al (18) suggested that the increased forces described 
above could indicate a reduction in pronation, consistent with findings from Noehren 
et al (20), and thus reduction in shock attenuation at the foot during the loading phase 
of gait, with potential transfer of ground reaction forces to proximal structures such as 
the patellofemoral joint (37). When considering these limited findings in light of 
greater navicular drop being reported as a risk factor for PFP (23, 36) and evidence 
supporting the prescription of foot orthoses designed to control foot pronation (76, 
77, 179), it is clear the relationship between foot biomechanics and PFP is poorly 
understood at this time.   
The influence of fatigue on kinematics was highlighted as an under-researched area by 
the 2014 PFP consensus statement (80). Limited evidence identified that when 
fatigued, runners with PFP demonstrate greater peak stance phase hip flexion in 
comparison to controls and greater peak hip flexion and anterior pelvic tilt in 
comparison to their pre-fatigue state (166). This may indicate runners with PFP 
increase both trunk flexion and limb compliance throughout a period of running, 
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possibly as a result of fatigue (182, 183), or in an attempt to reduce PFJ stress (184). 
Interestingly, moderate evidence indicates that the differences in hip adduction, 
internal rotation and contralateral pelvic drop between runners with PFP when 
compared to asymptomatic runners is no longer present once in a fatigued state (53, 
166, 168). It is important to note that the kinematics of runners with PFP do not 
change (e.g. reduced hip adduction) when fatigued, but rather the kinematics of 
asymptomatic runners become more akin to those with PFP (i.e. increased hip 
adduction). This suggests that runners with PFP demonstrate biomechanical features 
causally related to PFP from early in a run whereas those without pain only 
demonstrate these features when fatigued and likely close to finishing their run. This 
manifestation of injurious biomechanics from the initiation of high load exercise may 
be an important factor leading to symptom development. 
Electromyographic investigations have yielded limited evidence of shorter, and 
delayed, activation prior to foot contact of Gluteus Medius is present in runners with 
PFP, while no significant differences were identified for Gluteus Maximus (164). 
Impaired gluteal function may partially explain altered kinematics in runners with PFP. 
Supporting this notion is work by Willson et al (164), which identified a correlation 
between gluteus medius activation delay at foot contact and increased hip adduction 
excursion. Limited evidence of no differences in VMO activity were identified by this 
review (171, 172), which is in support of previous analyses that VMO impairment is 
highly variable, present in some individuals with PFP but also highly prevalent amongst 
asymptomatic individuals (185).  
Limited evidence identified a significant increase in patellofemoral reaction forces 
specific to the lateral facet of the patella during running (173), but no difference in 
peak total patellofemoral joint stress (170). These findings related to stress are 
inconsistent with other tasks evaluated in the literature, which indicates greater PFJ 
stress in individuals with PFP during walking (148) and squatting (149). It is plausible 
that it is not the total joint stress or reaction force, but spatially concentrated reaction 
forces leading to shear stress in specific patellofemoral joint facets, that may be 
responsible for symptom development (173). Another explanation may be variations in 
modelling approaches used. Wirtz et al (170), who provided running data for this 
review, suggest a possible underestimation of PFJ stress in their analyses, with an 
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absence of transverse plane kinematics in their modelling, which may explain the 
inconsistent findings. Importantly, hip internal rotation has been reported to 
contribute significantly to patellofemoral joint stress (50). Given the significant 
association between increased peak hip internal rotation and PFP identified by this 
review, further investigation to allow for greater understanding of joint stress and its 
mechanism on PFP development is warranted.  
4.4.2. Biomechanical effects of interventions 
Limited evidence indicates running retraining and proximal strengthening exercise 
both achieve improvements in pain and function in runners with PFP at short-term 
follow up. When evaluating the biomechanical effects and mechanisms for 
symptomatic improvement from running retraining, a significant reduction in peak hip 
adduction up to three months following a two-week running retraining intervention 
was identified (100, 101). However, findings from this review indicate no kinematic 
changes following exercise intervention (83, 84), indicating benefits may be derived by 
other mechanisms such as limb stiffness changes or nociceptive input processing 
alterations. Findings from Earl et al (84) provide some possible biomechanical 
explanation for the benefits of exercise rehabilitation in runners with PFP, reporting a 
significant reduction in peak internal knee abduction moments following an 8 week 
proximal strengthening program, although the data extracted did not produce a 
significant finding for this variable in the current review. Regardless, these changes to 
knee joint moments may be of potential clinical relevance and should be considered in 
future investigations.  
Whilst no definite mechanism have yet been identified to explain the efficacy of 
proximal strengthening exercise in reducing running-specific PFP, it is possible that 
changes to both instantaneous and average loading rates can be achieved alongside 
positive clinical outcomes, identified in a recent study by Escullier et al (186). It is 
essential however, to realise that this study was multi-modal in nature, encompassing 
exercise, advice on load management and training error, as well as instruction to alter 
running cadence and foot strike patterns. Therefore, these positive effects cannot be 
solely attributed to any one of these interventions in isolation, but the developing 
hypotheses about loading rates certainly warrant further investigation.  
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Foot orthoses are known to have positive effects on pain and function in individuals 
with PFP (76, 77, 179), but do not improve outcomes when combined with multi-
modal physiotherapy (179). The exact mechanism by which foot orthoses exert 
therapeutic effects is unclear, with several different paradigms outlined in the 
literature to explain the observed effects. This review identified limited evidence for a 
small reduction in both peak rearfoot eversion and peak ankle joint complex velocity 
with the prescription of medially posted foot orthoses designed to reduce rearfoot 
eversion (78, 175). Interestingly, this approach to prescription, which is similar to 
approaches with therapeutic supporting evidence (76, 77, 179), conflicts with findings 
suggesting that reduced rearfoot eversion may be a risk factor for PFP development 
(20). However, as concurrent measures of pain or function were not taken in these 
biomechanical orthoses studies (78, 175), the clinical relevance of these findings as 
potential mechanisms is unclear.  Interestingly, research has suggested that rearfoot 
kinematic changes do not correlate well with pain reduction (187) or reduced tissue 
loads/demands (188), which potentially suggests that the modification of kinetic 
parameters may be of greater relevance to symptom change. However, the kinetic 
effects of foot orthoses in runners with PFP are currently unclear due to a paucity of 
research, indicating this is an area of research requiring attention.  
4.4.3. Clinical implications  
The findings of this review indicate that peak hip adduction may be a modifiable risk 
factor for PFP in female runners. Based on the data included in this meta-analysis, 
results also suggest that a change in hip adduction of 5 degrees post-intervention 
could be considered clinically meaningful, with these changes associated with marked 
reductions in running-related pain (100, 101). Recent evidence has emerged that 2D 
video movement analysis demonstrates good intra-rater reliability and acceptable 
concurrent validity with respect to detailed three-dimensional movement analysis, but 
currently only for hip adduction measurement (108). As such there is a useful, readily 
accessible assessment tool when managing runners with PFP. It may be that future 
work on new methods for 2D measurement will improve reliability of measurement 
for variables such as rear-foot motion, which would yield a very useful clinical tool. 
Additionally, previous research also indicates functional tasks such as single leg small 
knee bend or single leg step down may provide an indication of hip adduction during 
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running (189), indicating possible valuable clinical correlates in clinical settings where 
running cannot be easily assessed.  
Both running retraining and proximal strengthening exercise have been reported to 
improve pain and function (83, 84, 100), but may have different effect mechanisms 
based on the findings of this review. Considering this, it is possible that a combination 
of the two interventions could lead to superior results. Considering the positive clinical 
outcomes identified for running retraining to reduce hip adduction, other running 
retraining strategies aimed at altering mechanics related to PFP may also be effective. 
For example, cadence manipulation has recently shown positive clinical outcomes in 
the management of tibial stress fractures (93) and has also shown favourable changes 
to patellofemoral joint forces (94) and lower limb joint mechanics (91) in normative 
cohorts. These additional running modification strategies may be positively augmented 
by proximal muscle training undertaken in a parallel fashion.    
4.4.4. Limitations and future research  
Some limitations must be considered when interpreting findings of this review. Not all 
studies provided data that allowed effect size calculation and subsequent potential for 
inclusion in meta-analysis. To address this, attempts to obtain data from 
corresponding authors were made, however, this did not prove successful in all 
instances, meaning some findings could not be considered when making conclusions 
and recommendations.  
Common themes of methodological limitation were identified during the quality 
assessment process.  For the prospective and case-control studies, only one study (18) 
ensured that their sample was representative of the entire recruitment population 
(failing to adequately state population source and subsequent participation 
percentages), only 6 studies reported reliability of their outcome measures (18, 20, 39, 
51, 53, 54) and no studies attempted to blind those measuring the main outcome 
measures in the case-control studies. Similar themes were identified for the 
intervention studies, where all studies failed to blind either subjects or raters to 
groupings and no randomisation was performed, although it should be recognised that 
this was due to the absence of a control group in the design.  
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The presence of just one HQ (18) and two MQ (20, 162) prospective studies highlights 
a dearth of research to differentiate between cause and effect, and addressing this 
should be a priority for future work. Subsequent prospective or cross-sectional studies 
of the biomechanics of runners with PFP should focus on variables that have been 
found to be associated with the condition. Future prospective or cross-sectional 
investigation is warranted for peak hip internal rotation, hip flexion, contralateral 
pelvic drop, anterior pelvic tilt, gluteal EMG, joint stress and plantar pressures.  
Only one cross-sectional study (51) provided a breakdown of kinematics for the 
individual sexes and only 5 studies (163, 165, 166, 168, 172) utilised a genuine mixed-
sex cohort. This means that applying kinematic findings of this review to male runners 
with PFP requires particular caution. Future studies investigating cohorts involving 
both sexes with enough participants to complete between sex comparisons are 
needed to better understand biomechanics associated with PFP in males.  
The clinical outcomes for running retraining can currently only be discussed relative to 
a short-term follow up (maximum 3 months) and future studies should seek to 
establish if these outcomes extend to a long-term follow up, with a minimum of 12 
months suggested to meet the Cochrane Group guidelines (190). Running retraining 
has not been evaluated in relation to a control group and this is essential to determine 
the efficacy of the intervention. Positive clinical outcomes are known to extend to long 
term follow up for proximal strengthening exercise (56), but this needs to be 
confirmed in a running specific population, alongside an analysis of potential 
mechanisms. This should also be a priority for future research, alongside establishing if 
a combined running retraining and exercise intervention yields superior results to 
either intervention in isolation. The recent best practice guide for PFP (69) has outlined 
strong efficacy for both tailored patella taping and bracing in relation to short-term 
pain relief in conjunction with multi-modal physiotherapy. The biomechanical effects 
of these interventions have not been investigated in a running population and this 
would be a positive direction for future studies to take. Intervention using orthoses 
during running needs to be examined in conjunction with assessment of both 
symptoms and function, to determine the clinical efficacy of this intervention in a 
running cohort.  
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4.5. Conclusion  
The quantity and quality of published literature concerning lower limb running 
biomechanics and the relationship to PFP has progressed markedly since the last 
systematic review on the topic, enabling more varied and stronger conclusions to be 
drawn. These conclusions relate to both symptom development and maintenance, as 
well as potential explanatory mechanisms for treatment effects. Very limited 
prospective evidence indicates that increased peak hip adduction is a risk factor for 
PFP development in female runners; in addition to limited evidence that running 
retraining changes both symptoms and function via a likely kinematic mechanism of 
reduced peak hip adduction. This is supported by moderate evidence from cross-
sectional research in mixed sex cohorts, with a correlation also identified between PFP 
during running and increased peak hip adduction, internal rotation and contralateral 
pelvic drop. Further prospective research is needed to clarify if these relationships are 
of a causal or associative nature, and therefore better target interventions aimed at 
treatment and prevention. Limited evidence also indicates that proximal strengthening 
exercise changes both symptoms and function at short-term follow up, but currently 
potential biomechanical mechanisms are unclear. Further research to establish long-
term efficacy for running retraining and an improved understanding of potential 
mechanisms for proximal strengthening exercise is needed 
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5. Increased peak hip adduction during running is associated 
with patellofemoral pain but differs between males and 
females: a case-control study   
The systematic review presented in chapter 4 included eight case-control studies that 
reported peak kinematic variables during running, identifying clear associations 
between persistent PFP and altered running kinematics. Just one of these case-control 
studies reported their data for male and female participants separately, identifying a 
significant difference between the sexes for peak hip adduction. Given the strength of 
evidence for kinematic associations identified when data is pooled for both sexes, this 
case-control study was designed to further determine if sex influences previously 
reported differences in kinematics between runners with and without PFP.  
As this chapter presents the first original data contribution within this thesis, the 
methodology for kinematic data collection during running is described in detail. The 
intra-rater reliability of marker placement for kinematic analysis is also presented.  
This study has been submitted for peer review in Clinical Biomechanics (impact factor 
1.874) and is currently awaiting an initial round of peer review.  
  
 
108 
5.1. Introduction 
Patellofemoral pain (PFP) is described as either retropatellar or peripatellar pain of 
atraumatic onset, associated with knee joint loading into flexion (4). Running is a 
common aggravating factor, with incidence rate reported to range from as low as 4% 
throughout a two year period (20), to as high as 21% during a ten week ‘start to run’ 
programme (17). A recent systematic review and meta-analysis identified no risk 
factors from pooled data for the development of PFP in a running population (191). 
Whilst there is a paucity of prospective research investigating risk factors for PFP in 
running populations, female runners with PFP have been reported to be at an 
increased risk of developing PFP in the presence of high peak hip adduction during 
running (20). Additionally, runners with persistent PFP have been reported to run with 
increased peak hip adduction and internal rotation, and reduced peak hip flexion 
compared to asymptomatic controls (82, 192). It is thought that these kinematic 
variations may contribute to the development and persistence of PFP by way of 
increasing patellofemoral joint stress, and thus provide treatment targets when using 
interventions such as gait retraining (100, 101).    
A higher prevalence of PFP is reported amongst females (21). However, despite the 
breadth of literature evaluating the kinematics of runners with PFP, current 
understanding of the influence of sex on kinematic differences is unclear. Multiple 
studies have evaluated females only (52, 53), while others have evaluated mixed-sex 
cohorts with no sub-analysis of the individual sexes (166, 172, 178).  
One previous study evaluated kinematic differences between males and females with 
PFP during running (51), reporting that females with PFP demonstrate greater peak hip 
adduction compared to both males with PFP and male controls. In contrast, males with 
PFP were reported to run with greater peak knee adduction when compared to both 
females with PFP and male controls. Limitations of this study include use of a fixed 
speed (3.35m/sec), which may result in different findings to when running at a self-
selected speed; and the lack of a female control group. Improving understanding of 
how kinematic associations with PFP may differ between sexes is important to guide 
the development of more tailored interventions for this often persistent condition (2). 
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3D motion analysis is a widely used tool for the assessment of human locomotion, to 
understand both the epidemiology of a condition and to assess the effects of a given 
intervention. Accurate placement of the chosen marker set is fundamental to the 
collection of reliable data, with 75-90% of day to day variability reported to be 
explained by inconsistent marker placement by Gorton et al (193). Whilst there will 
always be a degree of inherent variability between trials when assessing human 
locomotion, accurate marker placement was found to significantly reduce both the 
standard error of measure (SEM) and minimum detectable change (MDC) for multiple 
peak kinematic variables by Noehren et al (194). 
This case-control study aimed to evaluate running kinematics at self-selected speeds 
during a treadmill run between a mixed sex cohort with and without PFP, with further 
analysis of kinematics when these cohorts are divided into males and females. A 
further specific objective was to determine the intra-rater reliability of marker 
placement for kinematic data collection during a static standing calibration trial.  
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5.2. Methods 
The Queen Mary Ethics of Research Committee granted ethical approval for this study 
(QMREC2014/63) and all participants provided written informed consent prior to 
participation. 
5.2.1. Kinematic reliability participants  
Prior to recruitment of the case-control participants, a convenience sample of 
asymptomatic individuals was sought from a local university student population. Ten 
participants (four males, six females) aged 27.7 (+3.1) years, height 171.4 (±8.7) 
centimeters and weight 65.9 (±14.5) kilograms volunteered to participate.    
5.2.2. Case-Control participants  
A convenience sample of participants with and without PFP was sought from local 
sports medicine clinics and running clubs respectively. Using peak hip adduction data 
from previous work (51) (males with PFP 12.9˚ [±3.4], females with PFP 19.2˚ [3.0]), an 
a priori analysis revealed that 5 participants were required to determine the difference 
between males and females with PFP (α=5%, β=0.80). We therefore recruited 20 
participants per group defined either by sex or presence of PFP.   
20 runners with PFP (11 females, 9 males) and 20 asymptomatic runners (11 females, 9 
males) were recruited (see table 5). To be included in the PFP group, participants were 
required to have retropatellar or peripatellar pain rated at a minimum of three (out of 
a maximum of 10) using a numerical rating scale (NRS) during running and one other 
activity described by the most recent PFP consensus document (4). This definition of 
PFP was used as inclusion criteria to ensure that the outcomes of this study would be 
comparable to other studies completed in this field.  
Participants with patellofemoral instability, tibiofemoral pathology or previous lower 
limb surgery were excluded. To be included in the control group, participants were 
required to be free of running-related injury (RRI) for a minimum of three months and 
have no previous history of PFP. All participants were of either sex, currently or 
recently running a minimum of three times or >10 km/week and aged between 18 and 
45 years, to ensure a cohort of participants that met the criteria for a recreational 
runner described by Niemuth et al (102). Two-tailed, independent samples t-tests 
were used to determine statistical differences between pairs of groups (PFP versus 
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control) for participant characteristics, with the corresponding P value detailed in the 
final column of table 5.  
 
5. Participant characteristics for case-control kinematic study  
Variable  PFP  
Mean (SD) 
Controls 
Mean (SD) 
P 
Age (Years) 31.9 (5.8) 30.7 (4.8) 0.47 
Height (cm) 173.3 (8.4) 171.8 (7.7) 0.57 
Mass (kg) 67.5 (9.2) 65.7 (1.4) 0.59 
Average run volume  
(km) 
17.9 (8.9) 19.7 (11.9) 0.58 
Step rate (SPM) 164.6 (5.6) 167.1 (7.4) 0.23 
Symptom duration 
(Months) 
55.8 (51.6) N/A N/A 
Kujala scale  87.6 (6.8) N/A N/A 
Average NRS  3.3 (1.5) N/A N/A 
Worst NRS  6.8 (1.5) N/A N/A 
Key: SD=standard deviation; cm=centimeters; kg=kilograms; km=kilometers; SPM=steps per minute; 
NRS=numerical rating scale; N/A=not applicable.  
5.2.3. Experimental protocol 
Participants were required to present to the Human Performance Laboratory at Queen 
Mary University of London. Data pertaining to one limb, rather than two, was entered 
into the analysis to reduce type I error potential (195). For participants with bilateral 
symptoms, the limb that rated the highest on the numerical rating scale was included. 
For participants with equivalent symptoms, or for the control participants, the 
dominant limb (defined as the limb that would be used to kick a ball) was included 
(101). Prior to data collection, participants in the PFP group were required to rate their 
average and worst pain in the past week from 0 to 10 using an NRS. Participants in the 
PFP group also completed the Kujala Scale (196), a 13-question appraisal of subjective 
function in those with PFP, with a score of 100 representing no symptoms and a score 
of zero indicating complete disability. The Kujala Scale was chosen as it was originally 
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validated using participants that were recruited from a 10km running event (196), with 
10km the minimum weekly run distance required for participant eligibility.   
5.2.4. Kinematic measures  
Kinematic data were collected during running using a four-camera, infrared motion 
analysis system (CX-1, Codamotion, Charnwood Dynamics Limited, Leicestershire, UK) 
(197) (see figure 53).  
 
53. Component parts of the Codamotion analysis system  
24 infrared markers were placed on standard pelvic and lower limb anatomical 
landmarks adhering to the CAST protocol (198). Eight individual markers (powered by a 
drive box) were placed on bilateral pelvic (ASIS and PSIS) (see figure 57) and foot 
landmarks (lateral calcaneal tuberosity and head of fifth metatarsal). Specifically, 
bilateral foot markers were placed on a participant’s shoe as an estimation of the 
anatomical location (see figure 54), given the potential for barefoot running to effect 
running kinematics (199). Additionally, four rigid clusters of four markers were placed 
on the thigh and shank segments bilaterally (see figure 55). 
 
113 
 
54. Neutral Asics Nimbus shoe with bilateral infrared foot markers applied 
                           
55. Location of thigh (left) and shank (right) rigid clusters prior to securement  
Rigid clusters were applied using adjustable elastic straps and were secured with 
cohesive self-adherent bandage, to minimize the potential for cluster displacement 
during high force activity (see figure 56). Individual markers were applied using double-
sided adhesive tape and secured with transparent surgical tape.  
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56. Use of cohesive self-adherent bandage to secure rigid cluster position      
Virtual markers were also identified on the femoral epicondyles and the ankle malleoli, 
to allow for the calculation of relevant joint centers during an upright standing trial 
(see figure 57), which did not differ between male and female participants. The knee 
joint centre was estimated as the mid-point between the femoral epicondyle markers 
and the hip joint centre was estimated as a projection within the pelvis frame using 
the equation previously described by Bell et al (200):  
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57. Positioning of individual pelvic markers and identified virtual markers at knee and ankle, identified 
by the red dots 
Kinematic data were sampled at 200Hz. Whilst lower collection frequencies are 
acceptable for low velocity movements such as walking, high velocity movements such 
as running require a higher sampling frequency to ensure that movement peaks are 
not excluded. 200Hz is the sampling frequency used most commonly by studies 
collecting running kinematic data in PFP participants (20, 51, 52, 101) and is also the 
maximum collection frequency for the Codamotion system when using between 13-28 
infrared markers.    
For the assessment of reliability of kinematic marker placement, participants stood on 
a marked line on the laboratory floor, with their feet positioned underneath their hips 
and their arms crossed over their chest. 10 seconds (s) of data were collected one 
week apart whilst the participant was instructed to stand as still as possible.  
For the case-control study, participants were required to run in their usual running 
shoes and at a self-selected ‘steady state’ running speed on the laboratory treadmill 
(Kistler Gaitway, Kistler Group, Winterthur, Switzerland). Participants in the PFP group 
were given the option to cease data collection if their symptoms increased to four or 
greater on the NRS. Participants ran for a total of three kilometers (km), with 10s of 
data collected at 0.8/1.8/2.8km. A three km run with initial data collection at 0.8km 
was selected to ensure that a minimum of six minutes of running had been completed 
prior to data collection, reported to allow for normalisation to running surface and 
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thus ensure validity of kinematic data (201). Distance, as opposed to time, was chosen 
to act as a constant measure across a cohort of participants running at differing 
speeds.  
A minimum of 10 gait events has previously been reported to increase the intra-rater 
reliability of kinematic gait analysis completed using Codamotion hardware (202). As 
such, three separate acquisitions of kinematic data (10s), containing approximately 12-
15 foot strikes, were collected during a prolonged run, in attempt to ensure the most 
reliable pooled mean for each kinematic parameter. Variables of interest included 
peak hip adduction (HADD), internal rotation (HIR) and flexion (HFLEX) and peak knee 
flexion (KFLEX), based on between condition-determined group differences identified 
in our recent meta-analysis (82). 
5.2.5. Data analysis  
Data were analysed offline using a customised Matlab program (version 2015, 
Mathworks, Natick, Massachusetts, USA).  
For the reliability data, kinematic marker position was determined using Euclidean 
distance, the absolute distance between two markers in three-dimensional space, 
using the following equation (where d=distance, p=marker 1, q=marker2, 1= x plane, 2= y 
plane and 3= z plane):  
 
Euclidean distance for the following segments were determined: ‘ASIS’ [left ASIS to 
right ASIS]; ‘PSIS’ [left PSIS to right PSIS]; ‘left pelvis’ [left ASIS to left PSIS]; ‘right pelvis’ 
[right ASIS to right PSIS]; ‘left knee’ [left MFC to left LFC];  ‘right knee’ [right MFC to 
right LFC]; ‘left lateral shank’ [left LM to left LFC];  ‘left medial shank’ [left MM to left 
MFC]; ‘right lateral shank’ [right LM to right LFC];  ‘right medial shank’ [right MM to 
right MFC]. 
For the case-control data, initial foot contact and toe off were identified using the 
calcaneal tuberosity marker and the metatarsal head marker in the vertical (Z) plane. 
Consistent with previously described methods, initial foot contact was defined as the 
point at which the calcaneal tuberosity marker ceased its descent in the vertical plane 
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(203). Toe off was identified by determining peak acceleration of the fifth metatarsal 
marker within a specific time point, defined as >70% of the absolute maximum velocity 
region of the calcaneal tuberosity marker (203). All kinematic data were aligned to 
initial foot contact, interpolated and normalised to percentage of stride cycle (0% = 
initial contact, 100% = terminal stance).  
5.2.6. Statistical analysis  
All statistical testing were performed offline using Microsoft Excel (Microsoft 
Corporation, Albuquerque, New Mexico, USA). Data normality were determined using 
Kolmogorov-Smirnov (K-S) test, with all data identified to be normally distributed (P= 
0.29 – 0.97) and parametric statistical tests therefore employed.  
For the reliability data, single measure ICC with 95% confidence intervals were 
calculated using a two-way fixed effects model. ICC were interpreted as excellent (> 
0.90), good (0.75-0.90), moderate (0.50-0.75) and poor (< 0.50) respectively (204). 
Standard errors of measure [SD x √1-ICC] and minimum detectable change [SEM x 
1.96 x √ (2)] were also calculated.  
For case-control data, a one-way analysis of variance (ANOVA) with four sub-groups 
defined by sex and symptoms were conducted, with a Tukey’s post-hoc test, which 
does not require statistical correction for multiple comparisons. Two-tailed, 
independent samples t-tests were used to determine statistical differences between 
pairs of groups (PFP versus control). Statistical significance of data was set at α ≤ 0.05, 
with a trend defined as α ≤ 0.10. Cohen’s d was also calculated to determine the effect 
size of all identified inter-group differences, alongside the reporting of mean 
differences and 95% confidence intervals (CI). Cohen’s d was interpreted as small (< 
0.2), medium (>0.5) and large (>0.8) respectively (205). Minimum detectable change 
(MDC) data from previous work (194) were used to determine the clinical relevance of 
identified kinematic differences.  
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5.3. Results 
5.3.1. Participant characteristics  
Analyses of all characteristics between groups were non-significant and are detailed in 
table 5. Participants in the PFP group demonstrated a prolonged duration of pain (55.8 
[±51.6] months), but only a mild impairment in function, reflected by a mean Kujala 
scale score of 87.6 (±6.8).  
5.3.2. Kinematic reliability  
Reliability of kinematic marker placement was found to be moderate to excellent (ICC 
0.62-0.93) (table 6). The most reliable segment was found to be the ‘left pelvis’ (ICC 
0.93) and the least reliable segment the ‘left knee’ (ICC 0.62).  
6. Kinematic marker placement reliability data 
Variable  Mean Difference  ICC 95% CI SEM MDC 
 (mm)  Lower  Upper (mm) (mm) 
ASIS (IR) 4.2 0.78 0.37 0.94 4.9 13.7 
PSIS (IR) 5.0 0.66 0.15 0.90 7.8 21.6 
Left Pelvis (IR) 3.9 0.93 0.73 0.98 1.5 4.12 
Right Pelvis (IR) 0.6 0.89 0.62 0.97 2.9 8.1 
Left Knee (V) 5.5 0.62 0.07 0.89 4.2 11.6 
Right Knee (V) 1.0 0.75 0.28 0.93 2.6 7.1 
Left Lateral Shank  (V) 7.4 0.65 0.12 0.89 11.7 32.5 
Left Medial Shank (V) 1.7 0.79 0.35 0.94 8.9 24.9 
Right Lateral Shank (V) 3.1 0.66 0.08 0.90 14.7 40.7 
Right Medial Shank (V) 5.9 0.84 0.52 0.95 6.2 17.1 
Key: IR=infrared; V=virtual; ASIS=anterior superior iliac spine; PSIS=posterior superior iliac spine; 
mm=millimeters; ICC=intra class correlation coefficient; CI=confidence interval; SEM=standard error of 
measure; MDC=minimum detectable change.  
5.3.3. PFP versus control (mixed-sex)  
The mixed-sex PFP cohort ran with significantly greater peak hip adduction (mean 
difference=4.9˚, P=0.01, d=0.91, 95% CI 1.4-8.2) when compared to the control group 
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(see figure 58). No significant differences were identified for any other variable (table 
7). 
7. Comparison between participants with PFP and matched controls for kinematic data  
Variable PFP  
Mean (SD) 
Controls 
Mean (SD) 
Mean 
Difference  
P d 95% CI 
KFLEX 37.7˚ (5.5) 36.6˚ (5.7) 1.1˚ 0.54 0.19 -2.5 to 4.7 
HFLEX 26.0˚ (7.4) 23.8˚ (8.2) 2.2˚ 0.38 0.28 -2.8 to 7.2 
HADD 16.5˚ (4.5) 11.6˚ (6.2) 4.9˚ (+) 0.01* 0.92 1.4 to 8.2 
HIR 9.4˚ (7.6) 7.3˚ (7.0) 2.1˚ 0.37 0.28 -2.6 to 6.8 
Key: SD=standard deviation; KFLEX=peak knee flexion; HFLEX=peak hip flexion; HADD=peak hip 
adduction; HIR=peak hip internal rotation; CI=confidence interval; *=indicates significance; (+) mean 
difference exceeds MDC.  
 
 
58. Graph depicting pooled mean hip adduction for all four groups during running stance phase.  
Key: Solid and dashed error bars reflect 95% confidence intervals for female and male control subjects 
respectively.   
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5.3.4. Sub-group analysis 
Females with PFP ran with significantly greater peak hip adduction compared to 
female controls (mean difference=6.6˚, P=0.02, F=3.41, 95% CI 0.4 to 12.8), with a 
trend towards female runners having significantly greater peak hip adduction when 
compared to male controls (mean difference=6.3˚, P=0.06, F=3.41, 95% CI -0.3 to 12.8) 
(see figure 27). No significant differences were identified for any other variable. Full 
details can be found in table 8. 
 
8. Kinematic sub-analyses for the individual sexes when comparing between participants with and 
without PFP 
 
 
Female 
Controls 
(n=11) 
Mean (SD) 
P Female 
PFP (n=11) 
Mean (SD) 
P Male 
PFP (n=9) 
Mean (SD) 
P Male 
Controls (n=9) 
Mean (SD) 
KFLEX 35.3˚ (4.8) 0.74 37.7˚ (6.3) 1.00 37.7˚ (5.0) 0.99 38.2˚ (6.6) 
HFLEX 23.4˚ (9.7) 1.00 23.1˚ (7.7) 0.26 29.5˚ (5.6) 0.46 24.2˚ (6.5) 
HADD 11.5˚ (7.5) 0.03* 18.1˚ (3.8) 0.47 14.6˚ (4.7) 0.70 11.8˚ (4.5) 
HIR 9.6˚ (5.3) 0.99 10.2˚ (7.3) 0.94 8.4˚ (8.3) 0.67 4.5˚ (8.2) 
Key: SD= standard deviation; KFLEX=peak knee flexion; HFLEX=peak hip flexion; HADD=peak hip 
adduction; HIR=peak hip internal rotation; *=indicates significance.  
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5.4. Discussion 
Our findings indicate greater peak hip adduction during running in the PFP group, 
compared to matched controls when mixed sex comparisons are made. However, this 
difference appears to be influenced by participant sex, with greater peak hip adduction 
in female runners compared to female controls, but no differences in males with and 
without PFP.   
5.4.1. Frontal plane hip kinematics  
Findings of greater peak hip adduction in our mixed-sex cohort of runners with PFP 
compared to matched controls are consistent with Fox et al, who recently reported 
greater frontal plane hip motion during running in their chronic PFP cohort (defined by 
symptom duration >three months) (192). However, they conflict with other mixed-sex 
studies (166, 168, 172), which have reported no differences in peak hip adduction 
when comparing runners with PFP to asymptomatic runners.  
One potential explanation for this conflict is the inclusion of participants with more 
acute PFP by both Dierks et al (168) and Bazett-Jones et al (166) (minimum symptom 
duration one to two months), in contrast to our data from participants with more 
persistent symptoms (mean symptom duration 55.8 [±51.6] months). This hypothesis 
is supported by the recent case-control study by Fox et al (192), who did not report a 
difference in peak hip adduction for their acute PFP cohort compared to asymptomatic 
runners. Interestingly, the cohort from Esculier et al (172) included participants with 
more prolonged PFP symptoms (mean duration 38.1 [45.5] months), with no 
differences between groups reported for their mixed-sex comparison. However, they 
did report a significant difference in peak hip adduction between participants with and 
without PFP when performing a sub-analysis for female participants only, which is 
consistent with our findings. 
5.4.2. Frontal plane hip kinematics: the influence of sex  
Our findings indicate greater peak hip adduction in females with PFP compared to 
female controls. These data are in agreement with the three previous case-control 
studies comparing females with PFP to female controls (52, 53, 169), all of which 
reported higher peak hip adduction during running in the PFP cohorts. Our findings 
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indicate a trend toward greater peak hip adduction in females with PFP compared to 
male controls, but not males with PFP.  
These findings are interesting when considered alongside those reported by Willy et al. 
Consistent with our findings, they reported that females with PFP ran with greater 
peak hip adduction compared to male controls (51). However, contrary to our findings, 
they also reported that their female PFP cohort ran with significantly greater hip 
adduction compared with their male PFP cohort. As the mean difference from our data 
is above the MDC for hip adduction reported by Noehren et al (194) when comparing 
these groups (3.5˚ greater in the female PFP group), it is likely that our smaller sample 
size (n=11 versus n=18) accounts for the lack of statistical significance in our findings. 
Considering sex specific differences identified in our current, and previous studies, 
future studies evaluating running kinematics are advised to report data for males and 
females separately, irrespective of study design.  
5.4.3. Individual kinematic responses  
Some participants from both sexes do demonstrate individual kinematic patterns that 
are in contrast to the mean pooled data (see figure 59). In the male subgroup, there 
were two PFP participants with a peak hip adduction value below the pooled mean of 
the control group (9.8˚ and 6.9˚ respectively), and three control participants with a 
peak hip adduction value above the pooled mean of the PFP group (15.4˚, 15.5˚ and 
16.4˚ respectively). However, in the female subgroup, there were no PFP participants 
with a with a peak hip adduction value below the pooled mean of the control group 
and three control participants with a peak hip adduction value above the pooled mean 
of the PFP group (19.2˚, 19.6˚ and 21.6˚ respectively). Therefore, whilst there is an 
association between increased peak hip adduction during running and PFP, especially 
in females, it may not be a contributor to symptom development or persistence in all 
cases, and not all runners with increased peak hip adduction will develop PFP.  
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59. Individual peak hip adduction data points for participants with and without PFP, with each sex 
presented individually.  
Key: Dotted line - pooled mean of the PFP group; dashed line - pooled mean of the control group (CON).  
5.4.4. Kinematic treatment targets  
Running retraining, defined as any intervention that aims to modify an individual’s 
running technique (89), has an emerging evidence base. In previous observational case 
series, verbal and visual cues to reduce peak hip adduction during running have been 
reported to reduce pain and improve function in females with excessive frontal plane 
hip motion (defined as peak hip adduction > 20˚).  The mean reduction in peak hip 
adduction from both studies was approximately 5˚, which is similar to the magnitude 
of difference between our female PFP cohort and female controls (6.6˚). Considering 
this, and the fact that hip adduction does not seem to be associated with PFP in male 
runners in our, and other groups data (51), it could be suggested that retraining 
runners to reduce peak hip adduction may only be applicable to female runners with 
PFP. However, an absence of benefit from running retraining targeting the hip in males 
with PFP would need to be identified through further research to confirm this. If 
choosing to implement running retraining in males with PFP, alternative strategies 
such as transitioning to non-rearfoot strike or increasing step-rate may be more 
applicable (103, 206, 207).  
5.4.5. Limitations and future directions 
Findings from this study should be interpreted within the context of its limitations. The 
retrospective, case-control design does not allow for the interpretation of causality 
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and it may be that the observed kinematics are simply adaptations to persistent pain 
rather than the primary driver of symptoms (55). Whilst there is some data to support 
the notion that altered hip kinematics may increase the risk of future PFP development 
in female runners (20), there remains a dearth of prospective literature. Further 
research is needed to determine if males and females might have different running 
kinematic risk profiles for the development of PFP. Important participant 
characteristics data such as years of running experience, the presence of bilateral 
symptoms, training volume details and participant footwear choice were not collected. 
As a result, caution needs to be applied with respect to generalising these results to all 
runners in clinical practice and instead considered with respect to the characteristics 
data presented (table 5).    
Treadmill running gait, which was evaluated in this study, may not fully reflect 
kinematics of over ground running. However, it has been reported that hip and knee 
kinematics (208), as well as peak and rate of patellofemoral joint stress (209) are not 
significantly different when comparing treadmill with over ground running in 
asymptomatic populations. As participants were also given approximately six minutes 
to normalise their running gait to the treadmill condition (201), appropriate steps have 
been taken to ensure that the reported results are representative of a participant’s 
typical running gait.               
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5.5. Conclusion 
Our findings indicate runners with PFP have significantly greater peak hip adduction 
when compared to matched controls. This finding appears to be influenced by sex, as 
females, but not males, were found to have significantly greater peak hip adduction 
when compared to sex matched controls. These differences between sexes in 
kinematic profiles may highlight the need for different treatment targets in males and 
females. Future research is encouraged to report lower limb kinematic variables in 
runners with PFP separately for males and females. 
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6. The effects & mechanisms of increasing running step rate: a 
feasibility study in a mixed-sex group of runners with 
patellofemoral pain  
The systematic review presented in chapter four identified limited evidence of short-
term efficacy for running retraining in runners with PFP. Furthermore, it also identified 
limited evidence of a kinematic mechanism of effect, being a reduction in peak HADD. 
At the time of the design of this study, no investigations into the feasibility or efficacy 
of step rate retraining had been completed in a patellofemoral pain cohort. This 
chapter therefore presents a study designed to investigate the feasibility of a step rate 
intervention in a mixed sex cohort of runners with PFP, in addition to data collected to 
determine the effects and potential biomechanical mechanisms of the intervention.  
Preliminary results from this study were presented at both the 2015 (Manchester, UK) 
and 2017 (Gold Coast, Australia) International Patellofemoral Pain Research Retreats 
and the 2016 Danish Sports Medicine Congress in Copenhagen. This study was 
accepted for publication in Physical Therapy in Sport (impact factor 1.919) after two 
rounds of robust peer review (appendix D). A translational publication was also 
produced for the College of Podiatry ‘Podiatry Now’ journal, detailing the clinical 
application of step rate retraining using a case study (appendix E).    
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6.1. Introduction 
Recreational running positively influences cardiac (144), metabolic (146) and mental 
(145) health. Despite the reported benefits, recreational running is reported to bring 
about an increased risk of musculoskeletal pain (8, 12). Overall incidence of 
musculoskeletal pain amongst recreational runners ranges from 19% to 94% (8), with 
patellofemoral pain (PFP) thought to be the most common (14). Specific annual 
incidence of PFP amongst recreational runners ranges from 4% to 21% (19, 20, 27), 
with overall prevalence in sports medicine facilities suggested to be 17% (14).  
Running biomechanics have been reported to be a risk factor for, and associated with, 
running related PFP. Specifically, peak hip adduction during running has been reported 
to be significantly higher in female runners who develop subsequent PFP when 
compared to those who remain asymptomatic (20, 82). In addition, based on our 
recent meta-analysis (82), peak hip adduction, peak hip internal rotation and 
contralateral pelvic drop are also significantly higher in runners with PFP when 
compared to asymptomatic controls. For neuromuscular function, females with PFP 
have been reported to have a delayed gluteal onset prior to foot contact and shorter 
gluteal activation duration compared to asymptomatic controls (164).  
At present, evidence suggests that exercise interventions, whilst effective at reducing 
symptoms in runners with PFP in the short-term, do not result in full symptom 
resolution (83, 84). Moreover, exercise may not derive its effects by way of a kinematic 
mechanism, as multiple studies have demonstrated that exercise programs designed 
to increase hip strength do not alter running kinematics reported to be associated with 
PFP (84, 86-88). This brings into question the ability of exercise interventions to 
provide a long-term resolution to running related PFP, as it fails to target factors 
reported to be associated with the development and persistence of the condition. It is 
this premise that originally led to the development of what has been termed running 
retraining (210), or more specifically ‘the implementation of any cue or strategy 
designed to alter an individual’s running technique’ (89).    
Reports from observational studies, involving visual and verbal cues to reduce peak hip 
adduction, indicates running retraining may reduce pain and improve function in 
female runners with PFP who demonstrate more than 20˚ peak hip adduction during 
 
128 
running (82, 100, 101). The key limitation of this work is that the results can only be 
extrapolated to a minority of runners with PFP (i.e. females with high peak hip 
adduction). The majority of PFP research is done with female subjects, previously 
thought to reflect relative incidence, and there are retrospective indications that sub-
groups exist based on a range of presenting factors including sex (43). For these 
reasons, it was necessary to make sure recruitment was feasible for both sexes.  
In addition, a recently completed RCT has established efficacy for cues to transition 
from rearfoot to forefoot strike in combination with a load management running 
program in a mixed-sex, but again a predominantly female, cohort (103). The limitation 
of this study is that cues to transition to a forefoot strike are only applicable to those 
who rearfoot strike at baseline. Additionally, it is thought that such a change to 
running mechanics may also be injurious by virtue of the increase in Achilles tendon 
load that is observed with forefoot strike running compared to rearfoot strike running 
(104). This is reinforced by the fact that 25% (2/8) of the runners in this RCT who 
transitioned to a forefoot strike pattern reported ankle soreness at follow up (103). 
It has been reported that cues to increase running step rate do not increase Achilles 
tendon load (211) and thus may be a more widely applicable running retraining option 
to those previously studied. A recent feasibility study has reported that a step rate 
increase of 10% combined with running in a minimalist shoe was superior to foot 
orthoses at reducing pain and improving function at 12 week follow up in runners with 
PFP (79). An increase in step rate of 10% has also been reported to favourably alter 
patellofemoral joint stress in both runners with PFP and asymptomatic runners (95), 
though the actual reduction in step length reported was much greater (14%). In 
addition, no evaluation of symptoms could be reported in this study due to the 
limitation of the cross-sectional, observational design. Observational work in 
asymptomatic runners also indicates that more modest increases in running step rate 
of 5% or 7.5% may still reduce peak hip adduction (91, 93), albeit of a smaller 
magnitudes. The collection of biomechanical measures, and an indication of their 
magnitude, was therefore an important feasibility target.  
A recent three-arm RCT (85) found that a running retraining intervention to increase 
step rate was no more effective than education focused on load management, or 
compared to the same education combined with exercise therapy in runners with PFP. 
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Whilst no treatment group had superior outcomes, the step rate intervention did 
result in significant reductions in both worst and running specific pain. All three groups 
remained symptomatic at the primary end point (20 weeks), and running-related pain 
was higher (2.5/10) in the step rate group compared to previous studies where hip 
adduction (0.5/10) (100, 101) and strike pattern (1.0/10) (103) has been targeted. This 
could be explained by the absence of a faded-feedback protocol to facilitate the 
retraining intervention (107), which has been found to be effective by previous studies 
(100, 101, 103).  
A feasibility study design was chosen to prepare for a future efficacy study. Typical 
feasibility outcomes can include intervention development, randomisation 
mechanisms, and delivery experience and randomisationd acceptability, with a full 
range of possible outcomes considered for this study. PFP is a heavily researched topic, 
with a range of trials reported in a variety of groups (including running retraining 
interventions) in similar groups and care delivery settings to those in this study design, 
giving confidence that the feasibility focus could be narrowed. No issues have 
previously been identified suggesting recruitment would be problematic, nor were 
there any no-treatment or sham-treatment groups in the planned future efficacy 
study. It was therefore judged not to be a priority to assess the feasibility of 
randomization. In contrast, the nuances of cueing and the potential difficulties in 
collection of kinematic data were deemed as priorities for feasibility, as these included 
novel aspects hypothesised to be particularly challenging.       
The primary aim of this study was to investigate the feasibility of a pragmatic running 
retraining intervention, by cueing a 7.5% increase in running step rate using a faded 
feedback protocol. Specific objectives included (i) the recruitment of an appropriate 
number of both males and females from a clinical population and (ii) the collection of 
both symptom and function data to determine an estimate of the effects derived from 
the intervention. The secondary aim was to investigate the potential kinematic and 
muscle function mechanisms explaining any effects induced by the intervention.  
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6.2. Methods 
6.2.1. Participants  
Ethical approval for this study was granted by the Queen Mary Ethics of Research 
Committee (QMREC2014/63). All participants provided written informed consent prior 
to study commencement. Using the justification outlined in chapter five, PFP 
participants were recruited from a local sports medicine clinic. Sample size was based 
on the apriori power analysis conducted by the authors of the previous work on 
running retraining (100, 101), leading to a total of 10 participants being sought. 
Participants were of either sex, currently or previously running a minimum of three 
times or > 10 km/week and aged between 18 and 45 years. To be included, 
participants were required to have atraumatic retropatellar or peripatellar pain during 
running and one other activity described by the most recent PFP consensus document, 
which includes squatting, stair ambulation and jumping (4). Patellofemoral symptoms 
needed to be rated at a minimum of three (out of a maximum of 10) using a numerical 
rating scale (NRS). Potential participants with patellofemoral instability, previous 
surgery, tibiofemoral pathology or any pathology (musculoskeletal or otherwise) that 
precluded running participation were excluded.  
6.2.2. Experimental protocol 
Included participants were required to present to the Human Performance Laboratory 
at Queen Mary University of London. In the presence of bilateral symptoms, the knee 
that scored highest on the numerical rating scale was analysed. In the presence of 
equivalent symptoms, the dominant limb that would be used to kick a ball was 
analysed (101). Both limbs were not entered into the analysis in the presence of 
bilateral symptoms given the potential for type I error (195).  
6.2.3. Feasibility outcomes (in order) 
The primary aim of this study was to determine the feasibility of a step rate 
intervention. The following feasibility outcomes were therefore explored, which link 
closely to those explored in other feasibility studies such as Drew et al (212), with the 
planned exceptions as outlined in the introduction. These outcomes are presented in 
the same order throughout the relevant sections below. 
 
131 
Recruitment and eligibility  
Recruitment was assessed using the rate of eligibility (%) and conversion to consent 
(%), as well as the ability to recruit a mixed sex cohort.   
Adherence and acceptability  
Adherence was assessed by attendance to the weekly-supervised step rate retraining 
with the primary investigator (%) and a subjective report of adherence to the 
additional twice-weekly independent retraining sessions (%). Acceptability was 
assessed using the rate of attrition (%) and the number of adverse events reported by 
participants (n).   
Outcome measures    
The percentage of missing outcome data (symptoms, function, mechanistic) was to be 
recorded.  
6.2.4. Treatment efficacy outcomes 
Prior to data collection, participants were also required to rate their average and worst 
pain in the past week from 0 to 10 using an NRS. Participants also completed the 
Kujala Scale as a subjective measure of function (196). The Kujala Scale is a 13-question 
appraisal of subjective function in those with PFP, with a score of 100 representing no 
symptoms and a score of 0 indicating complete disability. Whilst there is no definitive 
outcome measure for use with a PFP cohort, the NRS and Kujala Scale are reported to 
be the most valid and responsive measures for detecting change at time of study 
commencement (213). Symptom and function outcomes were repeated at six weeks 
follow up.  
6.2.5. Mechanistic outcomes  
Running kinematics 
Previously described in detail in chapter five, participant movement data were 
collected during running using a four-camera, infrared motion analysis system (CX-1, 
Codamotion, Charnwood Dynamics Limited, Leicestershire, UK) (214). 24 infrared 
markers, consisting of eight individual markers and four rigid clusters of four markers, 
were placed on standard pelvic and lower limb anatomical landmarks using the CAST 
protocol (198). Markers from the pelvis frame to the knee joint centre tracked the 
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thigh segment and markers from the knee joint centre to the ankle joint centre tracked 
the shank segment. Individual markers were applied using double-sided adhesive tape 
and secured with transparent surgical tape, with the rigid clusters applied using 
adjustable elastic straps and secured with cohesive self-adherent bandage. Virtual 
markers were also identified on the femoral epicondyles and the ankle malleoli, to 
allow for the calculation of relevant joint centers during an upright standing trial.  
Participants were asked to run in their usual running shoes and self-select their typical 
‘steady state’ running speed on the laboratory treadmill (Kistler Gaitway, Kistler 
Group, Winterthur, Switzerland). Participants were instructed to run for a total of 
three kilometers (km), with the option to cease if symptoms increased to four or 
greater on the NRS. 10 seconds of data sampled at 200Hz were collected at 
0.8/1.8/2.8km, with distance as opposed to time chosen to act as a constant measure 
across a cohort of participants running at differing speeds. Multiple data collections 
were completed to increase reliability of gait analysis (202). In order to address 
between group differences identified in our recent meta-analysis (82) (chapter four) 
and the empirical data collected in chapter five, variables of interest included peak hip 
adduction, internal rotation and flexion, peak knee flexion and contralateral pelvic 
drop, given their cross-sectional association with PFP.    
Electromyography measures 
sEMG were collected simultaneously with the kinematic data using a wireless Delsys 
TRIGNO system (DELSYS Inc., Natick, Massachusetts, USA). Prior to application, 
participant’s skin was marked, shaved and cleaned with an alcohol swab. Self-
contained bipolar electrodes were placed at the motor points of the Gluteus Maximus 
(GMAX), Gluteus Medius (GMED), Semitendinosus (ST) and Vastus Medialis Obliqus 
(VMO) adhering to SENIAM guidelines (215). 10 seconds of sEMG data were sampled 
at 1926Hz, an intrinsic setting within the Delsys Trigno sensors designed to optimize 
the communication bandwidth and signal conditioning, and cannot be altered. sEMG 
data were collected at three specific distance points as described above, but were not 
synchronised to the kinematic data as digital synchronicity between Codamotion Odin 
and Delsys Trigno systems was not available at the time of data collection.      
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6.2.6. Running retraining intervention  
Participants completed 18 retraining sessions over the course of six weeks. Each week 
involved a total of three individual runs, equating to 18 runs in total. For the first four 
weeks, the initial run was completed in a supervised fashion with the primary 
investigator (BN). The additional two runs each week were completed independently. 
During the retraining sessions, participants were cued via an audio metronome set at 
7.5% above their baseline step rate (calculated during data acquisition by counting the 
number of foot contacts a participant made in 30 seconds and multiplying by two). The 
decision to increase step rate by 7.5% (rather than 5% or 10%) was made using the 
previous work of Willy et al (93), who reported significant reductions in peak HADD 
with this more modest increase. Whilst not measured by this study, a more modest 
step rate increase was chosen with the premise that it may be more sustainable for 
participants, as biomechanical changes to running gait can have a negative effect on 
running economy (216).  
A faded feedback protocol successfully used previously was adopted (100, 101). 
Feedback exposure was gradually reduced and treadmill run time was gradually 
increased from 10 minutes to 30 minutes (see figure 60), to facilitate skill acquisition. A 
slower progression from 10-30 minutes was used (18 sessions over six weeks) 
compared to previous work (8-10 sessions over two to four weeks), to better adhere to 
contemporary training progression approaches (105). Further, this pace of progression 
is used clinically in the chosen recruitment centre, minimising ethical issues from 
varying usual care. For the final two weeks, all completed sessions were performed 
independently, without any metronome feedback. All data were collected prior to, and 
after completion of, the running retraining intervention.  
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60. Running retraining schedule depicting the faded feedback protocol employed 
6.2.7. Kinematic data analysis  
Data were analysed offline using a custom written Matlab program (version 2015, 
Mathworks, Natick, Massachussets, USA). Initial foot contact and toe off were 
identified using the heel marker on the calcaneal tuberosity and the metatarsal marker 
on the fifth metatarsal head in the vertical (Z) plane. Consistent with previously 
described methods, initial foot contact was defined as the point at which the heel 
marker ceased its descent in the vertical plane (203). Toe off was identified using a 
combination of the heel and metatarsal markers. Specifically, peak acceleration of the 
metatarsal marker was identified within a specific time point, defined by 70% or 
greater of the absolute maximum velocity region of the heel marker (203). All 
kinematic data were aligned to initial foot contact, interpolated and normalised to 
percentage of stride cycle (0% = initial contact, 100% = terminal stance) to facilitate 
data analysis. Clinical relevance of kinematic data was interpreted with reference to 
the minimum detectable change data reported by Noehren et al (194). 
6.2.8. sEMG data analysis 
sEMG data were processed using an in-built band-pass filter from 25-500 Hz. Raw 
sEMG data were decomposed using wavelets (217). Post-wavelet decomposition, data 
were cut into strides using the mean total wavelet power of the VMO muscle, as the 
typical activation pattern of this muscle (onset/offset) during running is reported to 
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align closely to the initial contact (onset) and toe off (offset) phases of running gait 
(218). These stride cycle timings were then applied to all sEMG data. Pre and post 
retraining data were cut into strides independently, but were not used to describe 
sEMG data as though it were synchronised to the true kinematic gait cycle of the 
participant. As participants are unlikely to reach signal intensity akin to maximal 
voluntary isometric contraction (MVIC) during steady state running, data were 
normalised to the mean of the peak dynamic signal intensity across a single set of 
strides (0.8km trial, pre-retraining), which has been reported to be more valid than 
normalizing to maximal dynamic signal peak (219).  
6.2.9. Statistical analysis  
All statistical testing were performed offline using Microsoft Excel (Microsoft 
Corporation, Albuquerque, New Mexico, USA). Data normality were determined using 
Kolmogorov-Smirnov (K-S) test, with all data identified to be normally distributed (P= 
0.39 – 0.91) and parametric statistical tests therefore employed.  
Cohen’s d was calculated to determine the size of all identified interactions, alongside 
the reporting of mean differences and 95% confidence intervals (CI). Cohen’s d was 
interpreted as small (< 0.2), medium (>0.5) and large (>0.8) respectively (205). As a 
feasibility study, not powered apriori to detect statistical significance, dependent 
sample t-tests were not performed and p-values for differences not reported because 
of the potential for type II error and to avoid giving the impression of there being 
robust findings from a feasibility study design. The main outcomes were those of 
recruitment, retention and measurement feasibility.     
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6.3. Results 
6.3.1. Feasibility outcomes 
Recruitment and eligibility  
Potential participants presenting to the recruitment site were sequentially 
approached. All 11 participants approached were eligible to participate and consented 
to commence the study. A total of 10 (out of 11) participants (four male, six female) 
completed the study, reflecting successful recruitment of a mixed-sex cohort. One 
female participant was lost to follow up due to a switch of care provision to the 
National Health Service prior to commencing the intervention. Demographics and 
baseline characteristics of the participants who completed the study are described in 
table 9, which includes details of recruitment according to sex. 
9. Feasibility study participant characteristics   
Variable  Mean (SD) 
Sex (male/female) 4/6 
Age (years) 31.6 (5.5) 
Height (cm) 170.6 (7.8) 
Mass (kg) 67.7 (9.8) 
Symptom duration (months) 45.1 (32.1) 
Average run volume  (km) 17.0 (9.8) 
Step rate (SPM) 163.6 (4.7) 
Kujala scale  86.4/100 (6.9) 
Average NRS  3.0/10 (1.6) 
Worst NRS  6.8/10 (1.5) 
Key: cm=centimeters; kg=kilograms; km=kilometers; SPM=steps per minute; NRS=numerical rating scale. 
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61. Participant flow through the study (CONSORT diagram) 
Adherence and acceptability 
All 10 participants attended all four of their supervised retraining sessions with the 
primary investigator (100% adherence) and reported completing all of their additional 
independent retraining sessions (100% adherence), although this was not objectively 
measured. There was no additional attrition outside of the participant who was lost to 
follow up prior to study commencement and no participants reported an adverse 
event as a result of completing the study.   
Outcome measures  
All symptoms and function data were completed successfully without data loss. One 
participant’s kinematic data were corrupted and were excluded from the analysis and 
a different participant’s sEMG data were corrupted and also excluded from the 
analysis, reflecting 90% data retention.  
6.3.2. Treatment efficacy outcomes 
Large reductions in both average (d=1.7) and worst (d=2.0) pain were identified post-
retraining. The mean difference (MD) of these reductions was 2.1 and 3.9 NRS points 
respectively and individual participant worst pain responses to the retraining 
intervention ranged from 1 to 8 NRS points (see figure 61). A modest improvement in 
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function measured with the Kujala Scale was also identified (d=0.12), with a mean 
difference of 4.4 points. 
 
62. Mean pooled and individual worst pain responses at baseline (pre) and six weeks follow up (post) 
6.3.3. Mechanistic outcomes 
Spatiotemporal  
An increase in running step rate at six weeks follow up was observed, with a mean 
increase of 7.8% (range 2.3% - 11.1%). 3 participants did not achieve a step rate of > 
7.5% post retraining.  
Kinematics 
One participant was found to have consistently corrupted marker data throughout 
their trials and was therefore removed from the kinematic analysis. This resulted in a 
kinematic sample of nine participants (five females, four males). Moderate reductions 
in both peak knee flexion (MD=3.7˚, d=0.78) (see figure 62) and peak hip adduction 
(MD=2.4˚, d=0.54) (see figure 63) were identified post-retraining. A large reduction in 
peak hip internal rotation was also identified post retraining (MD=5.1˚, d=0.96) (see 
figure 64). A full breakdown of the kinematic analysis can be seen in table 10 and 
individual participant spatiotemporal and kinematic responses in relation to 
average/worst pain at six-week follow up are presented in table 11. 
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63. Mean pattern of hip knee flexion throughout stance at baseline (pre) and six week follow up (post).  
Key: Knee flexion is positive. Solid line = mean. Dashed line = 95% confidence intervals 
 
64. Mean pattern of hip adduction throughout stance at baseline (pre) and six week follow up (post).  
Key: Hip adduction is positive. Solid line = mean. Dashed line = 95% confidence intervals 
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65. Mean pattern of hip internal rotation throughout stance at baseline (pre) and six week follow up 
(post).  
Key: Hip internal rotation is positive. Solid line = mean. Dashed line = 95% confidence intervals 
10. Pre and post step-rate retraining means, standard deviations, mean differences, 95% 
confidence intervals and effect sizes 
Variable  Pre  Post  Mean Difference  95% CI Cohen’s d 
  Mean (SD) Mean (SD)      
Average Pain  3.0/10 (1.6) 0.90/10 (0.9) 2.1 (*) 0.88, 3.32 1.7 
Worst Pain  6.8/10 (1.5) 2.9/10 (2.3) 3.9 (*) 2.08, 5.72 2.0 
Kujala Scale  86.4/100 (6.9) 90.8/100 (5.4) 4.4 -10.22, 1.42 0.1 
Peak KFLEX 36.2˚ (5.3) 32.5˚ (4.2) 3.7˚ -1.08, 8.48 0.78 
 Peak HFLEX 26.7˚ (9.3) 23.1˚ (4.9) 3.6˚ -3.83, 11.03 0.51 
Peak HADD 15.6˚ (3.5) 13.2˚ (5.4) 2.4˚ -2.15, 6.95 0.54 
Peak CLPD  4.3˚ (2.7) 2.8˚ (2.4) 1.5˚ -1.05, 4.05 0.59 
Peak HIR  9.1˚ (7.7) 4.0˚ (2.9) 5.1˚ (*) -0.71, 10.91 0.96 
Key: (*)=mean difference exceeds MDC; SD=standard deviation; CI=confidence interval; HADD=hip 
adduction; HIR=hip internal rotation; CLPD=contralateral pelvic drop; KFLEX= knee flexion; HFLEX= hip 
flexion 
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11.  Individual participant kinematic, spatiotemporal and symptom responses to step-rate retraining 
Participant Peak 
KFLEX at 
Follow 
Up 
Peak 
HADD at 
Follow 
Up  
Peak HIR 
at Follow 
Up  
Peak 
KFLEX at 
Follow Up  
Baseline 
Step Rate 
Step Rate % 
Increase 
Average 
Pain at 
Follow Up 
(x/10) 
Worst 
Pain at 
Follow Up 
(x/10)  
1     160 11.1% 1 6 
2     172 2.3% 2 5 
3     168 7.7% 0 0 
4     164 8.9% 0 3 
5     168 7.7% 0 0 
6     164 8.9% 2 2 
7     164 5.7% 0 0 
8     158 10.2% 1 4 
9     158 6.0% 2 4 
Key: HADD=hip adduction; HIR=hip internal rotation; KFLEX=knee flexion; A-NRS= average pain; W-NRS=worst pain. 
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sEMG 
One participant was found to have consistently corrupted sensor data throughout 
their trials and was therefore removed from the sEMG analysis. This resulted in a 
sEMG sample of 9 participants (6 females, 3 males). A mean of peak muscle 
amplitudes, in addition to an integral (amplitude x duration) of each decomposed 
signal were calculated for each muscle pre and post retraining. For mean amplitude, 
minimal changes post-retraining were identified for GMAX (d=0.02), GMED (d=0.07) 
and ST (d=0.05). However, for VMO, an increase in mean amplitude was observed 
post-retraining, associated with a medium effect size (d=0.53, 95% CI -0.09, 0.03). For 
muscle integral, a similar interaction was identified, with minimal changes seen post-
retraining for GMAX (d=0.04), GMED (d=0.04) and ST (d=0.09). For VMO, an increase 
was observed, associated with a medium effect size (d=0.58, 95% CI -0.06, 0.02).  
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6.4. Discussion 
The results of this study suggest that a faded feedback protocol to increase running 
step rate by 7.5%, is feasible in a clinical setting. A mixed sex cohort was successfully 
recruited and a low dropout rate (n=1) was achieved. Furthermore, potential clinically 
relevant changes in both average and worst pain were identified post-retraining, 
suggesting that the intervention has potential efficacy and warrants further appraisal 
in an adequately powered RCT.  
The mean reductions in both average and worst pain seen within this study are smaller 
than those identified by previous running retraining studies (100, 101, 103), although 
no inference on average or worst pain as individual outcomes were made by these 
studies and the feedback employed was different. Further, both this feasibility study 
and the referenced works were essentially underpowered for all but the most 
preliminary of conclusions. When analysing the reductions in worst pain from this 
study, only 3/10 participants were asymptomatic at six-week follow up and just one 
participant had pain < 3/10. This means that the 6 remaining participants would 
continue to be eligible for inclusion into a clinical trial using currently accepted criteria 
(4), meaning that the intervention could be defined as unsuccessful in 60% of our 
cohort if using worst pain as the primary outcome.  
A recent high quality RCT identified that a 7.5% step rate increase, with the option of 
transitioning to a forefoot strike pattern if deemed necessary, was no more effective 
than comparative education or exercise interventions (85). When comparing the 
symptom reductions achieved in this study (6 week follow up) to the most relevant 
time point in the Esculier et al RCT (8 week follow up) (85), both average and worst 
VAS are comparable for our step rate intervention compared to all 3 intervention 
groups (education, exercise plus education, running retraining plus education). It could 
be suggested that running retraining is in fact a form of load management or graded 
exposure, which may explain why it was found to be no more effective than education 
on training loads by Esculier et al (85). However, Roper et al (103) reported efficacy of 
retraining from rearfoot to forefoot strike running. Importantly, this retraining strategy 
produced larger pain reductions when delivered using a faded feedback protocol, over 
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and above an equivalent progressive duration running protocol. This suggests that a 
form of feedback is required over and above a load management intervention where 
there is a clinical need. A further potential explanation for the more modest symptom 
responses to step rate retraining reported by Esculier et al (85), is that feedback is 
likely to have needed  to be subject or subgroup specific and not all participants will 
have a baseline step rate amenable to an increase.  
Previous studies on running retraining have established a potential kinematic 
mechanism at the hip to explain their positive effects, specifically a 5˚ reduction in 
peak hip adduction (100, 101). The results of this study are in line with this, identifying 
a smaller but still clinically meaningful mean difference of 2.4˚ that was associated 
with a moderate effect size (table 10). Our mixed-sex sample could explain this smaller 
mean difference, as the previous work of both Noehren et al (100) and Willy et al (101) 
purposefully recruited female participants with higher than average peak hip 
adduction, which may be more amenable to change. However, as our results have 
identified a reduction in peak hip adduction equivalent to a previous 7.5% step rate 
increase study in asymptomatic runners (93), it is suggested that a larger increase in 
step rate (10%) will result in greater reductions in peak hip adduction equivalent to 
those seen in asymptomatic runners (91). A 10% step rate increase is reported to 
reduce both patellofemoral joint stress (95) and pain (79) in runners with PFP, whereas 
a 7.5% step rate increase (85) resulted in non-significant changes in both peak 
patellofemoral reaction force and average patellofemoral loading rate in a recent RCT. 
Clinically, it may be sensible to start retraining with a more modest 7.5% step rate 
increase, increasing to 10% or greater if tolerated, especially in those with low baseline 
step rate.  
In addition to reducing peak hip adduction, the results of this study have identified two 
novel potential kinematic mechanisms, being a reduction in both peak hip internal 
rotation and knee flexion. The identified mean difference in peak hip internal rotation 
of 5.1˚ is above the MDC of 3.7˚ reported by Noehren et al (194) and was associated 
with a large effect size (d=0.96). Peak hip internal rotation is associated with running 
related PFP (82) and can result in increased patellofemoral joint stress by increasing 
contact pressures at the lateral patellar facet (220). Thus, given the plausibility for 
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reducing hip internal rotation during running gait to favourably alter PFP symptoms 
and the size of the identified effect, one could argue that a clinically meaningful 
change has been identified.  
A reduction in peak knee flexion of 3.7˚ is in line with the work of Lenhart et al (94), 
who reported a reduction in peak knee flexion of 3.3˚ with a 10% step rate increase in 
a normative cohort. Within this musculoskeletal model, (94) peak knee flexion 
correlates positively with patellofemoral joint force, indicating this finding may be 
clinically relevant. This effect is likely due to changes in patella contact pressures, as a 
subsequent modeling study reports that lateral patellar arthrokinematics were not 
significantly altered by a 10% step rate increase (221). At an individual level, kinematic 
changes seem to correlate poorly with symptom improvements post-step rate 
retraining (see table 11). For example, two participants (one male, one female) had an 
increased peak hip adduction post-retraining (see table 11), with both participants 
asymptomatic for both average and worst pain variables. For the female participant, 
the increase in peak hip adduction (6.6˚) exceeds the MDIC (2.6˚) and is thus less likely 
to be related to measurement error. Future studies should look to investigate 
alternative potential mechanisms of running retraining, such as kinetic changes, load 
management or graded exposure. 
Previous observational research investigating increasing step rate by 10% has 
identified increased quadriceps activation (96) comparable to the increase seen within 
this study. VMO activity is known to be altered in some individuals with PFP (185) and 
VMO weakness is reported to correlate with lateral patella shift (222). Whilst this study 
design prohibits inference of causality, this sEMG finding may be associated with the 
reduction in pain seen post-retraining.  
The lack of change in mean gluteal EMG identified by this study is perhaps not 
surprising given the work of Willson et al (164), who reported no differences in mean 
gluteal sEMG when comparing female runners with PFP to matched controls. Willson 
et al (164) do however report that female runners with PFP demonstrate a shorter 
GMED activation window and delayed onset prior to foot contact in females with PFP. 
Additionally, Willy & Davis (102) reported earlier GMED activation and an increased 
GMED activation duration in a small case series of two female runners with PFP post-
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mirror running retraining. Combined with findings from our study, this indicates that 
changes to gluteal muscle activation patterns rather than magnitude may provide 
mechanistic explanation for the reduction in pain. Further research is needed to 
explore this and a limitation of the current study is the fact that the sEMG were not 
synchronised to the kinematic system, meaning not all variables of interest from the 
previous literature could be investigated.  
6.4.1. Limitations and future directions 
Based on the results of this feasibility study, a future RCT should look to compare a 
step rate intervention against an exercise therapy control, with investigation of effects 
to long-term follow up at 12 months advocated. However, as no control arm was 
included in this feasibility study, the results cannot be used to directly inform a sample 
size calculation for a definitive trial. Post-intervention data from the exercise group of 
a comparable high quality study in a similar population (85) were therefore used to 
estimate required sample size. When using post-retraining ‘worst pain’ data from this 
study (mean NRS 2.9 ±2.3) and post-exercise ‘worst pain’ data taken from Esculier et al 
(85) at a comparative time point (four weeks post-intervention, mean NRS 4.4 ±2.5), a 
sample size of 42 participants per group with a two-tailed hypothesis is required to 
achieve α=0.05, 1-β=0.20, with a Cohen’s d of 0.6 (calculated using G*Power 3.1.9.2, 
Heinrich-Heine University, Germany).   
A further limitation of the absence of a control arm in this study is that it is difficult to 
be certain about the feasibility of recruitment and subsequent randomisation to a 
choice of interventions – in this case, usual care consisting of exercise therapy which is 
of proven efficacy. It could be suggested that the potential randomisation to an 
exercise therapy arm would not affect recruitment negatively, given the frequently 
reported effectiveness of exercise therapy for PFP and the genuine equipoise that 
could be communicated to, and engendered in, potential participants. Furthermore, an 
unusually high rate of eligibility was observed in this study (100%). This is likely to be 
reflective of either significant fortune or the nature of the recruitment centre (a 
private sports medicine facility), which is unlikely to be replicable in other settings.    
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Perhaps reflecting the relative ease of performing RCTs for PFP, feasibility studies are 
not commonly published in this field. Further, qualitative evaluation of the trial 
process and intervention delivery has not been found in any recently published PFP 
RCT, nor any recently published feasibility studies (79, 212), but could have been 
useful to inform subsequent trial design. For example, it may have informed the 
package of PPI activities essential to future efficacy trial design and delivery 
(www.invo.org.uk). Further, it would have added an additional element of process 
evaluation, such as helping develop a logic model and complementing the existing 
elements such as adherence. These improvements will be considered for future 
studies. 
If I, or other colleagues, were considering using our results to inform a large-scale 
intervention study, then a nested pilot study would be an appropriate part of the 
design. This would be particularly useful if an effectiveness rather than efficacy study 
were planned, given the difficulties in extrapolating efficacy findings to real-world 
usual-care settings, allowing for the investigation of both recruitment and 
randomization. A ‘stop/go’ approach should be applied, with the trial ceasing if issues 
with participant safety or difficulties in recruiting resultant from the comparative 
treatment arm were encountered. If one intervention arm was identified to 
demonstrate significant superiority over the other prior to the planned trial end point, 
the trial should also be ceased.      
Future work on running retraining should consider use of a faded feedback protocol, as 
it appears to result in superior outcomes. Recruitment of participants with a step rate 
of <160 (>1 SD below the mean of this cohort), who are more likely to be amenable to 
step rate retraining, or stratifying outcome analysis by baseline cadence, is worth 
considering – a strategy that would require greater samples but produce more 
generalisable findings. Sub-group analysis by baseline kinematic variables associated 
with PFP such as hip adduction may also be indicated, though kinematic variables do 
not appear to be sensitive to predicting those who may respond to a step rate 
intervention.  
Future studies should also ensure that a full compliment of participant characteristics 
is collected, to allow for results to be fully generalisable. Potentially important data 
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such as the presence of bilateral symptoms, the percentage of participants who had 
received previous intervention and years of running experience were not collected in 
this study, meaning that the results may not be applicable to all recreational runners 
with PFP.    
Whilst this feasibility trial was not powered apriori to investigate treatment effects, a 
post-hoc calculation using the mean difference of both average and worst pain 
revealed that a sample of 10 participants is adequate to investigate symptom changes 
post-step rate retraining with adequate statistical power (α=0.05, β=0.20). It is 
therefore advisable that future trials adhere to the so-called rule of 10, ensuring 
recruitment of 10 participants per individual variable investigated to minimize risk of 
bias (120). 10% of the biomechanical data in this study was lost due to data corruption 
and it is advisable that this be factored in to any sample size calculation for 
mechanistic outcomes in future studies.  
Comparing the results of this study to the previous work on running retraining proved 
challenging given the heterogeneity of pain outcomes collected. It is advisable that 
future work collects data on both average/usual and worst/running related symptoms 
to allow for more clinically meaningful comparisons. The mean difference in the Kujala 
scale identified falls well below the accepted MCID of 10 points (213) and given the 
high baseline scores seen in the population studied, a ceiling effect can be suggested. 
Future studies are advised to consider an alternative measure of subjective function, 
with the LEFS, used by previous studies (100, 101), and the recently developed 
patellofemoral subscale of the Knee Osteoarthritis Outcome Score (KOOS) (223), 
particularly worthy of consideration.  
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6.5. Conclusion 
The results of this study confirm that increasing running step rate using a faded-
feedback protocol is a feasible intervention, within the constraints of the feasibility 
outcomes assessed by this study, that has potential efficacy in a mixed sex UK cohort. 
Future studies should focus on investigating the long-term efficacy of running 
retraining in a cohort that have a clear treatment target (e.g. low step rate), compared 
to an appropriate control. A nested pilot study may be useful if effectiveness studies 
are planned. Based on this feasibility study, a sample size of ten participants per 
group/variable is adequate to detect minimum clinically important differences with 
adequate statistical power, although a more sophisticated calculation may be required 
if stratification is planned. In addition to future work establishing efficacy, exploration 
of different forms of feedback and treatment mechanisms is encouraged.  
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7. Is two-dimensional video a valid and reliable measure of 
three-dimensional kinematics in runners with PFP?  
The previous chapters presented in this thesis have identified data which suggest that 
lower limb biomechanics are associated with the development (chapter four), 
persistence (chapters four and five) and management (chapter six) of PFP in 
recreational runners. Specifically, peak HADD was identified to be associated with the 
development of PFP in female recreational runners, as well as being associated with 
the persistence of PFP in mixed-sex cohorts of runners. Furthermore, both reduced 
peak HADD and KFLEX were identified to be potential mechanisms of effect following 
step rate retraining. 
A limitation of these above data is the current divide between research and clinical 
practice, with respect to the measurement of human biomechanics. This fault lies not 
with our understanding of how biomechanical variables are associated with PFP, but 
with the paucity of validated clinical tools suitable for use in the clinical setting. Given 
the new knowledge identified by the previous chapters of this thesis, it was deemed an 
important translational piece of  work to consider a solution to enable clinicians to 
measure the relevant variables described in the wider literature and in this thesis. This 
penultimate thesis chapter therefore aimed to determine the accuracy of video gait 
analysis, which presents a pragmatic and clinically applicable solution to this problem.  
Data are presented for the concurrent validity and intra-rater reliability of high frame 
rate 2D video, with respect to 3D kinematic analysis.  
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7.1. Introduction 
Recreational running is a common form of exercise (15) associated with both positive 
health benefits (11) and high rates of musculoskeletal injury (12). The knee is reported 
to be the most prevalent joint involved in running-related musculoskeletal injury (14, 
15), with patellofemoral pain (PFP) reported as the most prevalent diagnosis (14). 
Whilst all musculoskeletal injuries are likely to be multi-factorial (140), peak hip 
adduction (HADD) has been reported as a risk factor for future PFP development in 
female runners (20) and is associated with the persistence of PFP in mixed-sex cohorts 
(82). Peak HADD of >20˚ and a reduction in peak HADD of 5˚ are also reported to be 
the treatment target and mechanism of effect underpinning running retraining in PFP, 
respectively (82, 90).  
Despite understanding of the associations between lower limb biomechanics and PFP 
improving positively in recent years, there remains a paucity of validated, clinical tools 
with which to measure these variables (82). Accurate 2D measurement of running 
kinematics has the potential to positively influence clinical practice, with guidelines for 
2D running gait analysis available (224). Multiple studies have reported intra- and 
inter-rater reliability of 2D video analysis during running in asymptomatic cohorts, 
covering gait phases (225), foot strike (226) and uniplanar hip and knee kinematics 
(227). However, 2D video has limited value unless construct validity in injured runners 
can be established, confirming that 2D observations are truly representative of three-
dimensional (3D) kinematic motion capture (228). 
Two previous studies provide support for the concurrent validity and reliability of high 
frame rate 2D video for measuring peak HADD in asymptomatic runners, in 
comparison to 3D kinematic motion capture (108, 109). Maykut et al (108) reported a 
significant moderate correlation between 2D and 3D measurement for peak HADD 
during treadmill running (r=0.53-0.62). In addition, Dinengen et al (109) reported a 
significant, positive correlation for peak HADD during over ground running, using a 
discrete 2D variable to predict the entire 3D kinematic curve from initial ground 
contact through to toe off. Both of these studies reported their 2D video methodology 
to be reliable (ICC 0.90-0.99). These findings are based on asymptomatic runners, 
  
152 
limiting the external applicability to clinical populations. Kinematics of runners with 
PFP may affect the relationship between 3D and 2D measurement, as runners in pain 
are theorized to have greater movement variability (167), and have been reported to 
move differently in multiple planes in comparison to asymptomatic runners. 
Investigating the validity and reliability of 2D and 3D measures of lower limb 
kinematics within a symptomatic population is therefore justified. 
Previous studies investigating construct validity for 2D video to measure peak HADD 
have failed to report perfect agreement between 3D and 2D measurement. Runners 
with PFP have also been reported to demonstrate increased peak hip internal rotation 
(HIR) in comparison to controls (39, 51-54, 82). Transverse plane motion at the hip is 
theorized to be coupled with HADD and tibial abduction, referred to in combination as 
dynamic knee valgus (45). Determining the impact of this movement direction on the 
variability observed between 3D and 2D measurement may therefore yield the answer 
as to the source of the expected imperfect agreement (229). 
A further limitation of previous studies has been their focus primarily on establishing 
validity for frontal plane variables, given their reported associations with common 
running-related pathology (82, 230, 231). In runners with PFP, peak knee flexion is also 
a variable of interest, as it is reported to affect patellofemoral joint stress (94) and may 
be associated with symptomatic improvements after a step rate retraining 
intervention (206). An investigation into the validity of clinical measurement of 
variables in the sagittal plane was therefore warranted.  
This study aimed to determine the accuracy of 2D video gait analysis for runners with 
PFP. The primary objective was to investigate the concurrent validity and intra-rater 
reliability of high frame rate 2D video in relation to 3D kinematic motion capture. 
Given the expected imperfect agreement between 3D and 2D kinematics, a secondary 
objective was to investigate the source of any identified disagreement using logistic 
regression, with peak HIR used as a covariate. The null hypothesis was that 2D video 
would not give useful measurements of acceptable accuracy with respect to 3D 
kinematic analyses.     
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7.2. Methods  
The Queen Mary Ethics of Research Committee (QMREC2014/24/103) gave approval 
for this study.  
7.2.1. Participants 
To be eligible, participants were required to report retropatellar or peripatellar pain 
for a minimum of one month, during at least one activity of running, squatting, stair 
ambulation and jumping (4). As described in chapter five, this definition of PFP was 
used to ensure that the outcomes from this study would be comparable to other 
studies in the field. A specific recreational running cohort was not sought for this 
chapter, as recruitment was nested within recruitment for a larger study requiring 
greater heterogeneity of sports and hobbies during which symptoms were present. 
Participants with patellofemoral instability, tibiofemoral pathology or other 
concomitant pathology were excluded.  
The Tegner Activity Scale was collected to act as a constant measure across a 
heterogeneous cohort of participants with PFP who participated in a variety of sports 
and hobbies (232). Height and mass were collected to allow for the calculation of BMI, 
reported to be higher in those with persistent PFP (136). Symptom duration, Kujala 
scale and average pain using an NRS were collected as a reflection of symptom severity 
and persistence, reported to alter running kinematics (192).   
7.2.2. Sample size calculation  
Using peak HADD 3D and 2D means and a pooled SD for the right limb from Maykut et 
al (108) (2D HADD 11.2˚ [±2.7], 3D HADD 14.0˚ [3.7]), a sample size of 21 participants 
was required to achieve α 5% and β 80%. 21 participants with PFP (10 male, 11 female) 
were conveniently sampled from local sports medicine clinics (see table 12). All 
participants provided written informed consent prior to participating.  
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12. Participant characteristics for 3D/2D study  
Variable Mean (SD) 
Age (years) 32.1 (12.9) 
Height (cm) 169.1 (45.2) 
Mass (kg) 69.8 (19.6) 
BMI  23.2 (2.6) 
Tegner score  5.5 (1.3) 
Symptom duration (months) 53.1 (84.5) 
Kujala scale 76.2 (12.9) 
Average NRS 4.7 (2.0) 
Key: SD=standard deviation; cm=centimeters; kg=kilograms; BMI=body mass index; NRS=numerical 
rating scale. 
7.2.3. 3D kinematics 
3D kinematic data were collected during running using a four-camera, infrared motion 
analysis system runnung Odin software (CX-1, Codamotion, Charnwood Dynamics 
Limited, Leicestershire, UK) (214).  
As described in detail in chapter five, a total of 24 infrared markers were placed on 
standard pelvic and lower limb anatomical landmarks using the CAST protocol (198). 
Intra-rater reliability of kinematic marker placement for the primary investigator (BN) 
had previously been identified to be moderate to excellent (ICC 0.62 – 0.93). Eight 
individual markers (powered by a drive box) were placed on bilateral pelvic landmarks 
(ASIS and PSIS) and foot landmarks (lateral calcaneal tuberosity and head of fifth 
metatarsal). Specifically, bilateral foot markers were placed on the participant’s shoe 
as an estimate of the anatomical location, given the potential for running barefoot to 
effect running kinematics (199). Additionally, four rigid clusters of four markers were 
placed on the bilateral thigh and shank segments.  
Individual markers were applied using double-sided adhesive tape and secured with 
transparent surgical tape. Rigid clusters were secured using a combination of 
adjustable elastic straps and cohesive self-adherent bandage, to minimise the 
potential for cluster displacement during a high force activity. Virtual markers were 
also identified on the femoral epicondyles and the ankle malleoli bilaterally, using a 
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pointer tool during a static calibration trial. These virtual markers allowed for the 
calculation of relevant joint centres, which did not differ between male and female 
participants.  
7.2.4. 2D kinematics 
2D kinematic data were captured using two high frame-rate smartphone cameras 
(iPhone 6, Apple Corporation, California, USA) recording at 240/frames per second. 
Cameras were mounted on stable tripods 1.0 metre from the laboratory floor. The 
camera recording in the sagittal plane was placed at a distance of 2.5 metres from the 
centre of a ground-embedded force plate, which participants subsequently ran past. 
The camera recording in the frontal plane was placed 6.5 metres from the centre of a 
ground-embedded force plate, which participants ran directly towards (see figure 66).  
 
66. Laboratory set up for 3D/2D motion analysis project  
7.2.5. Experimental protocol  
Participants presented to the Human Performance Laboratory at Queen Mary 
University of London. Both 3D and 2D data were captured during trials of over-ground 
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running. Participants were provided with neutral running shoes in their required size 
(Asics Nimbus, Asics, Cheshire, UK), to minimise potential effects of footwear variation 
on running kinematics (233). Participants were instructed to run in a straight line for a 
distance of 10.0 meters at a self-selected speed, landing the foot of their symptomatic 
limb on a ground-embedded force plate (Type 9281CA, Kistler Corporation, 
Switzerland).  
 
67. 3D real time view within Odin software detailing force plate contact and vertical ground reaction 
force output (pink)  
The ground-embedded force plate was 5.0 metres from the trial start-point, with 
participants typically making contact with their fifth step. Several practice runs were 
permitted to allow for familiarisation and to ensure adequate force plate contact 
during a participant’s natural running gait (see figure 67). This process was repeated 
until five successful trials were obtained, with a successful trial defined as an 
appropriate landing of the correct foot directly onto the force plate without visual 
adjustment of running gait. Each trial was initiated by a member of the research team, 
with the 3D system and both 2D cameras manually synchronised using a numerical 
countdown.  
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68. Flowchart depicting application of infrared markers, virtual markers and subsequent data collection  
7.2.6. Data analysis  
To reduce the potential for type I error, data pertaining to one limb only were entered 
into the analysis (195). For participants with bilateral symptoms, the limb that rated 
the highest on the numerical rating scale was evaluated. In the presence of equivalent 
symptoms the dominant limb was evaluated, defined by the limb that the participant 
would use to kick a ball.   
3D kinematic analysis  
Data were analysed offline using a customised Matlab program (version 2015, 
Mathworks, Natick, Massachussets, USA), using a graphical user interphase (GUI). 
Initially, a 20N threshold from the ground-embedded force plate was used to 
determine initial contact and toe-off respectively (see figure 69). 
 
69. Vertical ground reaction force within data analysis GUI  
Kinematic data were processed within this event window, defined as running stance 
phase. An International Society of Biomechanics advocated XYZ (sagittal, frontal, 
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transverse) cardan rotation sequence was used. Peak joint angles for both peak hip 
adduction (HADD) and knee flexion (KFLEX) were visualised and subsequently exported 
to a Microsoft Excel ‘comma separated value’ (.csv) file for statistical analysis.  
 
70. Section of Matlab code within GUI detailing identification of relevant peak joint angles   
 
71. Raw kinematic data trace for both hip and knee within running stance phase event window  
2D kinematic analysis 
Videos from successful trials were subsequently imported into the Hudl Technique 
application (Hudl, Agile Sports Technologies Inc., Nebraska, USA) for analysis. Two 
independent 2D angles, hip adduction (HADD) and knee flexion (KFLEX) were 
identified. HADD was determined using methods described by Dingenen et al (109), 
where the contralateral pelvic drop (CLPD) angle is added to the femoral adduction 
(FADD) angle. CLPD was defined as the angle formed by a horizontal line from the 
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stance limb anterior superior iliac spine (ASIS) (referenced from the laboratory floor) 
and the swing limb ASIS (see figure 72). FADD was defined as the angle formed by a 
horizontal line from the stance limb ASIS (referenced from the laboratory floor) and 
the centre of the stance limb tibiofemoral joint (an estimation of the knee joint centre) 
(see figure 72). Infrared ASIS and PSIS markers used for 3D kinematic data collection 
were used to determine the location of these landmarks on 2D video.  
KFLEX was defined as the angle formed by a line drawn from the stance limb greater 
trochanter to the lateral femoral condyle and a second line drawn from the stance 
limb lateral femoral condyle to the stance limb lateral malleolus (see figure 72). For 
both variables, a peak angle was estimated, determined to be when the participant 
reached the peak of mid-stance, manually defined as the point where maximal foot 
contact had occurred and no upward/downward motion was occurring (108).    
 
72. Figure demonstrating the calculation of 2D joint angles 
7.2.7. Statistical analysis 
All analyses were performed using SPSS (version 22 for MacOS, IBM, New York, USA). 
Data normality were determined using Kolmogorov-Smirnov (K-S) test, with all data 
identified to be normally distributed (P= 0.31 – 0.74) and parametric statistical tests 
therefore employed. 
  
160 
Concurrent validity  
Means of the five 3D and 2D trials were calculated, leaving one pooled mean 3D and 
2D value for each participant for both variables of interest (HADD and KFLEX). The 
difference between the 3D and 2D means was determined using two-tailed, paired t-
tests. Scatter plots were used to visualise the directionality of the relationship 
between 3D and 2D measurement. To determine concurrent validity between 3D and 
2D measurement, single measure ICCs with 95% confidence intervals were calculated 
using a two-way mixed effects model with absolute agreement. ICCs were defined as 
excellent (> 0.90), good (0.75-0.90), moderate (0.50-0.75) and poor (< 0.50) 
respectively (204). Bland and Altman plots with 95% limits of agreement (LOA) were 
used to visually represent the agreement between the 3D and 2D values (234). In 
addition, a backward linear regression was performed to assess the effect of including 
3D hip internal rotation (HIR) in a predictive model, with the F change statistic used to 
determine the significance of 3D HIR as a covariate.  
Intra-rater reliability 
Peak HADD and KFLEX values from the first run trial of all participants was analysed 
twice, with 24 hours between analyses. Reliability was determined using single 
measure ICCs with 95% confidence intervals using a two-way mixed effects model with 
absolute agreement.   
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7.3. Results  
7.3.1. Concurrent validity 
There was a significant difference between 3D and 2D measured peak KFLEX, but peak 
HADD was not significantly different between 3D and 2D measures (table 13). ICC’s 
identified poor agreement for both peak HADD and peak KFLEX between 3D and 2D 
measurement (table 14).  
13. 3D and 2D data for both peak HADD and KFLEX  
Variable 3D Measurement 
Mean (SD) 
2D Measurement 
(Mean  (SD) 
Difference 
Mean  
P d 
HADD 12˚ (4.7) 13˚ (3.2) -1˚  0.25 -0.27 
KFLEX 38˚ (5.5) 43˚ (3.3) -5˚ <0.01* -1.13 
Key: 3D= three-dimensional; 2D=two-dimensional; SD=standard deviation; HADD=hip adduction; 
KFLEX=knee flexion. 
 
73. Scatter plot for peak 2D and 3D peak HADD  
Key: dashed lines represent a line of identity, solid line represents the line of best fit.  
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74. Scatter plot for peak 2D and 3D peak KFLEX  
Key: dashed lines represent a line identity, solid line represents the line of best fit.  
 
14. Construct validity data for peak HADD and KFLEX comparing 3D and 2D measurement 
Outcome  HADD KFLEX 
ICC (95% CI) 0.06 (-0.35, 0.47) 0.42 (-0.10, 0.75) 
Upper LOA 9.4 2.6 
Lower LOA -12.3 -12.1 
 
Key: HADD=hip adduction; KFLEX=knee flexion; ICC=intraclass correlation coefficient; CI=confidence 
interval; LOA=limits of agreement. 
 
For peak HADD, Bland and Altman analysis identified wide limits of agreement and a 
broad spread of data with no bi-modal distribution (see figure 75). This indicates poor 
agreement (ICC 0.06) between 3D and 2D measurement that is not resultant of a 
systematic bias. For peak KFLEX, Bland and Altman analysis again reveals wide limits of 
agreement indicating poor agreement between 3D and 2D measurement (see figure 
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76). There is however a linear directionality to these data, suggesting the identified 
poor agreement (ICC 0.42) is result of a systematic bias, further indicated by the line of 
equivalence observed on the scatter plot for these data (see figure 73).      
 
75. Bland and Altman plot for peak HADD  
Key: dashed lines represent upper and lower limits of agreement, solid line represents the pooled mean 
difference between 3D and 2D measurement.  
 
76. Bland and Altman plot for peak KFLEX  
Key: dashed lines represent upper and lower limits of agreement, solid line represents the pooled mean 
difference between 3D and 2D measurement.  
  
164 
7.3.2. Intra-rater reliability 
Moderate intra-rater reliability was identified for peak HADD (ICC 0.65 95% CI 0.34, 
0.83) and peak KFLEX (ICC 0.61 95% CI -0.09, 0.87).  
7.3.3. Logistic regression  
A multiple variable, backward linear regression was calculated to predict 3D peak 
HADD (dependent variable) using 2D HADD (independent variable1) and 3D HIR 
(independent variable2). R2 of the model was 0.06, with a non-significant F change 
(0.07, p = 0.93) identified after the removal of 3D HIR (R2 change = -0.01).    
A second multivariable backward linear regression was calculated to predict 3D KFLEX 
(dependent variable) using both 2D KFLEX (independent variable1) and 3D HIR 
(independent variable2). R2 of the model was 0.60, with a non-significant F change 
(3.76, p = 0.06) identified after the removal of 3D HIR (R2 change = -0.08). 
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7.4. Discussion 
This study aimed to determine the appropriateness of clinical gait analyses for runners 
with PFP, by investigating the concurrent validity and intra-rater reliability of high 
frame rate 2D video. Accepting our null hypothesis, a poor correlation between 3D and 
2D measurement was found for both peak HADD and peak KFLEX, reflected by poor 
ICCs and wide limits of agreement. In the presence of acceptable intra-rater reliability, 
these data suggest that pragmatic 2D video does not have acceptable accuracy with 
respect to 3D kinematic outcomes for runners with PFP when measuring both peak 
HADD and peak KFLEX.     
Our findings for peak HADD conflict with the work of both Maykut et al (108) and 
Dingenen et al (109), who reported significant correlations between 3D and 2D 
measured peak HADD. The primary explanation for this disagreement is the 
investigation of a cohort of participants with PFP in comparison to participants who 
are asymptomatic. Reflective of a typical cohort with persistent PFP (mean symptom 
duration 53.1 months), our participants had a higher BMI (mean 23.2) than the 
previously studied asymptomatic cohorts. This may have negatively affected the 
accuracy of 2D video digitisation by increasing the visual distortion of necessary bony 
landmarks. Furthermore, our PFP cohort had a lower physical activity level (mean 
Tegner Scale 5.5) in comparison to the elite asymptomatic cohorts investigated by 
both Maykut et a(108) and Dingenen et al (109) (estimated Tegner Scale 8-10). Elite 
runners are reported to have more consistent kinematics than recreational runners 
(235), which is likely to have resulted in a more stable mean and thus, increased 
agreement between 3D and 2D measurement (236).      
A further explanation for this conflict is the statistical methodologies employed. 
Maykut et al (108) calculated a Pearson’s Correlation Coefficient (r) which may over-
estimate the agreement between two variables when data demonstrates a linear 
trend (237). Peak HADD data from our study does not appear to have a systematic bias 
(i.e. consistently over or under predict) and the data does not follow a linear trend, 
with a Pearson’s r comparable to the calculated ICC (r=0.07). Dingenen et al (109) 
employed statistical parametric mapping, which does not confirm that the 2D method 
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used can accurately predict a discrete 3D value at a specific point within the gait cycle. 
Clinicians often seek a discrete kinematic variable within the gait cycle to employ 
clinical prediction rules, such as a 5˚ reduction in peak HADD as a predictor for running 
retraining success (100, 101), and the clinical applicability of this study is therefore 
limited. 
An additional discrepancy between our study and the work of both Maykut et al (108) 
and Dingenen et al (109) is the software used to assess the 2D videos. We evaluated 
the construct validity of the Hudl Technique application (Hudl, Agile Sports 
Technologies Inc., Nebraska, USA), given its ease of clinical application. Hudl Technique 
is free of cost at the point of access and can be installed on a variety of devices (mobile 
phones and tablets) and operating systems. The Dartfish software (Dartfish, Fribourg, 
Switzerland) used in previous studies may offer greater precision, where digitizing 2D 
video is completed using a mouse rather than the assessor’s finger on a touch screen. 
The limitation of Dartfish as a method of 2D video digitization is the associated cost 
(£204-£880 per calendar year). Table 15 summaries the similarities and differences 
between this study and the previous work of both Maykut et al (108) and Dingenen et 
al (109).  
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15. Similarities/differences between this study and previous 3D/2D running kinematic 
measurement 
 This study  Maykut et al  
(108) 
Dingenen et al  
(109) 
Population studied Physically active 
persons with PFP 
(m=10, f=11) 
Asymptomatic 
elite runners  
(m=14, f=10) 
Asymptomatic 
elite athletes  
(m=6, f=9) 
Participant BMI  
Mean (SD) 
23.2 (2.6) 20.0 (1.4) 21.1 (2.1) 
Participant age (years) 
Mean (SD) 
32.1 (12.9) 19.9 (1.3) 18.7 (1.6) 
Running method Over ground Treadmill Over ground 
2D analysis software HUDL Dartfish  Dartfish  
Statistical method ICC Pearson’s r SPM 
Frontal plane camera 
distance from axis  
6.5 meters ? 4.5 meters 
Key: SD=standard deviation; 2D=two dimensional; m=male; f=female; ICC=intraclass correlation 
coefficient; SPM=statistical parametric mapping; ?=unable to determine.  
Our novel investigation of peak KFLEX also resulted in a poor correlation between 2D 
video and 3D kinematic motion capture. There is a linear pattern to these data, which 
results in a Pearson’s r that over-estimates construct validity (r=0.74). There also 
appears to be a systematic bias within these data, with 2D video consistently over-
predicting peak KFLEX by a mean of 5˚. Ortiz et al (229) hypothesised that transverse 
plane hip motion may affect the accuracy of 2D measured frontal plane hip and knee 
kinematics. Consistent with this hypothesis, there is a statistical trend towards 3D peak 
HIR being a covariate for this outcome (F change 3.76, p=0.06, R2 change -0.08). Whilst 
this may explain the systematic bias within these data, this potential model has limited 
clinical applicability, as transverse plane hip data is not readily collectable by a 2D 
camera.  
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7.5. Limitations and future directions   
This study is not without limitations, which must be considered when interpreting the 
results. In an attempt to best replicate clinical practice, participants completed only a 
short over ground run, with data collected on the fifth step on average. Dingenen et al 
(236) recently reported that a minimum of seven steps are required to allow for a 
stable mean of a 2D measured kinematic variable. These data refer to analysis 
completed with Kinovea (http://www.kinovea.org), software that is free of cost at the 
point of access to Microsoft Windows users. Kinovea offers similar precision to 
digitization with Dartfish and has been reported to be reliable for measuring a variety 
of 2D running kinematic variables (236) when data were collected using retroflective 
markers. Given the apparent potential for increased precision to result in greater 
construct validity, a future study using either Dartfish or Kinovea involving runners 
with PFP is warranted.   
It could also be that repeating this study using a treadmill running protocol similar to 
that used by Maykut et al (108) may return a different outcome. Although kinematic 
comparisons between treadmill and over ground running have been reported to be 
equivalent (238), a treadmill protocol would allow for the frontal plane camera to be 
placed closer to the runner, increasing the video quality and reducing the potential for 
parallax error. Retroflective markers should also be encouraged to increase the 
precision of 2D video digitisation in future studies, regardless of the chosen analysis 
method.  
Whilst not statistically significant, there is a trend for peak HIR data to explain the 
observed poor agreement between 3D and 2D measurement, particularly for peak 
KFLEX. As a result, future studies are encouraged to investigate methods for clinical 
gait analysis that may allow for measurement of all movement planes, such as an 
inertial measurement unit (239). Inertial measurement unit data has been collected in 
a small sample during a marathon run (240), but is yet to be completed in the clinical 
setting or be compared to 3D motion capture to the best of our knowledge.  
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7.6. Conclusion 
A poor correlation between 3D kinematic motion capture and high frame rate 2D video 
was identified for both peak HADD and KFLEX in runners with PFP. This may be 
attributed to the increased variability in running kinematics in runners with PFP, but 
could also be explained by employed 2D video or statistical methodologies. Further 
investigation of software with increased precision, such as Dartfish or Kinovea, is 
warranted, aiming to improve the ability of high frame rate 2D video to accurately 
predict 3D kinematics in the clinical setting. At present, clinical gait analysis conducted 
using the Hudl Technique application should be interpreted with caution, as the 
accuracy of 2D measurement cannot be guaranteed, even in the presence of moderate 
intra-rater reliability. 
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8. Discussion and conclusions 
This thesis had the overarching aim of determining the influence(s) of lower limb 
biomechanics on the development, persistence and management of PFP in 
recreational runners. Given the reported high prevalence of musculoskeletal injury 
amongst runners (18-92%) (12), the first thesis aim centred on defining the magnitude 
of PFP by exploring its epidemiology (risk factors and incidence). 
8.1. Risk factors for PFP development 
The primary finding from the systematic review completed to fulfil aim one was that 
limited risk factors from pooled data existed to explain the development of PFP. 
Furthermore, no risk factors from pooled data existed to explain the development of 
PFP in recreational runners. This highlights a clear dearth of prospective literature that 
can guide the design of interventions aiming to prevent future PFP and is suggested as 
the primary research priority for the field.        
Multiple variables often reported as being cross-sectionally associated with PFP such 
as height, body mass, BMI, body fat percentage, age and Q-angle, were not found to 
be causally associated with PFP in any cohort. As such, preventative programmes for 
PFP that seek to modify these variables are unlikely to yield success. For body mass 
and body fat percentage, reported to be associated with PFP once symptoms have 
developed (136), these data suggest that persistence of PFP (2) results in wider health 
problems. As recreational running has been reported to reduce both adiposity (9) and 
body fat percentage (10), there is a clear need to improve understanding of the 
epidemiology of PFP amongst recreational runners.  
We identified moderate evidence that quadriceps weakness is a risk factor for future 
PFP in military recruits. This aligns well with the study by Coppack et al (135), where a 
predominantly quadriceps-based exercise programme reduced the incidence of PFP in 
the military. However, the most recent consensus statement from the international 
patellofemoral research network (241), and the most recent systematic reviews 
relating to exercise therapy in PFP (56, 81) both report superior outcomes when 
gluteal and quadriceps exercises are combined. It may therefore be that exercise 
programmes designed to either prevent or manage PFP in the military have different 
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treatment targets to other populations. No study to date has investigated the role of 
quadriceps strength in the development of PFP amongst recreational runners. As 
quadriceps weakness has been reported in this group once PFP has developed (31), 
prospective investigation is encouraged to aid in determining if this variable is 
associated more with the development or persistence of PFP in a recreational running 
cohort.       
Moderate evidence also existed that identified increased hip abduction strength as a 
risk factor for future PFP development in adolescents, questioning the preventative 
role that exercise interventions may have in this population. Given the identified high 
incidence figure (11%) and wider health implications of a musculoskeletal disorder 
with a poor prognosis in young people (134), the development of preventative 
strategies should be of an urgent priority. As muscle strength deficits have also not 
been reported in adolescents once PFP is persistent (129) and the reported 
effectiveness of education as an intervention (132), it is here that preventative 
strategies may be best placed.   
Prospective hip abduction strength data in adolescents is in conflict with the limited 
data that exists investigating the role of gluteal muscle strength in relation to PFP 
development in recreational runners. Ramskov et al (19) reported that higher eccentric 
hip abduction strength reduced the incidence of PFP amongst novice recreational 
runners, though these data were not presented in a manner allowing for meta-
analysis. This suggests that an exercise programme targeting eccentric gluteal strength 
may reduce the risk of PFP development in novice runners (19), though this hypothesis 
is yet to be investigated.  
Previous systematic reviews looking to identify risk factors for running-related injury as 
a heterogeneous entity have reported associations between running 
frequency/volume and risk of future injury (8, 12). More specifically, runners who 
increased their weekly volume by more then 30% were reported to be at a greater risk 
by Nielsen et al (143), compared to runners who progressed by a more conservative 
10%. Furthermore, measurement of activity using the acute:chronic workload method 
has been reported to both predict and prevent subsequent injury in multiple sports 
(242-245).  
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It is plausible to suggest that both quadriceps weakness (in the military) and increased 
hip abduction strength (in adolescents), which we identified to be risk factors for 
future PFP, could be confounded by participant activity level. In support of this 
hypothesis, Smith et al (16) highlight that the highest incidence rate for PFP amongst 
military recruits come from populations where military conscription remains a law. It is 
therefore advised that future prospective studies both record and investigate activity 
level as an exposure, especially in recreational runners where future PFP is the 
outcome.  
8.2. Incidence and prevalence of PFP   
When heterogeneous data were pooled from all included prospective studies, PFP 
incidence was identified to be 10%. Within the identified homogenous populations, 
incidence figures for military recruits, adolescents and recreational runners were in 
agreement with the recent systematic review and meta-analysis of Smith et al (16). 
These identified incidence data, and prevalence data reported by both Smith et al (16) 
and Taunton et al (14) are summarised in figure 77, with prevalence exceeding 
incidence for all populations. The discrepancy between incidence and prevalence 
questions the notion that PFP is a self-limiting condition (16, 246) and affirms the 
suggestion that long-term outcomes for PFP are currently sub-optimal in all 
populations (2).  
 
77. A summary of PFP incidence and prevalence data in multiple cohorts  
There is a frequent suggestion throughout the wider literature, often without 
substantiation, that females are more at risk of developing PFP than males (112). This 
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is perhaps due to the increased risk of females developing other knee injuries that 
have an equivalent theoretical biomechanical mechanism, such as ACL rupture (247). 
That said, females have previously been reported to be twice as likely to develop PFP 
than males during basic military training (21). Data from studies included in the 
systematic review completed to fulfil aim one did not identify sex as a risk factor for 
future PFP development, but the largest proportion of females developing PFP was 
identified amongst recreational runners. This may explain why such a significant 
proportion of both case-control and intervention studies relating to running 
investigate all female populations. This identified parity between the sexes in terms of 
PFP development resulted in the decision to investigate mixed-sex samples in the 
studies that formed chapters five through seven.     
Figure 78 incorporates the study designed to complete and achieve the aim of 
exploring the epidemiology of PFP. Having identified limited risk factors for PFP 
development and defined the incidence of the condition, the second aim of this thesis 
centered on determining the biomechanical factors associated with the development, 
persistence and management of PFP in recreational runners. 
 
 
78. Study, outputs and research space(s) identified by work completed in relation to aim one 
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8.3. Biomechanics and running-related PFP  
8.3.1. Biomechanics and PFP development  
Only data from a single study indicated that a kinematic variable, peak HADD, was a 
risk factor for future PFP development in recreational runners (20). Despite the 
statistical significance, caution is advised in interpreting this very limited evidence. 
Noehren et al (20) investigated a female only cohort and had a high risk of bias 
resulting from the low patellofemoral sample size. This is consistent with another 
prevalent running injury, iliotibial band syndrome (ITBS), with peak HADD reported as 
the only kinematic risk factor in female runners (231). As a result, evidence for isolated 
kinematic variables as risk factors for PFP development amongst recreational runners 
is therefore extremely limited and ripe for further scientific exploration.  
A similar kinematic risk profile has also been reported for both ACL injury and PFP in 
adolescent females, with an eight degree increase in peak HADD increasing the risk of 
subsequent ACL rupture (248). In a subsequent study a kinetic variable, a higher knee 
abduction moment (>25Nm), determined those who developed subsequent ACL 
rupture rather than PFP (249). It is reasonable to suggest that those with an 
appropriate biomechanical profile may be at risk of either PFP or ACL rupture, 
dependent on their choice to perform a predominantly sagittal plane, lower force 
sport (recreational running) or a multiplanar, higher force sport.    
Limited evidence was also identified to indicate that increased peak force under the 
2nd/3rd metatarsal heads and time to peak force at the lateral heel during running 
increased the risk of future PFP development. Such plantar loading variables have also 
been reported as risk factors for the development of Achilles tendinopathy (37). As 
increased vertical load rate has also been reported as prospectively associated with 
future injury in female runners (250), it could be that total limb loading, rather than 
increased load at a specific anatomical region, is the variable that increases injury risk.  
Very limited evidence for an association between reduced rearfoot eversion (20) and 
future PFP development was also identified. This is in conflict with the wider literature 
where increased navicular drop has also been reported to be a risk factor for future 
PFP development (36). This conflict is perhaps unsurprising, given that global foot 
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kinematics in asymptomatic participants have been reported to be highly variable (61). 
Consequently, understanding of the role of foot biomechanics in relation to PFP risk 
amongst recreational runners is limited, requiring further investigation.   
8.3.2. Biomechanics and PFP persistence  
Despite limited prospective links, multiple associations were observed between 
altered running kinematics and PFP, including increased peak HADD, HIR and CLPD 
when compared to controls. As these associations come from the case-control 
literature, it is not possible to determine if these kinematic differences existed prior to 
symptom development, or are simply adaptations to pain. This is again consistent with 
the literature surrounding ITBS, with both male and female runners with ITBS reported 
to run with greater peak HADD when compared to controls (230, 251, 252). 
There is a plausible mechanistic explanation as to why an equivalent kinematic variable 
(peak HADD) is associated with two differing types of knee pain. It could be that 
trochlear dysplasia, reported to result in reduced patellofemoral contact area during 
both open and closed chain tasks (253), magnifies the effect of increased peak HADD 
during running. Including an imaging component to future prospective and case-
control studies would add a significant amount to the understanding relating to 
kinematics and their association with knee pain. An example of where imaging has 
improved treatment outcomes is patellofemoral arthroplasty, with implants 
customised to the recipients geometry reported to be superior in those with trochlear 
dysplasia (254).          
It may also be that running kinematics are effected by symptom persistence, with a 
recent case-control study (192) reporting that increased peak HIR and increased peak 
HADD were associated with acute (< one month duration) and persistent (> three 
months duration) PFP respectively. This suggests that increased peak HADD could 
therefore be an adaptation to persistent pain, but conflicts with the data of Noehren 
et al (20), who reported increased peak HADD as a risk factor for future PFP in female 
runners.  
Overall, the strength of evidence for the association between running biomechanics 
and PFP is typically associative rather than causal. A longitudinal cohort study would 
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be required to investigate the biomechanical variables that contribute to the 
development and subsequent persistence of PFP, which may differ, and may also not 
provide plausible treatment targets. However, the identified associations between hip 
kinematics and persistent PFP justified the inclusion of these variables in the 
experimental studies that form chapters five through seven.   
Whilst the first systematic review of this thesis did not identify the female sex as a risk 
factor for future PFP development, larger proportions of females were observed in the 
included recreational running studies. Asymptomatic females have previously been 
reported to demonstrate both increased peak HADD and HIR during running in 
comparison to asymptomatic males (255). Despite the strength of evidence identified 
for cross-sectional associations between altered running kinematics and PFP, the 
majority of included studies (seven out of eight) reported data on either female only or 
mixed-sex cohorts. It was therefore plausible to suggest that the females amongst the 
cohorts may have significantly affected any differences identified between mixed-sex 
PFP and control cohorts.   
Just one previous case-control study reported kinematic data for both sexes separately 
(51), with females demonstrating increased peak HADD during running when 
compared to both males with PFP and asymptomatic males. The mean difference 
between males and females with PFP (6.3˚) is greater than the mean difference 
reported by Chumanov et al (255) in asymptomatic runners (2.9˚). This suggested that 
kinematic data from females with PFP might significantly alter the pooled mean for 
peak HADD when data for both sexes are combined. Given the emergence of 
interventions that are reported to have a potential kinematic treatment target and 
mechanism such as running retraining (>20˚ peak HADD reduced by ~5˚) (100, 101), it 
was deemed necessary to determine if these altered hip kinematics exist in both sexes.  
Having confirmed the reliability of kinematic marker placement, our mixed-sex data 
further confirmed that runners with PFP demonstrated increased peak HADD when 
compared to controls. When sub-grouped by sex, females with PFP demonstrated 
significantly greater peak HADD during running when compared to asymptomatic 
females, but not asymptomatic males or males with PFP. The absence of statistically 
significant differences between males and females with PFP in our analysis was 
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attributed to the sample imbalance towards females (n=11 versus n=9), but was 
considered clinically relevant as the mean difference between the groups exceeded 
the accepted MDC (3.5˚) (194). Thus, when considered in combination with the data of 
Willy et al (51), it is suggested that future studies investigating lower limb kinematics in 
a PFP cohort during running report data for males and females separately. This will 
mitigate the potential for a spurious outcome that may arise when pooling data for 
both sexes.  
8.3.3. Biomechanics and observed mechanisms of treatment effects   
Three interventions; exercise therapy, orthoses and running retraining, were 
investigated by studies included in the systematic review completed to partially fulfil 
aim two. Whilst exercise therapy and orthoses have been included in multiple previous 
PFP consensus documents (65, 80, 241), running retraining is a novel intervention for 
which the evidence base is in its infancy. Data from these studies were pooled in 
relation to both treatment effects and biomechanical mechanisms.  
Foot orthoses  
Increased peak rearfoot eversion has been reported in individuals with PFP during 
running (256) and very limited evidence of reduced peak rearfoot eversion with foot 
orthoses in-situ was identified. However, no inferences on treatment effects were 
made by the observational study from which these data come, heavily limiting their 
clinical applicability. In keeping with the previously reported efficacy of foot orthoses 
in other cohorts (76, 77, 179), the recent study of Sinclair et al (257) also reported 
positive short-term effects of foot orthoses in runners with PFP. In conflict with 
Rodrigues et al (78), no significant kinematic changes at the rearfoot were reported by 
Sinclair et al (257).  
On the whole, the evidence for foot orthoses in managing runners with PFP is 
conflicting, both with respect to treatment effects and biomechanical mechanisms. 
This is a consistent theme throughout the literature, with two recent systematic 
reviews reaching conflicting conclusions regarding the use of orthoses in plantar heel 
pain (258, 259). This may be explained by the methodological challenges presented by 
attempting to investigate the effects and mechanisms of orthoses; namely a likely 
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inability to control biomechanical effects across a population, rendering mean pooled 
data insignificant secondary to high variability (260). Despite this, there is an emerging 
positive narrative in the field of PFP, meaning that future investigation of both the 
effects and mechanisms of foot orthoses in recreational runners is worthwhile.   
Exercise therapy 
Exercise therapy is described as the gold standard intervention for PFP by the most 
recent consensus statement from the international patellofemoral research network 
(241). Consistent with this statement, moderate evidence was identified that exercise 
therapy reduces pain and improves function in recreational runners to short-term 
follow up. In keeping with previous work in asymptomatic runners (88), no kinematic 
changes were identified after exercise therapy. This means that the mechanism 
underpinning these positive effects is unknown, leaving clinicians unable to tailor 
exercise therapy to a biomechanical treatment target in recreational runners.  
It could be that the mechanisms of exercise therapy in recreational runners with PFP 
are not biomechanical in nature. For example, improvements in both strength and 
proprioception have been reported as potential mediators of the effects of exercise 
therapy in osteoarthritis management (261). Alternatively, it may be that exercise 
therapy can improve the kinetic factors associated with knee injury, as observed in 
females who are ‘at risk’ of subsequent ACL injury after a neuromuscular protocol 
(262). There is limited evidence of this skill transfer in recreational runners, with single 
leg squat kinematics, but not running kinematics, improving after an exercise protocol 
in asymptomatic runners (88).    
Moreover, it has recently been reported that clinicians are currently unable to 
replicate published exercise therapy protocols for PFP secondary to inadequate 
reporting standards (263). This may go some way to explaining why exercise therapy 
was not found to be superior to an education intervention in runners with PFP at six 
month follow up (85). As a result, future work would be necessary to determine if and 
how exercise therapy should be best implemented to manage PFP in recreational 
runners.    
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Running retraining  
Best defined as ‘the implementation of any cue or strategy designed to alter an 
individual’s running biomechanics or technique’ (89), running retraining was also 
identified to reduce pain and improve function in recreational runners at short-term 
follow up. Pooled data for the effect of running retraining on symptoms resulted in a 
larger SMD when compared to pooled data for exercise therapy (3.8 [2.7,5.0] versus 
1.8 [1.2,2.4]), though the identified level of evidence (limited) was equivalent. As an 
advantage over exercise therapy, running retraining had an apparent kinematic 
mechanism of effect, being a reduction in peak HADD during running of 5˚. This limited 
evidence is now supported by two further studies (79, 103), both of which reported 
short-term reductions in pain, despite again using different forms of feedback 
(forefoot strike and step rate plus minimalist shoe respectively). The identified larger 
effect size and potential mechanism of effect lead to the decision to investigate a 
running retraining intervention within the projects forming this thesis.  
Figure 79 incorporates the studies designed to completed and achieve the second aim 
of this thesis into the overall thesis narrative. Having identified associations between 
running kinematics and PFP persistence, and the effects and biomechanical 
mechanisms of running retraining from pooled data, the third aim of this thesis 
centered on determining the feasibility, effects and potential biomechanical 
mechanisms of a step rate intervention in runners with PFP. As there was a clear 
female bias in the sampling of the previous studies on the topic, and having affirmed 
the potential for the female sex to influence kinematic outcomes, a mixed-sex cohort 
was actively sought. 
Increasing step rate was chosen as the form of feedback for multiple reasons. It has 
greater clinical applicability than the direct HADD feedback by Noehren & Willy (100, 
101) and a lower potential to result in secondary ankle pain compared to the forefoot 
strike feedback used by of Roper et al (103). When combined with the use of a 
minimalist shoe, data from a pilot RCT suggested efficacy of increasing step rate in 
runners with PFP (79), with further favourable biomechanical changes post-step rate 
increase reported amongst the observational literature (90). It was yet to be 
investigated in a manner necessary to meet the requirements of a running retraining 
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intervention described by Davis (107) in a PFP cohort; requiring extrinsic feedback 
delivery within a faded feedback protocol.   
 
 
79. Study, outputs and research space(s) identified by work completed in relation to aim two 
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8.4. Step-rate retraining and running-related PFP 
Determined by investigating recruitment and eligibility and adherence and 
acceptability, we determined that increasing running step rate appears to be a feasible 
intervention in a mixed-sex group of runners with persistent PFP. Whilst not 
anticipated to present a problem for a future efficacy trial, the absence of a control 
arm in this study prohibited the investigation of randomisation. As a result, we advise 
that a future efficacy trial commence with a nested pilot study design, allowing for trial 
cessation should randomisation to a comparative arm prove to be difficult.  
Consistent with the previous running retraining literature, we identified that a step 
rate intervention resulted in a significant reduction in pain at short-term (six-week) 
follow up. In agreement with the work of Noehren and Willy (100, 101), we also 
identified a reduction in peak HADD post-retraining, though the difference was small 
(2.4˚). This was most likely explained by our mixed-sex sample, as the mean difference 
in peak HADD was consistent with other observational studies completed using 
asymptomatic, mixed-sex samples (91, 93). Significant reductions in both peak HIR and 
KFLEX following step rate retraining were also identified. This suggests that the 
kinematic mechanisms of step rate retraining may exist outside of the frontal plane 
and should be included in future mechanistic investigations post-running retraining.      
Female runners with PFP have previously been reported to have delayed gluteal onset 
relative to foot contact and reduced gluteal activation duration when compared to 
controls (264). Increasing step rate in an asymptomatic group of runners has 
previously been reported to result in an earlier onset of lower limb musculature, but 
have no effect on muscle activity during running stance phase (96). Consistent with the 
work of Chumanov et al (96), we did not identify any changes to muscle amplitudes 
during running stance phase post-step rate retraining. Future mechanistic sEMG 
investigations post-running retraining should allow for the analysis of muscle activity 
relative to kinematic data rather than in isolation, which is a limitation of our work. 
Whilst data following step rate retraining add weight to the suggestion of a kinematic 
mechanism, there are clearly some participants in our small cohort for whom this is 
not the case. Increasing step rate has been reported to reduce average vertical loading 
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rate (265), a variable which is associated with both injury risk (250)  and injury 
prevention in recreational runners (207). Increasing step rate has also been reported 
to result in a consequential shift towards a forefoot strike pattern (99), which in turn 
has been reported to be effective in managing both PFP (103) and exercise induced leg 
pain (90). There are therefore a plethora of potential mechanisms that may underpin 
the positive effects observed following step rate retraining, all of which warrant 
further investigation. Furthermore, expert opinion taken from a mixed methods study 
with which I was involved, advocates running retraining as an intervention for multiple 
conditions, which future work should seek to explore (90).  
Based on the systematic review findings from chapter four and the intervention data 
reported in chapter six, both exercise therapy and running retraining (irrespective of 
feedback) appear effective in reducing symptoms of PFP at short-term follow up. A 
future RCT comparing a high quality and clinically replicable exercise therapy 
intervention with a running retraining intervention delivered using a faded feedback 
protocol is advocated, with a comparative load management education arm similar to 
that included by Esculier et al (85). Adhering to the suggestion from the international 
patellofemoral research network (241) that treatment be tailored, it would be 
desirable to stratify by a specific deficit, such as a low baseline step rate. Secondary 
analyses could also seek to explore if a strength programme is more effective in 
participants with true muscle weakness or an education intervention in participants 
who breach recommended acute:chronic workload ratios. To truly examine this 
hypothesis of tailored treatment, one could also include treatment arms where the 
intervention is delivered to participants without said specific deficit, though this would 
present challenges with stratification and require a significant sample size. Figure 80 
depicts a CONSORT diagram for this potential RCT design, using the sample size 
calculation performed in chapter six using empirical data from this chapter and 
comparative data from Esculier et al (85).  
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80. Potential design for three-arm RCT to investigate optimal management of PFP in recreational 
runners   
Figure 81 incorporates the study designed and completed to achieve the third aim of 
this thesis into the overall thesis narrative. Having adequately established feasibility 
for the future investigation of the efficacy of step rate retraining in a mixed-sex cohort 
of runners with PFP, there was motivation to further increase the clinical applicability 
of this potentially impactful intervention. There was preliminary evidence to suggest 
that a kinematic mechanism may underpin the positive effects of step-rate retraining, 
and chapters four through six of this thesis identified associations between altered 
lower limb kinematics and PFP, both with respect to symptom development and 
persistence. In attempt to increase the clinical applicability of measuring these 
kinematic variables, the final aim of this thesis was to investigate the accuracy of 2D 
video gait analysis.  
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81. Study, outputs and research space(s) identified by work completed in relation to aim three 
8.5. Bridging the gap between laboratory and clinical practice  
In conflict with the previous 2D video studies that used asymptomatic runners, our 
investigation identified poor agreement between 3D and 2D kinematic motion analysis 
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for both peak HADD and KFLEX, despite acceptable intra-rater reliability. This 
disagreement could simply be explained by our investigation of a cohort of runners 
with PFP, who we identified to demonstrate more variable running kinematics 
compared to runners without symptoms (82). However, in an attempt to make this 
investigation as clinically applicable as possible, there were also differences in 2D video 
data collection and digitisation that could also account for the identified discrepancies. 
Improving upon the clinical applicability of kinematic gait analysis in runners with PFP 
therefore remains a priority area for further research. A repeat investigation of the 
treadmill analysis protocol used by Maykut et al (108) in runners with PFP is 
advocated. This would allow for the frontal plane camera to be much closer to the 
participant, and should therefore increase the precision of data analysis via increased 
video footage quality. It is also plausible to investigate the concurrent validity of 
Kinovea software, as this was recently reported to be both inter- and intra-rater 
reliable for a variety of running kinematics (236). Until such time, clinicians are advised 
to exercise caution with their use of 2D video to analyse kinematics in runners with 
PFP, as collected data may not reflect the gold standard measurement.  
Figure 82 incorporates the study designed and completed to fulfill this final aim into 
the overall thesis narrative. 
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82.         Study, outputs and research space(s) identified by work completed in relation to aim four 
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8.6. Conclusions  
This thesis had the overarching aim of determining the influence of lower limb 
biomechanics on the development, persistence and management of PFP in 
recreational runners. Limited data existed to support the premise that biomechanics 
influence the development of PFP. Innovative approaches are required to further 
develop understanding regarding the development of PFP. Multiple associations 
between PFP and running biomechanics were identified from the cross-sectional 
literature, with an inability to distinguish cause from effect. Further studies are 
encouraged to investigate which variables are genuine mediators of either persistent 
symptoms or treatment effects. For peak HADD, the variable with the strongest 
association with PFP, it is important that future data be both presented and analysed 
for the individual sexes, given the potential for data from females to influence 
outcomes.  
Increasing step rate was associated with multiple potential mechanisms. These should 
be further investigated to determine if the intervention could be tailored to 
individually determined treatment targets, such as sub-groups defined by baseline 
activity level or step rate. There remains a clear barrier between laboratory and clinical 
practice, as the kinematic variables determined to be of interest by this thesis were 
not accurately measurable using pragmatic 2D video. This needs to be addressed to 
allow for understanding of the influence of lower limb biomechanics on PFP to fully 
impact upon the management of PFP in recreational runners.  
Overall, optimal management for PFP in recreational runners is yet to be determined. 
However, increasing step rate appears to be a feasible intervention with indications of 
efficacy in runners with PFP from both sexes, warranting further appraisal in an 
efficacy trial. Future studies should also seek to determine if exercise therapy and 
running retraining could be used as a combined intervention, as advocated by the 
international patellofemoral research network.  
This thesis has added to the understanding of PFP epidemiology. It has explored how 
lower limb biomechanics are associated with both the development (limited evidence) 
and the persistence (moderate to strong evidence) of PFP in recreational runners. The 
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impact of the female sex on running kinematics is now better understood and should 
allow for increased validity in future analyses. This thesis has identified adequate 
feasibility for a running retraining (step rate) intervention and has prepared the 
ground for future clinical trials in the field. Finally, the translation of kinematic data 
into clinical practice has been shown to be warranted. 
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Running Retraining Instructions 
 
 
Participant:           Metronome setting:            Treadmill speed:    
 
INITIAL TEST 
 
Week 1: 3 sessions of: (Run 1min : Walk 1min) x 10 (metronome feedback for all) 
 
 
Week 2: 3 sessions of: (Run 2min : Walk 1min) x 8 (metronome feedback on numbers 1-3 and 5-7) 
 
 
Week 3: 3 sessions of: (Run 3min : Walk 1min) x 8 (metronome feedback on numbers 1, 3, 5, 7) 
 
 
Week 4: 3 sessions of: (Run 4min : Walk 1min) x 8 (metronome feedback on numbers 1 and 5) 
 
 
Week 5: 3 sessions of: (Run 5min : Walk 1min) x 6 (no metronome feedback) 
 
 
Week 6: 3 sessions of: (Run 10min : Walk 1min) x 3 (no metronome feedback) 
 
RE – TEST 
 
Week 7: 3 sessions of: (Run 15min : Walk 1min) x 2 
 
 
Week 8: 3 sessions of: Run 20min continuous 
 
 
Week 9: 3 sessions of: Run 25min continuous 
 
 
Week 10: 3 sessions of: Run 30min continuous 
 
 
Week 11: 3 sessions of: Run 35min continuous 
 
 
Week 12: 3 sessions of: Run 40min continuous 
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17. Appendix H: Tegner activity scale    
 
 
  
       
      Dr T W Munting Specialist Orthopaedics CC 
MBChB(UCT), DA(SA), FCS Orth(SA) 
Consultant Orthopaedic Surgeon 
     
 
MP No: 0408417 
Practice No: 028-
000/0167339 
Reg No: CK2006/098534/23 
Vat Reg: 
4310230208 
Cape Town Sports and Orthopaedic Clinic 
Room 702, The Annex 
*Chris Barnard Memorial Hospital 
162 Longmarket Street Cape Town 8001 
PO Box 2079 
Clareinch, 7740 
Cell No: 082 0629625 
Tel No:021-424 0725/6      
Fax No: 021-424 0728 
E-mail: drthane@ctorth.com 
 
----------------------------------------------  
Private and confidential information intended for above mentioned person or persons only. Please destroy or 
return to Dr TW Munting if erroneously received. Failure to do so will result in prosecution. 
 
 
Consultation	Questionaire	Hip	Patients	
Name: ______________________     Side:   Right / Left 
Date: ______________________  
	
QUESTIONS		
1. Activity	Levels,	please	look	at	the	scale	below	and	answer	the	score	for	your	activity	level	before	and	after	the	
problem	began	or	the	surgery	took	place. 
TEGNER ACTIVITY LEVEL SCALE 
Please indicate in the spaces below the HIGHEST level of activity that you participated in BEFORE 
YOUR INJURY and the highest level you are able to participate in CURRENTLY.  
 
BEFORE INJURY: Level__________ CURRENT: Level___________   See scale below 
 
 
Level 10  Competitive sports- soccer, football, rugby (national elite)  
Level 9  Competitive sports- soccer, football, rugby (lower divisions), ice hockey, wrestling, gymnastics, 
basketball etc 
Level 8  Competitive sports- racquetball, squash or badminton, track and field athletics (jumping, etc.), down-
hill skiing etc 
Level 7  Competitive sports- tennis, running, motorcars speedway, handball  
Recreational sports- soccer, football, rugby, bandy, ice hockey, basketball, squash, racquetball, 
running,MTB,dancing etc  
Level 6  Recreational sports- tennis and badminton, handball, racquetball, down-hill skiing, jogging at least 5 
times per week  
Level 5  Work- heavy labor (construction, etc.)  
Competitive sports- cycling, cross-country skiing,  
Recreational sports- jogging on uneven ground at least twice weekly  
Level 4  Work- moderately heavy labor (e.g. truck driving, etc.)  
Level 3  Work- light labor (nursing, etc.)  
Level 2  Work- light labor  
Walking on uneven ground possible, but impossible to back pack or hike  
Level 1  Work- sedentary (secretarial, etc.)  
Level 0  Sick leave or disability pension because of hip problems  
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18. Appendix J: Skills points record   
The knowledge and skills that I have developed during the course of my PhD extend 
beyond the chapters presented in this thesis. Over the past four and a half years I have 
immersed myself amongst the literature, not just in relation to my topic of 
patellofemoral pain, but also in relation to the wider scientific method. These skills 
have been tested and strengthened further by the submission and subsequent 
presentation of abstract findings at a variety of national and international conferences.    
I have developed my teaching skills by successfully completing the first module of my 
certificate in learning and teaching (CILT), which I shall formally complete in the next 
academic year. I have successfully supervised three MSc students to the successful 
completion of their dissertation and subsequent degrees. I am particularly proud of 
the patellofemoral pain research group that I co-supervised throughout 2016/17 with 
my colleague Dr Simon Lack, which contained five iBSc students, all of whom 
successfully passed their dissertation component.  
I have no doubt that the knowledge and skills that I have gained throughout the course 
of my PhD will serve me well throughout my future career, both as an academic and as 
a clinician.    
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